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CEO  
FOREWORD
The Australian Criminal Intelligence Commission’s annual Illicit Drug Data Report, now in  
its 17th edition, continues to provide an authoritative picture of illicit drugs in Australia. It  
informs policy and operational decisions across government, industry and the not-for-profit 
sector and focuses efforts to reduce the impact of illicit drugs on our communities.
Serious and organised criminals are at the centre of Australia’s illicit drug market, motivated  
by greed, power and profit. We know serious and organised crime groups continue to  
generate significant profits from the sale of illicit substances, with the price paid for illicit  
drugs in Australia among the highest in the world. The estimated street value of the weight  
of amphetamines, MDMA, cocaine and heroin seized nationally in 2018–19 is around  
$3.5 billion, underlining the size of the black economy that relates to illicit drugs alone.  
It would appear that Australian drug markets continue to grow. As such, the importation, 
manufacture, cultivation and distribution of illicit drugs and related precursors in Australia  
remain a focal point of government, law enforcement and intelligence agencies.
Illicit drug use cannot be addressed by law enforcement alone—a multi-faceted approach 
is needed. This report combines illicit drug data from a variety of sources including law 
enforcement, forensic services, health and academia, which inform our understanding and  
assist in focusing our collective efforts to respond to the issue of illicit drugs. The risk and  
harm posed by illicit drugs to the Australian community is ever-growing, which underscores  
the need for law enforcement and health agencies to work collaboratively to combat both the 
supply and demand for illicit drugs in Australia. In 2018–19, new records were set and include:
  5.1 tonnes of ATS (excluding MDMA) detected at the Australian border
  5,378 national cocaine seizures
  5,016 national cocaine arrests
  1,029 national hallucinogen arrests.
Over the last decade, during which time the Australian population increased around 13 per cent:
  the number of national illicit drug seizures increased 77 per cent (from 63,670 in 2009–10  
to 112,474 in 2018–19)
  the weight of illicit drugs seized nationally increased 241 per cent (from 7.8 tonnes in  
2009–10 to 26.6 tonnes in 2018–19)
  the number of national illicit drug arrests increased 80 per cent (from 85,252 in 2009–10  
to 153,377 in 2018–19).
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These upward trends not only highlight the continued vigilance of law enforcement in reducing 
the supply of all illicit drugs; they also highlight why illicit drugs continue to be a concern for 
law enforcement and the wider community, and the ongoing need to reduce demand.
The weight of ATS (including MDMA) detected this reporting period is more than double the 
combined weight of cannabis, heroin and cocaine detections. Methylamphetamine, which 
accounts for the majority of ATS, remains the most consumed illicit drug of those monitored 
by the National Wastewater Drug Monitoring Program based on available dose data. It is 
estimated that 11,516 kilograms of methylamphetamine is consumed annually in Australia, 
with 4,418 kilograms of amphetamines—the majority of which is methylamphetamine—seized 
nationally in 2018–19. 
It is also important that the Australian Criminal Intelligence Commission and law enforcement 
continue to look at emerging markets as well as the highest risk markets. Although the 
markets for other drugs remain relatively small, the anaesthetics market, particularly GHB/
GBL and ketamine, appears to be expanding. The number of detections of anaesthetics 
(including GHB, GBL and ketamine) at the Australian border increased 1,934 per cent over 
the last decade, from 67 in 2009–10 to a record 1,363 in 2018–19. The number of clandestine 
laboratories detected nationally manufacturing GHB/GBL has also increased to record levels 
in recent years, with 200 litres of the GHB precursor 1,4-butanediol also seized in a single 
jurisdiction this reporting period.
I commend the efforts of all who contributed to this report, from law enforcement, forensic 
services, academia and the Australian Criminal Intelligence Commission. If not for your vital 
contributions and continued support, it would not be possible to understand the complex  
and evolving Australian drug market.
 
 
Michael Phelan APM 
Chief Executive Officer 
Australian Criminal Intelligence Commission
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INTRODUCTION
The Australian Criminal Intelligence Commission’s Illicit Drug Data Report (IDDR) is the only report of  
its type in Australia, providing governments, law enforcement agencies and interested stakeholders 
with a national picture of the illicit drug market. The IDDR presents data from a variety of sources 
and provides an important evidence base to assess current and future illicit drug trends, offers a brief 
analysis of those trends, and assists decision-makers in the development of strategies to combat the 
threat posed by illicit drugs.
The Australian Criminal Intelligence Commission collects data annually from all state and territory  
police services, the Australian Federal Police, the Department of Home Affairs, state and territory 
forensic laboratories and research centres. Illicit drug data collected and presented in this report  
for the 2018–19 financial year include:
  arrest
  detection
  seizure
  purity
  profiling
  price.
The purpose of this report is to provide statistics and analysis to assist decision-makers in developing 
evidence-based illicit drug supply, demand and harm reduction strategies. The data also assist the 
Australian Government to meet national and international reporting obligations.
The Australian Criminal Intelligence Commission uses the National Illicit Drug Reporting Format  
(NIDRF) system to standardise the arrest, seizure and purity data received from police services and 
contributing forensic organisations.
The current format and structure of the IDDR provides a more concise report, while still retaining key 
illicit drug market information and insights. Similar to previous reports, each chapter in the 2018–19 
report provides an overview of changes since the previous reporting period and also includes some 
longer-term trends in key market indicators—including border detections, national seizures and  
arrests, price, purity, forensic analysis, wastewater analysis and drug user survey data—which inform  
and enhance our understanding of Australia’s illicit drug markets and the ability to identify changes 
within them. 
Australian Criminal Intellegence Commission 
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EXECUTIVE SUMMARY2
Variations exist in drug markets, both internationally and domestically, within and between states and 
territories, and over time. No single dataset provides a national picture of Australian illicit drug markets  
and it is only through the layering of multiple data—both current and historical—that we are able to  
enhance our understanding of illicit drug markets.
Cannabis and amphetamine-type stimulants (ATS) remain the two primary illicit drug markets in  
Australia, and their predominance is reflected in most supply and demand indicators. By number,  
cannabis was the most commonly detected illicit drug at the Australian border in 2018–19, with the  
weight of ATS (including MDMA) detected this reporting period more than double the combined weight  
of cannabis, heroin and cocaine detections. Cannabis accounted for the greatest proportion of the  
number of national illicit drug seizures and arrests this reporting period, with ATS accounting for the  
greatest proportion of the weight of illicit drugs seized nationally in 2018–19.
Overall, based on supply and demand indicators for the main illicit drug markets in Australia in 2018–19:
  The ATS market, which in Australia is primarily comprised of methylamphetamine, is large and expanding.
  The cannabis market remains large and relatively stable.
  The heroin market remains small but experienced growth in some areas.
  The cocaine market continues to expand.
  Although the markets for other drugs remain relatively small compared to the above drug markets,  
the anaesthetics market, particularly GHB/GBL, appears to be expanding, with some growth also  
seen in relation to hallucinogens.
In addition to domestic border detections and seizures, international operations and collaboration also 
impact Australian drug markets. A summary of some current international operations and initiatives is 
included in Appendix 1.
PROFILE OF ILLICIT DRUG DETECTIONS AT THE AUSTRALIAN BORDER
Number of illicit drug detections—comparison between 2017–18 and 2018–19  
Amphetamine-type stimulants (ATS) Cannabis Heroin Cocaine
ATS (excluding MDMA) MDMA
 -18%
2,451 à 2,022
 7%
3,530 à 3,777
 -36%
17,383 à 11,133
 -31%
265 à 184
 -2%
2,741 à 2,695
Cannabis accounted for the greatest number of border detections in 2018–19, followed by MDMA,  
cocaine, ATS3 and heroin.
  The number of ATS, cannabis, heroin and cocaine detections at the Australian border decreased  
in 2018–19.
  The number of MDMA detections increased this reporting period.
2 Key for tables in the Executive Summary:  
= Decrease   = Relatively stable   = Increase       = Highest on record       = Highest in last decade
3 ATS border detection data excludes MDMA, which is reported separately.
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Weight of illicit drug detections—comparison between 2017–18 and 2018–19  
Amphetamine-type stimulants (ATS) Cannabis Heroin Cocaine
ATS (excluding MDMA) MDMA
 74%
2,952kg à 5,148kg
 50%
1,420kg à 2,124kg
 212%
580kg à 1,811kg
 49%
190kg à 283kg
 13%
926kg à 1,049kg
ATS accounted for the greatest proportion of the weight of border detections in 2018–19, followed by 
MDMA, cannabis, cocaine and heroin.
  The weight of detected ATS, MDMA, cannabis, heroin and cocaine increased this reporting period, 
with the weight of ATS detected in 2018–19 the highest on record, the weight of MDMA and cannabis 
the highest recorded in the last decade, and the weight of cocaine the second highest on record.
  The weight of ATS detected in 2018–19 was almost as much as the combined weight of detected 
MDMA, cannabis, heroin and cocaine.
 Proportion of illicit drug detections, by importation stream in 2018–19  
Drug Type Importation stream, by number, 
2018–19
Importation stream, by weight, 
2018–19
ATS (excluding MDMA) International mail              86%
Air cargo                               12%
Air passenger/crew              2%
Sea cargo                             <1%
Sea cargo                                 72%
Air cargo                                   17%
International mail                   10%
Air passenger/crew                  1%
MDMA International mail              98%
Air cargo                                 2%
Air passenger/crew            <1%
Sea cargo                              <1%
Air cargo                                  48%
International mail                   28%
Sea cargo                                  24%
Air passenger/crew                <1%
Cannabis International mail              97%
Air cargo                                 2%
Air passenger/crew              1%
Sea cargo                              <1%
Sea cargo                                 83%
International mail                   11%
Air cargo                                     6%
Air passenger/crew                <1%
Heroin International mail              81%
Air cargo                               17%
Air passenger/crew              1%
Sea cargo                                1%
Air cargo                                  68%
International mail                   21%
Sea cargo                                  11%
Air passenger/crew                <1%
Cocaine International mail              94%
Air cargo                                 5%
Air passenger/crew              1%
Sea cargo                              <1%
Sea cargo                                 72%
International mail                   12%
Air cargo                                   12%
Air passenger/crew                  4%
The international mail stream continues to account for the greatest proportion of the number of illicit 
drug detections at the Australian border, however the importation stream accounting for the greatest 
proportion of the weight detected varies by drug type.
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PROFILE OF NATIONAL ILLICIT DRUG SEIZURES
Number of national illicit drug seizures—comparison between 2017–18 and 2018–19  
National ATS Cannabis Heroin Cocaine Other &  unknown drugs
 <1%
112,827 à 112,474
 3%
37,093 à 38,250
 -5%
59,139 à 56,491
 5%
1,977 à 2,080
 6%
5,096 à 5,378
 8%
9,522 à 10,275
  The number of national illicit drug seizures remained relatively stable this reporting period.
  In 2018–19, cannabis accounted for the greatest proportion of the number of national illicit drug 
seizures (50 per cent), followed by ATS (34 per cent), other and unknown drugs (9 per cent),  
cocaine (5 per cent) and heroin and other opioids (2 per cent).
  The number of national cannabis seizures decreased this reporting period.
  The number of national ATS, heroin, cocaine and other and unknown drug seizures increased this 
reporting period, with the record 5,096 cocaine seizures in 2017–18 further increasing in 2018–19 
to a record 5,378 seizures, and the 2,080 heroin seizures this reporting period the second highest 
number reported in the last decade. 
The number of national illicit drug seizures increased 77 per cent over the last decade, from 63,670  
in 2009–10 to 112,474 in 2018–19.
Weight of national illicit drug seizures—comparison between 2017–18 and 2018–19  
National ATS Cannabis Heroin Cocaine Other &  unknown drugs
 -13%
30.6t à 26.6t
 -22%
11,205kg à 8,776kg
 -11%
8,655kg à 7,740kg 
 -14%
229kg à 197kg
 -17%
1,970kg à 1,638kg
 -2%
8,540kg à 8,345kg
  The weight of illicit drugs seized nationally decreased this reporting period from a record  
30.6 tonnes in 2017–18.
  The weight of ATS, cannabis, heroin, cocaine and other and unknown drugs seized nationally 
decreased this reporting period.
  In 2018–19, ATS accounted for the greatest proportion of the weight of illicit drugs seized  
nationally (33 per cent), followed by other and unknown (31 per cent), cannabis (29 per cent), 
cocaine (6 per cent) and heroin and other opioids (1 per cent).
The weight of illicit drugs seized nationally increased 241 per cent over the last decade, from  
7.8 tonnes in 2009–10 to 26.6 tonnes in 2018–19.
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Comparison of the weight of methylamphetamine, MDMA, heroin and cocaine seized nationally  
in 2018–19 and estimated consumption  
Drug Estimated consumptiona 
(kilograms per annum)
2018–19 national seizures 
(gross kilograms)
Percentage of total estimated 
consumption seized (%)
Methylamphetamine 11,516 4,418b 38
MDMA 2,226 1,560 70
Heroin 941 197 21
Cocaine 4,636 1,638 35
a. Consumption estimates are based on data derived from Year 3 of the National Wastewater Drug Monitoring Program.
b. At this time it is not possible at a national level to provide a further breakdown of drugs within the amphetamines category. As such national 
seizure figures reflect the weight of amphetamines seized. Amphetamines include amphetamine, methylamphetamine, dexamphetamine 
and amphetamine not elsewhere classified. Based on available data, methylamphetamine accounts for the majority of amphetamines 
seized.
Wastewater analysis provides a measure of licit and illicit drug consumption within a given population. 
The Australian Criminal Intelligence Commission has used wastewater data collected between August 
2018 and August 2019 as part of the National Wastewater Drug Monitoring Program (NWDMP) to 
estimate the annual weight of methylamphetamine, MDMA, heroin and cocaine consumed nationally.4 
Based on the reported gross weights seized nationally by Australian law enforcement in 2018–19 and 
consumption estimates from the NWDMP:
  The weight of amphetamines seized equated to 38 per cent of the total estimated weight of 
methylamphetamine needed to meet national demand.
  The weight of MDMA seized equated to 70 per cent of the total estimated weight of MDMA  
needed to meet national demand.
  The weight of heroin seized equated to 21 per cent of the total estimated weight of heroin  
needed to meet national demand.
  The weight of cocaine seized equated to 35 per cent of the total estimated weight of cocaine  
needed to meet national demand.
PROFILE OF NATIONAL ILLICIT DRUG ARRESTS
National illicit drug arrests—comparison between 2017–18 and 2018–19  
National ATS Cannabis Heroin &  other opioids Cocaine
Other &  
unknown drugs
 3%
148,363 à 153,377
 4%
44,887 à 46,437
 -2%
72,381 à 71,151
 3%
3,029 à 3,129
 16%
4,325 à 5,016
 16%
23,741 à 27,644
  The number of national illicit drug arrests increased this reporting period.
  In 2018–19, cannabis accounted for the greatest proportion of national illicit drug  
arrests (46 per cent), followed by ATS (30 per cent), other and unknown drugs (18 per cent),  
cocaine (3 per cent) and heroin and other opioids (2 per cent).
  The number of national cannabis arrests decreased this reporting period.
  The number of national ATS, heroin and other opioids, cocaine and other and unknown drug arrests 
increased this reporting period, with the number of cocaine arrests in 2018–19 the highest on record.
4 The public NWDMP reports are available on the ACIC website. See <https://www.acic.gov.au/publications/reports/ 
national-wastewater-drug-monitoring-program-reports>.
Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
IN
TRO
D
U
CTIO
N
13
The number of national illicit drug arrests increased 80 per cent over the last decade, from 85,252  
in 2009–10 to 153,377 in 2018–19.
Arrest data in the IDDR incorporate recorded law enforcement action against a person for suspected 
unlawful involvement in illicit drugs. It includes action by way of arrest and charge, summons, diversion, 
infringement and caution. The action taken by law enforcement is influenced by a number of factors, 
including but not limited to which state or territory the incident occurs in, the drug type and quantity 
and related legislation/regulation. In 2018–19, summons accounted for the greatest proportion of 
national drug arrests (44 per cent), followed by charge (33 per cent) and caution/diversion/infringement 
(23 per cent). These proportions vary between drug type, with charge accounting for the greatest 
proportion of national heroin and other opioid arrests (60 per cent), summons accounting for the 
greatest proportion of national hallucinogen arrests (52 per cent) and caution/diversion/infringements 
accounting for the greatest proportion of national cannabis arrests (37 per cent).
Males accounted for the majority of national illicit drug arrests (76 per cent) in 2018–19, with females 
accounting for less than one quarter of arrests. While there was some variation in the proportion of 
arrests involving males across drug types, males consistently accounted for the greatest proportion 
of arrests across all drug types this reporting period, ranging from 72 per cent of national other and 
unknown drug arrests to 86 per cent of national cocaine and steroid arrests.
In 2018–19, consumer arrests accounted for the greatest proportion of national illicit drug arrests  
(90 per cent). While consumer arrests account for the greatest proportion of arrests across all drug 
types, the proportion attributed to them varies, from 76 per cent of national cocaine arrests to  
92 per cent of national cannabis arrests.
PROFILE OF NATIONAL CLANDESTINE LABORATORIES AND PRECURSORS
National clandestine laboratory detections—comparison between 2017–18 and 2018–19  
No. of detections Size and production capacity Location
 -29%
432 à 308
 Addict-based 53% à 47%
 Other small 26% à 33% 
 Medium 19% à 18%
 Industrial 2% à 2%
 Residential 71% à 69%
 Commercial/industrial 4% à 10%
 Vehicle 10% à 9%
 Rural 7% à 5%
 Other 5% à 5%
 Public place 4% à 3%
The number of clandestine laboratories detected nationally decreased for the seventh consecutive 
reporting period in 2018–19.
  The majority of laboratories detected in Australia continue to be addict-based and situated in 
residential locations.
  The majority of laboratories detected in Australia this reporting period were producing 
methylamphetamine, with the hypophosphorous method of production the predominant  
process identified.
Australian Criminal Intellegence Commission 
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  Drug profiling data of both border and domestic seizures indicate ephedrine and pseudoephedrine 
remain key methylamphetamine precursors, with increases in the proportion of methylamphetamine 
seizures manufactured using P2P-based methods.
Number of ATS precursor border detections—comparison between 2017–18 and 2018–19
ATS Precursors
ATS (excluding MDMA) MDMA
 -2%
332 à 325
 100%
1 à 2
The number of ATS precursor detections at the Australian border decreased in 2018–19, while the 
number of MDMA precursor detections increased.
Weight of ATS precursor detections—comparison between 2017–18 and 2018–19
ATS Precursors
ATS (excluding MDMA) MDMA
 -47%
4,912kg à 2,621kg
 7,700%
5g à 390g
The weight of ATS precursors detected at the Australian border decreased in 2018–19, while the weight 
of MDMA precursors detected increased.
  While the weight of ATS precursors detected at the Australian border almost halved this reporting 
period, the weight detected in 2018–19 is the second highest on record.
2018–19 FEATURE—ONLINE MARKETS
KEY POINTS
  The ability to buy and sell illicit substances online is an established and resilient feature of 
global illicit drug markets. Among several platforms and avenues for purchasing illicit drugs 
online, darknet markets in particular are dynamic and show significant potential for expansion.
  In Australia, while there are limited supply and demand indicators directly linked to online 
illicit drug purchases, available data suggest that online markets are a relatively niche, but 
nonetheless established, source of illicit drugs.
  Factors making the online purchase of illicit drugs attractive—particularly from darknet 
markets—include the ability to undertake transactions remotely, avoidance of direct physical 
contact while purchasing and selling, the anonymity provided, the variety of substances 
available, their accessibility and pricing.
  International and domestic mail streams are critical to the importation and/or distribution  
of illicit drugs purchased online, with Europe a key source region.
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INTRODUCTION
Increasingly, as with many legitimate activities, criminal activities are committed with the 
assistance of technology either via the online environment or through advances in technological 
capabilities. The online environment has enabled crime to be committed remotely and with 
relative anonymity—characteristics that are attractive to serious and organised crime groups and 
other motivated individuals, making the identification and prosecution of offenders more difficult.
The Australian illicit drug market is best seen as a component of the global market. The internet 
has facilitated the expansion of the global drug market, with users able to access drugs, 
information about availability and purity of new drugs, and manufacturing manuals online.  
Virtual marketplaces are used to sell and traffic various commodities, including illicit drugs and 
precursor chemicals. The development of these online marketplaces is important as they have 
created new opportunities for illicit drug trafficking globally and present unique risks for end  
users and unique challenges for law enforcement.
Over the last decade, the establishment of internet-based markets that connect buyers and sellers 
of illicit commodities has been an important development in global illicit drug markets. These 
online markets include both surface websites, often referred to as the ‘clearnet’, which reflect 
the publicly accessible internet and includes social media platforms and networking applications 
or ‘apps’ (including Facebook, WhatsApp, Twitter) and dark websites, often referred to as the 
‘darknet’, which is not accessible through standard browsers. The latter are typically encrypted 
and unindexed websites and communications that are accessed using specific software and may 
utilise cryptocurrencies to facilitate financial transactions. 
INTERNATIONAL TRENDS
The size and global footprint of online illicit drug markets is exceedingly difficult to assess. 
Contributing to this is the relatively transient nature of darknet markets. However, there are 
indications that online drug markets are becoming more common. 
The United Nations Office on Drugs and Crime assessed that among a cohort of internet users 
who use illicit drugs, the proportion who reported purchasing drugs via the darknet more than 
doubled, from 5 per cent in 2014 to 11 per cent in 2019 (UNODC 2019).
Darknet markets offer a variety of goods and services. According to the European Monitoring 
Centre for Drugs and Drug Addiction, in 2017 it was estimated that 62 per cent of the offers  
on darknet markets were drug-related. Of these, approximately 77 per cent were illicit drugs,  
18 per cent were drug-related chemicals and 5 per cent were pharmaceuticals. New psychoactive 
substances (NPS) are less commonly sold on darknet markets and tend to represent a small 
proportion of trade (EMCDDA 2017).
Several studies of online marketplaces for illicit drugs suggest that these markets are expanding 
and largely mirror the types of illicit drugs bought and sold offline. For example, in an analysis of 
63 cryptomarkets5 over the period February 2014 to January 2020, the National Drug and Alcohol 
Research Centre noted the following trends: 
 
 
5 Defined as ‘anonymous online trading platforms that facilitate the purchasing of illicit goods and services via multiple sellers’.
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  The number of drug listings (the total number of substances advertised for sale across the 
analysed markets) increased, from 11,308 across four markets to 41,880 across five markets.
  Over the period, cannabis accounted for the majority (29 per cent) of drug listings across all 
analysed markets, followed by MDMA (15 per cent), cocaine (9 per cent), benzodiazepines  
(8 per cent), NPS (7 per cent) and methyl/amphetamine (6 per cent).
  The greatest increases in the number of drug listings were reported for cannabis and  
MDMA. Cannabis listings increased from 2,970 in February 2014 to 14,965 in January 2020, 
with MDMA listings increasing from 1,605 in February 2014 to 7,887 in January 2020  
(Mathur et al. 2020).
There does however remain some uncertainty in characterising online markets given that the 
number of illicit drugs available does not equate to what is sold. For example, while cannabis 
may be prevalent in drug listings, this may not mean that other illicit drugs are not bought and 
sold in similar quantities. Some studies suggest that cannabis, MDMA, amphetamines, cocaine, 
pharmaceutical opioids and performance and image enhancing drugs are equally available on 
darknet markets (Broadhurst et al. 2020; ADF 2018; Place 2018).
Several characteristics of online markets may explain their attractiveness to both sellers and 
buyers of illicit drugs. Available price data suggest that illicit drugs may be cheaper to purchase 
online than in-person. Other aspects may include the ability to avoid physical interactions 
with local dealers, the perceived anonymity and convenience in purchasing and the variety 
of substances available. There is also a perception of increased and consistent purity of drugs 
purchased online and the perceived certainty of receiving the substances, given assurances 
provided by the sellers (Décary-Hétu & Giommoni 2016; Rhumorbarbe et al. 2016). 
DOMESTIC TRENDS
It is almost certain that a significant proportion of online purchases rely on the mail stream 
for delivery. As such, border detections and domestic seizures of illicit drugs trafficked using 
international and local mail streams may provide an indication of the extent of drug supply  
which occurs using online markets and networks.
While the detection of illicit drugs in the mail stream does not directly correlate with online 
purchases, border detection data may provide some insight into the scale of online drug 
purchasing in Australia, although this would require further analysis. The international mail stream 
has consistently accounted for the greatest proportion of the number of border detections for 
key illicit drug types for over a decade, while the importation stream accounting for the greatest 
proportion of the weight detected varies across drug types and reporting periods. Over the 
last decade, border detection data for most drugs indicate an increase in the proportion of the 
number of detections in the international mail stream, while the weight detected decreased. The 
exceptions are a decrease in the proportion of the number of ATS (excluding MDMA) detections 
from 2009–10 to 2018–19 and an increase in the weight of cocaine detected (see table below).
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Trends in the proportion of border detections via the international mail stream, by drug type, 
2009–10 to 2018–19  
ATS 
(excluding 
MDMA)
MDMA Cannabis Heroin Cocaine
Proportion by number     
Proportion by weight     
The proportion of detections identified in the international mail stream varies across drug types 
and reporting periods. For example, by number, heroin reported the greatest increase in the 
proportion of international mail stream detections over the last decade, which almost doubled 
from 2009–10 to 2018–19. By weight, the proportion of international mail stream detections 
of ATS (excluding MDMA), MDMA, heroin and cannabis fluctuated greatly over the last decade, 
though overall the proportions decreased. The proportion of cocaine detections (by weight) in 
the international mail stream also fluctuated, though to a lesser extent, and overall remained 
relatively stable between 2009–10 and 2018–19 (see figures below).
Number of international mail detections at the Australian border, as a proportion of the total 
number of detections, by drug type, 2009–10 to 2018–19
Note: Silk Road, considered the first darknet market, was founded in February 2011.
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Weight of international mail detections at the Australian border, as a proportion of the total 
weight of detections, by drug type, 2009–10 to 2018–19
Note: Silk Road, considered the first darknet market, was founded in February 2011.
National law enforcement data on embarkation points of illicit drugs purchased online are limited. 
In 2018–19, the Northern Territory reported that for drugs identified as being linked to darknet 
markets, the majority were sourced internationally, primarily from Europe. 
DOMESTIC MARKET INDICATORS
Information on the domestic use of online markets is limited and in most cases does not include 
historical data. Examples of studies providing insights into the use of online markets in Australia  
to purchase illicit drugs include the Ecstasy and Related Drugs Reporting System (EDRS) and the 
Drug Use Monitoring in Australia (DUMA) program. 
The EDRS collects self-report information on drug use and related harms annually from individuals 
in Australian capital cities who regularly use ecstasy and other stimulants. According to this 
national study in 2019, 73 per cent of respondents arranged the purchase of illicit or non-
prescribed drugs via social networking applications in the past year, 10 per cent obtained drugs 
via the darknet and 5 per cent purchased drugs on the surface web. In the same year, 12 per cent 
of respondents reported purchasing drugs on the darknet at least once in their lifetime, while 
26 per cent reported having accessed the darknet but never purchased from it. Within the EDRS 
population, 12 per cent of respondents reported receiving illicit drugs via post in the last  
12 months (Peacock et al. 2019).
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The DUMA program collects criminal justice and drug use information from police detainees.  
In 2014, the DUMA program interviewed police detainees to examine their access to the internet 
and frequency of engagement in online activities, including illicit drug purchasing. Thirty one  
per cent of respondents reported that they sourced information about illicit drugs online, with  
five per cent of respondents reporting they purchased illicit drugs online. The drugs6 about  
which detainees most commonly reported accessing information were methylamphetamine  
(42 per cent), cannabis (27 per cent), MDMA (27 per cent), pharmaceuticals (20 per cent),  
heroin (14 per cent) and alcohol (7 per cent; Goldsmid & Patterson 2015). 
In 2018, the DUMA program interviewed police detainees to examine the use of mobile phones 
to buy and sell illicit drugs. Excluding those who had never used a mobile phone, 59 per cent of 
respondents had used mobile phones to buy, deliver or supply drugs. Of these, 53 per cent used 
messaging apps for buying or supplying drugs. Findings of this study again illustrate that not all 
drug dealing using technology involves encrypted communications and how technology may  
be used to facilitate drug transactions (Sullivan & Voce 2020).
PRICE
Analysis of available price data for illicit drugs suggests that online markets may offer lower  
prices than other sources of illicit drugs. 
National law enforcement data on darknet drug prices are limited. Victoria was the only 
jurisdiction to provide darknet prices by Australian vendors in 2018–19.7 Although prices vary 
among suppliers based on the drug’s ‘quality’ and market demand, in general drug prices on  
the darknet—particularly for methylamphetamine and MDMA—are reportedly cheaper than  
local street prices. In 2018–19, the quoted price for one gram of methylamphetamine on the 
darknet was $179 compared to a street price of $200 in Victoria and a national median street  
price of $385. The price for one gram of MDMA on the darknet was $79 compared to between 
$100 and $200 in Victoria and a national median street price of $200 in 2018–19. There was not  
as much variation in prices reported for one gram of heroin on the darknet ($390) and the 
Victorian and national median street price ($400). Similarly, the price for one gram of cocaine 
on the darknet ($330) was close to the Victorian (between $300 and $400) and national median 
street price ($350).
DOMESTIC ONLINE VENDORS
Information on the location of providers, substances offered, delivery methods and the purchase 
process is limited. The collection of these data rely on monitoring specific darknet marketplaces, 
sometimes in combination with forensic analysis, with some studies and jurisdictional cases 
suggesting Australia-based vendors may have a significant presence in online markets.
6 Detainees could nominate more than one substance.
7 The provided price was converted from Bitcoin to Australian dollars on 21 October 2019.
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In Australia, jurisdictional case studies identified several vendors selling a range of drugs using 
darknet markets. These included methylamphetamine, cocaine, MDMA, cannabis, psylocibin, 
LSD, fentanyl and benzodiazepines. For example, since 2015, the Western Australia Police 
Force has conducted over 500 online investigations into illicit drug-related matters linked to 
online purchasing—the majority of which related to surface web purchases. Based on these 
investigations, the Western Australia Police Force assesses that the buying or selling of illicit  
drugs (as opposed to precursor chemicals used in illicit drug manufacture) is more frequent on  
the surface web—predominantly on social media applications where anonymity is facilitated 
through temporary and closed groups.8  
Studies that used data from two (now closed) darknet markets (Evolution and Silk Road 2) from 
December 2013 to March 2015 to examine the nature and extent of activities on these markets,  
as well as their links to Australia and Switzerland, found that: 
  Of the 48,029 listings identified in Evolution market between January 2014 and March 2015, 
3,047 (6 per cent) were listed as shipping from Australia, the fifth most mentioned country 
after the United States, the United Kingdom, the Netherlands and Germany.
  Australia’s illicit drug trafficking on Evolution and Silk Road 2 was mainly domestic and only a 
small number of foreign vendors were able to ship to Australia. This is likely due to factors such 
as geographic isolation and the higher price range of illicit drugs when shipping to Australia. 
  ATS (particularly MDMA and methylamphetamine) and cannabis were the predominant illicit 
drugs sold on these virtual markets. Although ATS were the drugs most commonly offered by 
vendors, according to these studies cannabis was the substance most frequently purchased 
(Rhumorbarbe et al. 2016; Broseus et al. 2017 and Morelato 2018).
SEIZURES
The figures below are seizures from Operation Vitreus and Operation Parthenon, and seizures 
through the domestic mail system that are highly likely to be sourced online.
In 2018–199, 2,890 national seizures were linked to online purchases. Of these, 1,234 seizures  
(43 per cent) were cannabis, 741 seizures (26 per cent) were methylamphetamine, 410 seizures  
(14 per cent) were cocaine, 387 seizures (13 per cent) were MDMA and 118 seizures (4 per cent) 
were heroin. 
In 2018–19, 52,956 grams of illicit drugs seized nationally was linked to online purchases.  
Of this, 41,031 grams (77 per cent) was cannabis, 4,851 grams (9 per cent) was MDMA,  
4,704 grams (9 per cent) was cocaine, 2,118 grams (4 per cent) was methylamphetamine  
and 249 grams (<1 per cent) was heroin.
8 These closed groups are created and dissolved over time, moving clients from one group to another. The majority of these groups 
are invitation only and require admission via an established and credible online identity.
9 The number and weight of online market-related seizures were provided by ACT Policing, New South Wales Police Force, Northern 
Territory Police, Queensland Police Service and Western Australia Police Force and reflect seizures where a link to online markets 
was identified. 
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The National Forensic Rapid Laboratory (NFRL) is a multi-agency capability, coordinated by the 
Australian Federal Police, which targets high-frequency, low-volume importations typically through 
the mail stream. The NRFL aims to identify convergences in concealment methods, drug profiling, 
embarkation country and other relevant characteristics to assist investigations. Based on NFRL 
data collected from January 2014 to March 2015, up to 75 per cent of all seized mail items were 
suspected to contain substances purchased online. MDMA was the most seized illicit drug by the 
NFRL, followed by methylamphetamine, cocaine and NPS. Cannabis was rarely seized in parcel-post 
consignments (Morelato 2018).
LAW ENFORCEMENT ACTION
As a result of the increase in online sales and the use of postal services for illicit drug distribution, 
Australian law enforcement agencies have developed a range of responses to the threat posed  
by online markets. 
Several law enforcement operations targeting online markets have resulted in the identification  
and prosecution of providers and consumers using online markets to distribute and purchase 
drugs. Specific operations aiming to investigate and disrupt the related criminal activity include:
  Operation Vitreus―while not specifically focused on darknet activity, work completed as part  
of semi-regular weeks of action includes a national mail screening operation to detect and 
disrupt the flow of illicit drugs through the Australian postal service. By focussing on drug 
detections in the mail stream, it is possible to disrupt some movement of drugs sourced from 
darknet markets. Specific operations conducted as part of Operation Vitreus include Operation 
Detect in Queensland and Operations Outpost and Viridian in Victoria.
  Strike Force Royden (New South Wales Police Force)―to investigate an online darknet vendor.
  Joint Task Force Icarus (Victoria Police in partnership with the AFP, the Australian Border Force  
(ABF) and the Department of Home Affairs (DHA))―worked closely with Operation Vitreus to  
target illicit drug distribution through the domestic mail stream.
  Operation Salamanca (Victoria Police)―commenced in June 2018 to target vendors advertising  
on the darknet ‘Dream Market’. 
  Operation Parthenon (Northern Territory in partnership with the AFP, ABF, DHA and  
ACIC)―established to investigate the use of cryptocurrency and darknet markets to order  
illicit drugs from international suppliers.
  Joint Agency Ice Strike Team (led by South Australia Police)―a multi-agencytaskforce 
commencing in February 2019 targeting the importation and trafficking of methylamphetamine, 
its precursors and other high risk and emerging drugs into South Australia via air cargo, sea  
cargo and the domestic and international mail streams, and the identification of the 
international origins and supply chains of related significant domestic seizures.
Online drug markets are resilient and again highlight the need for a multi-dimensional approach 
that targets supply, demand and harm reduction. As it is a global issue, international collaboration  
is vital to disrupting and impacting these markets. This is best illustrated through the successful  
take downs of whole markets, such as AlphaBay and Hansa.
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In July 2017, the Federal Bureau of Investigation and several international law enforcement 
agencies collaborated to shut down AlphaBay, one of the largest darknet marketplaces that sold 
drugs and other contraband goods. Launched in 2014, AlphaBay operated as an online marketplace 
for drugs, data, computer programs, stolen passwords or user accounts, and other physical or  
digital goods and was reported to be ‘ten times the size of the Silk Road’, the first darknet black 
market that was taken down in October 2013.
Lessons learnt from the take down of Silk Road were applied to the take down of AlphaBay and 
Hansa, in particular the tendency of online users to switch almost immediately from one online 
market to another. In effect, the international collaboration meant that many AlphaBay users 
transitioned to Hansa, which was law enforcement controlled at the relevant time. This example 
demonstrates the scope of the issue and the necessity of close international collaboration to 
take down online marketplaces of this type. Law enforcement agencies worldwide benefit from 
such take downs through receipt of data on buyers and sellers, which may generate follow up 
investigations in Australia and elsewhere.
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ABBREVIATIONS
1,4-BD   1,4-butanediol
4-MMC  4-methylmethcathinone
AAS  Anabolic-androgenic steroids
ACIC  Australian Criminal Intelligence Commission
ACT  Australian Capital Territory
AFP  Australian Federal Police
ANSPS  Australian Needle and Syringe Program Survey
ASSAD                Australian Secondary Students Alcohol and Drug Survey
ATS  Amphetamine-type stimulants
CEN  Cannabis Expiation Notice
CIR  Cannabis Intervention Requirement
DIN  Drug Infringement Notice
DUMA  Drug Use Monitoring in Australia
EDRS  Ecstasy and Related Drugs Reporting System
ENIPID  Enhanced National Intelligence Picture on Illicit Drugs
Eph  Ephedrine
FDI  Forensic Drug Intelligence
GHB  Gamma-hydroxybutyrate
GBL  Gamma-butyrolactone
IDDR  Illicit Drug Data Report
IDRS  Illicit Drug Reporting System
INCB  International Narcotics Control Board
LSD  Lysergic acid diethylamide
MDMA  3,4-methylenedioxymethamphetamine
NEC  Not elsewhere classified
NMI  National Measurement Institute
NPS  New psychoactive substances
NSW  New South Wales
NT  Northern Territory
NWDMP             National Wastewater Drug Monitoring Program
P2P  Phenyl-2-propanone
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PIED  Performance and image enhancing drug
PSE  Pseudoephedrine
Qld  Queensland
SA  South Australia
SCON  Simple Cannabis Offence Notice
Tas  Tasmania
THC  Delta-9-tetrahydrocannabinol
UK  United Kingdom
UNODC  United Nations Office on Drugs and Crime
US  United States
Vic  Victoria
WA  Western Australia
WCO  World Customs Organization
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  The weight of ATS seized globally continued to increase in 2017—primarily due to increases in the 
weight of global methylamphetamine seizures.
 – While the weight of global amphetamine seizures decreased and the weight of ecstasy seizures 
remained stable in 2017, the weight of methylamphetamine seizures increased.
 – Methylamphetamine accounted for the majority of global ATS seizures in 2017.
  Drug profiling data of analysed border and domestic seizures indicate that ephedrine and 
pseudoephedrine remain key methylamphetamine precursors, however the proportion of 
methylamphetamine seizures manufactured using P2P-based methods has increased in recent years.
  Several indicators of ATS supply and demand in Australia suggest that the markets for both 
methylamphetamine and MDMA are expanding:
 – While the number of ATS (excluding MDMA) detections at the Australian border decreased in  
2018–19, the weight detected increased and is the highest weight on record.
 – Both the number and weight of MDMA detections at the Australian border increased in 2018–19, 
with the weight detected the highest reported in the last decade.
 – Data from the National Wastewater Drug Monitoring Program indicate that the population-
weighted average consumption of methylamphetamine in capital city and regional sites, and  
MDMA consumption in regional sites, increased from August 2018 to August 2019.
AMPHETAMINE- 
TYPE STIMULANTS
KEY POINTS 
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MAIN FORMS
Amphetamine-type stimulants (ATS) are a group of central nervous system stimulants, which  
include amphetamine, methylamphetamine and 3,4-methylenedioxymethamphetamine (MDMA).
  Owing to differences in chemical composition, methylamphetamine is more potent than 
amphetamine, resulting in a stronger nervous system reaction.
  Methylamphetamine has four common forms: tablet, crystalline (often referred to as ‘ice’  
and considered the most potent form of the drug), base (also referred to as ‘paste’) and powder  
(also referred to as ‘speed’). Methylamphetamine can be swallowed, snorted, smoked or injected.
  MDMA is a derivative of amphetamine, but has an important difference in chemical structure  
which provides MDMA’s hallucinogenic (in addition to stimulant) properties.
  Amphetamine is most commonly found in powder and tablet form, which can be swallowed,  
snorted, smoked or (less commonly) injected.
  MDMA (also referred to as ‘ecstasy’), is most commonly found in tablet form of varying colours  
and sizes, often imprinted with a picture or symbol. MDMA is also found in capsule, powder and 
crystal form. While MDMA is most commonly ingested, it can also be snorted, inhaled and injected 
(ADF 2019a; ADF 2019b; EMCDDA 2015; Degenhardt & Hall 2010).
INTERNATIONAL TRENDS
According to the 2019 United Nations Office on Drugs and Crime (UNODC) World Drug Report, the 
total weight of ATS seized globally has continued to increase over the last two decades—primarily 
due to increases in methylamphetamine seizures. Between 2016 and 2017, the total weight of global 
methylamphetamine seizures increased 16 per cent, from 158 tonnes to 184 tonnes. Over the same 
period the weight of amphetamine seizures decreased approximately 18 per cent, from 70 tonnes to  
58 tonnes, while seizures of ecstasy remained stable at approximately 14 tonnes (UNODC 2019). 
Similar to most years since 1998, the majority of ATS seizures in 2017 were methylamphetamine,  
seized predominantly in North America, particularly the United States (US) and in East and  
South-East Asia, particularly China. The UNODC has also noted a 40 per cent increase in 
methylamphetamine seizures in tablet and crystal form being seized annually in East and South-East  
Asia (UNODC 2018; UNODC 2019). 
Europe continued to account for the greatest proportion of global ecstasy seizures in 2017. The weight 
of ecstasy seized in Europe increased from 2.2 tonnes in 2013 to 6.4 tonnes in 2017. The UNODC reports 
that increasing quantities of ecstasy have also been seized in Asia—particularly in East and South-East 
Asia—between 2013 and 2017. The weight of ecstasy seized in Asia increased from 0.6 tonnes in 2013  
to 2.9 tonnes in 2017, with East and South-East Asia accounting for 96 per cent of ecstasy seizures in Asia 
over that period. Approximately 9 million ecstasy tablets were seized in East and South-East Asia in 2017, 
compared to approximately 3 million ecstasy tablets seized annually in East and South-East Asia between 
2014 and 2016 (UNODC 2019).
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According to the World Customs Organisation (WCO), the number and weight of methylamphetamine 
and amphetamine seizures reported by WCO agencies increased in 2018. Methylamphetamine was the 
most frequently seized substance within the ‘psychotropic substance’ category, followed by MDMA. 
The number and weight of MDMA seizures reported by WCO agencies continued to decrease in 2018, 
with the weight of MDMA seized decreasing by 847.3 kilograms in 2018. MDMA was the only substance 
within the ‘psychotropic substances’ category to record a decrease in the weight seized in 2018. Specific 
data for the number and weight of methylamphetamine, amphetamine and MDMA seized in 2018 were 
not available (WCO 2019). 
DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
Overall, the number of ATS (excluding MDMA) detections increased 201 per cent over the last decade, 
from 672 in 2009–10 to 2,022 in 2018–19, although since 2014–15 has steadily decreased. The number 
of detections decreased 18 per cent this reporting period, from 2,451 in 2017–18.
The weight of ATS (excluding MDMA) detections fluctuated greatly over the last decade, although  
there was an increase in the long-term trend—the weight increased 7,619 per cent from 66.7 kilograms 
in 2009–10 to 5,148.4 kilograms in 2018–19, the highest weight on record (see Figure 1). The weight 
detected this reporting period increased 74 per cent, from 2,952.5 kilograms in 2017–18.
In 2018–19, 277 of the 2,022 ATS (excluding MDMA) detections (14 per cent) weighed one kilogram  
or more. With a combined weight of 5,028.8 kilograms, these 277 detections accounted for 98 per cent 
of the weight of ATS (excluding MDMA) detected in 2018–19.10
FIGURE 1: Number and weight of ATS (excluding MDMA) detections at the Australian border,  
2009–10 to 2018–19 (Source: Department of Home Affairs)
The number of MDMA detections at the Australian border fluctuated over the last decade, but  
the long-term trend indicates an overall increase—increasing 7,026 per cent from 53 detections in  
2009–10 to 3,777 in 2018–19. The number of detections increased 7 per cent this reporting period, 
from 3,530 in 2017–18.
10 See Appendix 2 for significant border detections of ATS (excluding MDMA) in 2018–19.
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The weight of MDMA detections also fluctuated over the last decade, increasing 32,592 per cent  
from 6.5 kilograms in 2009–10 to 2,124.9 kilograms in 2018–19, the highest recorded weight in the  
last decade (see Figure 2). The weight detected increased 50 per cent this reporting period, from  
1,420.8 kilograms in 2017–18.
In 2018–19, 173 of the 3,777 MDMA detections (5 per cent) weighed one kilogram or more. With a 
combined weight of 1,988.3 kilograms, these 173 detections accounted for 94 per cent of the weight  
of MDMA detected in 2018–19.11
FIGURE 2: Number and weight of MDMA detections at the Australian border, 2009–10 to 2018–19 
(Source: Department of Home Affairs)
IMPORTATION METHODS
In 2018–19, detections of ATS (excluding MDMA) at the Australian border occurred in the air cargo,  
air passenger/crew, international mail and sea cargo streams. By number, the international mail stream 
accounted for the greatest proportion of ATS (excluding MDMA) detections (86 per cent), followed by 
air cargo (12 per cent), air passenger/crew (2 per cent) and sea cargo (<1 per cent). By weight, sea cargo 
accounted for the greatest proportion of detections (72 per cent), followed by air cargo (17 per cent), 
international mail (10 per cent) and air passenger/crew (1 per cent).
In 2018–19, detections of MDMA at the Australian border occurred in the air cargo, air passenger/crew, 
international mail and sea cargo streams. By number, the international mail stream accounted for the 
greatest proportion of MDMA detections (98 per cent), followed by air cargo (2 per cent), air passenger/
crew (<1 per cent) and sea cargo (<1 per cent). By weight, the air cargo stream accounted for the greatest 
proportion of detections (48 per cent), followed by international mail (28 per cent), sea cargo (24 per cent) 
and air passenger/crew (<1 per cent). 
11 See Appendix 2 for significant border detections of MDMA in 2018–19.
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EMBARKATION POINTS
In 2018–19, 63 countries were identified as embarkation points for ATS (excluding MDMA) detected  
at the Australian border, compared with 50 countries in 2017–18. By weight, Thailand was the primary 
embarkation point for ATS (excluding MDMA) detected in 2018–19. Other key embarkation points by 
weight this reporting period include Mexico, the US, Singapore, Canada, Malaysia, Laos, Germany, India 
and China (including Hong Kong).
In 2018–19, 33 countries were identified as embarkation points for MDMA detected at the Australian 
border, compared with 32 countries in 2017–18. By weight, Germany was the primary embarkation  
point for MDMA detected in 2018–19. Other key embarkation points by weight this reporting period 
include Turkey, the Netherlands, the United Kingdom, Belgium, France, Austria, Spain, Italy and Poland.
DRUG PROFILING
METHYLAMPHETAMINE
The Australian Federal Police (AFP) Forensic Drug Intelligence (FDI) team operates a forensic drug 
profiling capability through the National Measurement Institute (NMI), which enables the identification 
of the synthetic route of synthesis for samples of methylamphetamine submitted from seizures made 
at the Australian border12 and seizures provided to the AFP by international agencies for the purpose of 
chemical profiling.13 The capability also allows for comparisons within and between seizures to identify 
distinct batches of drugs, the origin of drugs, or to demonstrate links between groups involved in illicit 
drug manufacture or trafficking. The following data relate to seizures investigated by the AFP between 
2010 and June 2019 from which samples were submitted to the NMI for routine analysis and profiling.14
The proportion of methylamphetamine found to be manufactured from a P2P (1-phenyl-2-propanone) 
precursor increased this reporting period. The proportion of mixed/unclassified seizures also increased 
in 2018–19. This is largely due to seizures of methylamphetamine being found to have indications of 
more than one ‘type’ of methylamphetamine. These are split into their relevant sections by weight in 
Table 2, highlighting that the unclassified seizures make up a small proportion of the total weight.
  In 2018, 103 seizures of methylamphetamine were sent to NMI for analysis. A total of 78 seizures, 
representing a bulk weight of 3.2 tonnes, were found to be suitable for profiling. The remaining 
seizures (totalling 28.4 kilograms) were unsuitable for profiling.
  In 2018, the top four seizures by weight accounted for 79 per cent of the total weight of 
methylamphetamine seized (see Table 2).
  In 2018, a 993.6 kilogram seizure of methylamphetamine was found to be manufactured  
from a P2P precursor.
  In the first six months of 2019 there were 39 seizures, totalling a record 4.3 tonnes of 
methylamphetamine.
12 This data may also include seizures destined for Australia which occurred offshore.
13 Data from this samples/seizures have not been included in this summary.
14 Profiling data relate to seizures investigated by the AFP between 2010 to June 2019, and from which samples were submitted to the 
National Measurement Institute (NMI) for routine analysis and profiling. For all reporting years, the data represent a snapshot across 
the applicable reporting period. These figures cannot reflect seizures that have not been submitted for forensic examination due to 
prioritisation of law enforcement resources or those that have passed through the border undetected. Certain seizures/samples, such as 
those containing swabs or trace material, have been omitted from the analysis as they are not amenable to chemical profiling. It is difficult 
to extrapolate the impact of any observed border trends on drugs reaching consumers i.e. street level seizures in Australia. Samples from 
selected state and territory jurisdictions are submitted for chemical profiling as part of the Enhanced National Intelligence Picture on Illicit 
Drugs (ENIPID) capability.
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  Similar to 2018, the top three seizures by weight in the first six months of 2019 accounted for  
90 per cent of the total methylamphetamine seized.
  Operation HOTH accounted for 1.7 tonnes of the methylamphetamine seized in 2019, which  
was found to be synthesised from a P2P precursor.
  It should be noted that single seizures involving a mixture of both P2P and Eph/PSE samples are  
listed under the “Mixed/Unclassified” category in Table 1. However, when classifying by weight, 
the bulk weight of these seizures is separated and attributed to the relevant precursor. As such, 
the “Mixed/Unclassified” category in Table 2 only includes the weight of samples that could not be 
attributed to either P2P or Eph/PSE. As the 2017 reporting period was the first year FDI employed  
this method of classification, no conclusions should be drawn from the notable decrease between  
the 2017 and 2016 figures observed in Table 2. 
TABLE 1: Synthetic route of manufacture of methylamphetamine samples as a proportion of analysed 
AFP border seizures classified by precursor, 2010–June 2019 (Source: Australian Federal Police, 
Forensic Drug Intelligence)15
Year
Synthetic Route
Eph/PSE % P2P % Mixed/Unclassified %
Jan–Jun 2019 34.2 42.9 22.9
2018 48.7 35.9 15.4
2017 52.6 36.9 10.5
2016 81.9 7.0 11.1
2015 77.0 18.6 4.4
2014 77.9 13.8 8.3
2013 66.9 23.2 9.9
2012 71.8 19.1 9.1
2011 56.8 13.6 29.6
2010 80.4 5.9 13.7
15 This data may also include seizures destined for Australia which occurred offshore.
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TABLE 2: Synthetic route of manufacture of methylamphetamine samples as a proportion  
of total bulk weight of analysed AFP border seizures classified by precursor, 2010–June 2019             
(Source: Australian Federal Police, Forensic Drug Intelligence)16
Year
Synthetic Route
Eph/PSE % P2P % Mixed/Unclassified %
Jan–Jun 2019 51.1 48.8 0.1
2018 a 33.5 66.4 0.1
2017 70.2 28.4 1.4
2016 63.4 1.7 34.9
2015 65.7 29.4 4.9
2014 48.0 5.5 46.5
2013 76.4 14.7 8.9
2012 72.2 27.8 –
2011 35.6 62.8 1.6
2010 48.5 1.8 49.7
a. Due to a change in the sampling methodology for large illicit drug seizures made by the AFP, seizure weights cannot be accurately attributed 
for seizures with mixed profiling. The weight has been assigned to the most prevalent chemical profiling determination.
The Enhanced National Intelligence Picture on Illicit Drugs (ENIPID) project extends this profiling to 
include state and territory seizures involving heroin, methylamphetamine and cocaine. This enables the 
identification of convergences between supply routes into different jurisdictions, links between different 
criminal groups, as well as comparison of trends between jurisdictions.17 
  Samples submitted to the ENIPID capability in 2018 and the first six months of 2019 (see Tables 1  
and 2 of Appendix 3) show a comparable split between methylamphetamine manufactured from 
Eph/PSE and P2P. This is comparable to trends seen at the border over a similar period, highlighting 
the recent increase of methylamphetamine manufactured using P2P.
  The number of mixed/unclassified samples in this reporting period remained stable. It is likely these 
samples are a result of evolving routes of manufacture. 
MDMA
Due to changes in the Memorandum of Understanding between the NMI and the AFP, since November 
2016 MDMA is no longer routinely chemically profiled. Historical forensic profiling data for MDMA are 
available in previous Illicit Drug Data Reports.
16 This data may also include seizures destined for Australia which occurred offshore.
17 The Proceeds of Crime Act-funded ENIPID project officially concluded on 30 June 2016. Since then, the ENIPID capability has been 
integrated into core AFP FDI duties to ensure its continued delivery through AFP Forensics.
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DOMESTIC MARKET INDICATORS
No single dataset provides a comprehensive picture of illicit drugs, or the Australian illicit drug  
market. Each has benefits and limitations, and it is only through the layering of multiple data that  
we are able to enhance our understanding of the extent of the supply and demand trends in Australia’s 
illicit drug markets.
AMPHETAMINES
The National Wastewater Drug Monitoring Program (NWDMP) collects wastewater samples every  
two months in capital city sites and every four months in regional sites. Aimed at acquiring data on  
the population-scale use of substances causing potential harm, the program provides a measure of  
the consumption of 13 illicit and licit drugs. According to data from the NWDMP for August 2018 to 
August 2019:
  Of the substances monitored by the program with available dose data, methylamphetamine  
remains the most consumed illicit drug by a considerable margin.
  Methylamphetamine consumption was higher per capita in regional sites than capital city sites.
  The population-weighted average consumption of methylamphetamine in capital city sites increased.
  The population-weighted average consumption of methylamphetamine in regional sites increased.
  The ACIC estimates that around 11.5 tonnes of methylamphetamine was consumed annually in 
Australia, an increase from the estimated 9.8 tonnes of methylamphetamine consumed in the 
previous year (ACIC 2020).
The below data reflect drug use within sentinel groups. As such, they are not representative of all  
people who use drugs, or drug use in the general population. However, they provide valuable insight  
into patterns of drug use and market trends and can assist in the identification of emerging issues  
that require further monitoring.
The Illicit Drug Reporting System (IDRS) collects self-report information on drug use and related  
harms annually from individuals in Australian capital cities who regularly inject drugs. According to  
this national study:
  The proportion of respondents reporting methylamphetamine as their drug of choice increased  
over the last decade, from 16 per cent in 2010 to 33 per cent in 2019. In 2018 this proportion was  
35 per cent.
  While heroin remains the reported drug of choice within this user group, over the last decade the 
proportion of respondents reporting methylamphetamine as the drug most injected in the past 
month increased, from 19 per cent in 2010 to 42 per cent in 2019. In 2018 this figure was 44 per cent.
  Over the last decade the proportion of respondents reporting weekly or more frequent crystal 
methylamphetamine use increased, from 11 per cent in 2010 to 48 per cent in 2019. Crystal 
methylamphetamine was reported as the second most used drug within this user group after 
cannabis for the second consecutive year.
  The proportion of respondents reporting the recent use18 of any form of methylamphetamine 
increased over the last decade, from 60 per cent in 2010 to 78 per cent in 2019. In 2018 this 
proportion was 77 per cent. Crystal methylamphetamine is the most commonly reported form  
of methylamphetamine used within this user group.
18 In both the IDRS and EDRS studies, recent use refers to reported use in the six months preceding interview.
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  Over the last decade the reported median number of days of use of any form of methylamphetamine 
in the six months preceding interview increased, from 14 days in 2010 to 48 days in 2018 and 2019 
(Stafford & Burns 2011; Peacock et al. 2019a).
The Ecstasy and Related Drugs Reporting System (EDRS) collects self-report information on drug use  
and related harms annually from individuals in Australian capital cities who regularly use ecstasy and  
other stimulants. According to this national study:
  The proportion of respondents reporting the recent use of any form of methylamphetamine  
decreased over the last decade, from 56 per cent in 2010 to 33 per cent in 2019. In 2018 this  
proportion was 32 per cent.
  Powder methylamphetamine remains the most commonly reported form of methylamphetamine  
used within this user group.
  The reported median number of days of use of any form of methylamphetamine in the six months 
preceding interview remained relatively stable over the last decade, increasing from 4 days in  
2010 to 5 days in 2019. In 2018 the reported number of days was 4 (Sindicich & Burns 2011;  
Peacock et al. 2019b).
The Australian Needle and Syringe Program Survey (ANSPS) collects self-report information and  
capillary blood samples19 annually to monitor blood borne viral infections and associated risk  
behaviour among individuals who inject drugs. According to the ANSPS National Data Report:
  The proportion of respondents reporting methylamphetamine as the drug last injected increased  
over the last decade, from 24 per cent in 2009 to 48 per cent in 2018. In 2017 this proportion was  
41 per cent.
  Between 1995 and 2014 heroin was the most commonly reported drug last injected; however  
since 2015, the proportion of respondents reporting methylamphetamine as the drug last injected  
has exceeded heroin (Iversen & Maher 2015; Heard et al. 2019).
The Drug Use Monitoring in Australia (DUMA) program collects criminal justice and drug use information 
on a quarterly basis from police detainees, comprising an interviewer-assisted self-report survey and the 
voluntary provision of a urine sample, which is tested to detect licit and illicit drug use.20 According to  
data from the DUMA program:
  Over the last decade the proportion of detainees testing positive21 to amphetamines22 and 
methylamphetamine increased, reaching record levels in 2018–19.
  The proportion of detainees testing positive to amphetamines increased over the last decade,  
from 15 per cent in 2009–10 to 57 per cent in 2018–19. In 2017–18 this proportion was 48 per cent.
  Of the detainees testing positive to amphetamines, the majority tested positive to methylamphetamine.
  The proportion of detainees testing positive to methylamphetamine increased over the last decade, 
from 13 per cent in 2009–10 to 56 per cent in 2018–19. In 2017–18 this proportion was 46 per cent.
  The self-reported recent use of methylamphetamine increased from 49 per cent in 2013–14 (the first 
period for which data are available) to 59 per cent in 2018–19. This proportion was 56 per cent in 
2017–18 (see Figure 3).
19  Individuals participating in the survey are invited to provide a blood sample for HIV and HCV antibody testing.
20  Detainees can participate in the survey without providing a urine sample. Cases with missing data are excluded from the relevant analysis.
21  Amphetamines and their metabolites can be detected in urine up to 2 to 4 days after administration. 
22  Amphetamines in the DUMA program include results for methylamphetamine, MDMA and other amphetamines. 
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FIGURE 3: National proportion of detainees testing positive for amphetamines/methylamphetamine 
compared with self-reported recent use, 2009–10 to 2018–1923 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
The Australian Secondary Students Alcohol and Drug (ASSAD) Survey collects self-report information  
on alcohol, tobacco, over-the-counter drugs and illicit substance use among Australian secondary school 
students (aged 12 to 17) and is conducted every three years. According to the 2017 ASSAD survey:
  2 per cent of respondents reported having used methylamphetamine at least once in their lifetime.
  1 per cent of respondents reported having used methylamphetamine in the past month.24
  ASSAD data collected between 1996 and 2017 indicates that amphetamine use among secondary  
school students was low and declining (Guerin & White 2018; Guerin & White 2019).
MDMA
According to data from the NWDMP from August 2018 to August 2019:
  MDMA consumption was higher per capita in regional sites than capital city sites.
  The population-weighted average consumption of MDMA in capital cities increased.
  The population-weighted average consumption of MDMA in regional sites increased.
  The ACIC estimates that around 2.2 tonnes of MDMA was consumed annually in Australia,  
an increase from the estimated 1.1 tonnes of MDMA consumed in the previous year (ACIC 2020).
23 From 2013–14, the self-report question changed from including ‘amphetamine/speed/methylamphetamine’ to ‘methylamphetamine/speed/ice’.
24 Due to changes in the ASSAD questionnaire (which previously focused on amphetamines), data specific to methylamphetamine are not available 
prior to 2017. Data for reported amphetamines use for both recent use and use in lifetime in 2014 were 1 per cent and 2 per cent respectively.
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According to the EDRS study:
  The proportion of respondents reporting ecstasy as their drug of choice decreased over the last 
decade, from 37 per cent in 2010 to 32 per cent in 2019. This proportion was 36 per cent in 2018.
  The proportion of respondents reporting the recent use of ecstasy pills decreased over the last 
decade, from 98 per cent in 2010 to 67 per cent in 2019. Over the same period the proportion 
reporting the recent use of powder ecstasy (from 17 per cent to 29 per cent), capsules (from  
47 per cent to 77 per cent) and crystal (from 28 per cent in 2013 to 63 per cent) increased. 
  For the first time since the study commenced in 2003, capsules were the most common form  
of ecstasy recently used in 2019.
  Over the last decade the reported median number of days of any ecstasy use in the six months 
preceding interview remained relatively stable at 12 days in 2010, 2018 and 2019 (Sindicich &  
Burns 2011; Peacock et al. 2019b).
According to data from the DUMA program:
  Over the last decade the proportion of detainees testing positive to MDMA remained low and 
relatively stable, increasing from 1 per cent in 2009–10 to 2 per cent in 2018–19. In 2017–18  
this proportion was less than 1 per cent.
  While the proportion of detainees self-reporting recent MDMA use fluctuated over the decade,  
it decreased from 19 per cent in 2009–10 to 12 per cent in 2018–19. This proportion was  
16 per cent in 2017–18 (see Figure 4).
FIGURE 4: National proportion of detainees testing positive for MDMA compared with                 
self-reported recent use, 2009–10 to 2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
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According to data from the 2017 ASSAD survey:
  The proportion of respondents reporting ecstasy use at least once in their lifetime increased,  
from 2 per cent in 2008 to 6 per cent in 2017.
  The proportion of respondents reporting ecstasy use at least once in the past month remained 
relatively stable, increasing from 1 per cent in 2008 to 2 per cent in 2017.
  Data collected between 1996 and 2017 indicate that most secondary school students surveyed  
had never used ecstasy, with lifetime use increasing with age (Guerin & White 2018; Guerin &  
White 2019).
CLANDESTINE LABORATORIES
The number of clandestine laboratories detected nationally decreased over the last decade, from  
694 in 2009–10 to 308 in 2018–19. Methylamphetamine remains the main drug produced in  
clandestine laboratories detected nationally over the last decade. 
The number of ATS (excluding MDMA) clandestine laboratory detections decreased 72 per cent over 
the last decade, from 585 in 2009–10 to 164 in 2018–19. The number of MDMA laboratory detections 
fluctuated over the last decade, decreasing from 17 in 2009–10 to 6 in 2018–19 (see Clandestine 
laboratories and precursors chapter).
PRICE
This section includes available price data for crystal methylamphetamine—the prevalent form of 
methylamphetamine available in Australia—and MDMA. Price data for amphetamine and  
non-crystal methylamphetamine are reported in the Statistics chapter. 
At the street level, methylamphetamine is measured as a street deal (0.1 grams) or in grams.  
According to price data provided by the jurisdictions:
  Nationally, the price for a street deal of crystal methylamphetamine remained relatively stable  
over the last decade, ranging between $50 and $200 in 2009–10 to between $20 and $200 in  
2018–19. In 2017–18 the price ranged from $20 to $100. The national median price for a street  
deal decreased over the last decade, from $82.50 in 2009–10 to $62.50 in 2018–19. In 2017–18  
the median price was $75. 
  Nationally, the price for 1 gram of crystal methylamphetamine decreased over the last decade, 
ranging between $300 and $1,000 in 2009–10 to between $140 and $800 in 2018–19. In 2017–18  
the price ranged from $150 to $1,000. The national median price for a gram almost halved over the 
last decade, from $750 in 2009–10 to $385 in 2018–19. In 2017–18 the median price was $350. 
  Nationally, the price for 1 kilogram of crystal methylamphetamine decreased over the last decade, 
ranging between $160,000 and $325,000 in 2009–10 to between $50,000 and $140,000 in 2018–19. 
In 2017–18 the price ranged from $75,000 to $300,000. 
At the street level, the price for MDMA is measured as individual tablets or in grams. According to  
price data provided by the jurisdictions:
  Nationally, the price for a single MDMA tablet/capsule remained relatively stable over the last 
decade, ranging between $10 and $50 in 2009–10 to between $9 and $50 in 2018–19. In 2017–18  
the price ranged from $15 to $45. The national median price for a single MDMA tablet/capsule 
decreased over the last decade from $29.50 in 2009–10 to $25 in 2018–19. In 2017–18 the median 
price was $27.50.
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  No price data were available for 1 gram of MDMA in 2009–10. Nationally, the price for 1 gram  
of MDMA ranged between $100 and $300 in 2017–18 to between $100 and $350 in 2018–19.  
The national median price for a gram of MDMA was $200 in 2017–18 and 2018–19.
  No price data were available for 1 kilogram of MDMA in 2009–10. New South Wales and  
Queensland were the only jurisdictions to report the price for 1 kilogram of MDMA in 2018–19,  
which ranged between $35,000 and $60,000, compared with a national price range of $37,000  
to $80,000 in 2017–18. 
PURITY
Since 2009–10, with the exception of the Australian Capital Territory, the annual median purity of 
analysed amphetamine25 samples remained low and relatively stable for most jurisdictions, ranging 
between less than 1 per cent and 78 per cent. In 2018–19, the annual median purity ranged from 
8 per cent in Victoria to 71 per cent in New South Wales. This reporting period New South Wales and 
Western Australia reported increases in the annual median purity of amphetamine, while Victoria and 
Queensland reported decreases (see Figure 5). 
FIGURE 5: Annual median purity of amphetamine samples, 2009–10 to 2018–19
Since 2009–10, the annual median purity of analysed methylamphetamine samples ranged between  
4 per cent and 83 per cent. The annual median purity increased over the last decade and since  
2012–13, has remained high and relatively stable. In 2018–19, the annual median purity ranged  
from 67 per cent in Tasmania to 83 per cent in Victoria. With the exception of South Australia which 
decreased, all states reported an increase in the annual median purity of methylamphetamine this 
reporting period (see Figure 6).
25 Amphetamine is a manufacturing by-product of some commonly used methods of methylamphetamine production. This can result in two 
separate purity figures for a single drug sample—one for methylamphetamine with considerable purity and another for amphetamine with 
low purity.
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FIGURE 6: Annual median purity of methylamphetamine samples, 2009–10 to 2018–19
Since 2009–10, the annual median purity of analysed phenethylamine26 samples ranged between 
2 per cent and 83 per cent. While fluctuating, the annual median purity of phenethylamine increased 
over the last decade, particularly in New South Wales. In 2018–19, the annual median purity ranged 
from 28 per cent in Queensland to 75 per cent in New South Wales. With the exception of South 
Australia which reported a decrease, all states reported an increase in annual median phenethylamine 
purity this reporting period (see Figure 7).
FIGURE 7: Annual median purity of phenethylamine samples, 2009–10 to 2018–19
26 Phenethylamines are synthetic drugs similar in composition to amphetamines. The most widely known phenethylamine  
is MDMA.
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AVAILABILITY
User surveys provide mixed results for the availability of methylamphetamine. The reported 
availability of crystal methylamphetamine remained relatively stable while the availability of powder 
methylamphetamine decreased. The same surveys indicate that the availability of ecstasy increased  
for all forms (powder, capsules and crystal) except pills.
In a 2019 national study of people who regularly inject drugs:
  The proportion of respondents reporting crystal methylamphetamine as ‘easy’ or ‘very easy’ to  
obtain increased, from 94 per cent in 2018 to 95 per cent in 2019. This is an increase from the  
75 per cent reported 2010. 
  The proportion of respondents reporting powder methylamphetamine as easy or very easy to  
obtain decreased, from 80 per cent in 2018 to 77 per cent in 2019. This figure is similar to the 
proportion reported in 2010 (79 per cent).
  The proportion of respondents reporting base methylamphetamine as easy or very easy to obtain 
decreased, from 69 per cent in 2018 to 67 per cent in 2019. This is a decrease from 81 per cent in 
2010 (Stafford & Burns 2011; Peacock at al. 2019a).
In a 2019 national study of people who regularly use ecstasy and other stimulants:
  The proportion of respondents reporting crystal methylamphetamine as easy or very easy to  
obtain remained stable at 94 per cent. This is an increase from the 78 per cent reported in 2010. 
  The proportion of respondents reporting powder methylamphetamine as easy or very easy to  
obtain increased, from 65 per cent in 2018 to 68 per cent in 2019. This is a decrease from the  
80 per cent reported in 2010.
  The proportion of respondents reporting ecstasy in powder, capsule or crystal form as easy or  
very easy to obtain increased from 2018 to 2019―from 68 per cent to 76 per cent for powder;  
from 85 per cent to 92 per cent for capsules; and from 74 per cent to 81 per cent for crystal. 
  The proportion of respondents reporting ecstasy pills as easy or very easy to obtain decreased,  
from 83 per cent in 2018 to 81 per cent in 2019 (Sindicich & Burns 2011; Peacock at al. 2019b).
SEIZURES 
The number of national ATS seizures increased 263 per cent over the last decade, from 10,543 in  
2009–10 to 38,250 in 2018–19. The number of national ATS seizures increased between 2009–10  
and 2015–16 and has since remained high and relatively stable. This reporting period the number  
of national ATS seizures increased 3 per cent, from 37,093 in 2017–18 to 38,250 in 2018–19. 
The weight of ATS seized nationally increased 1,206 per cent over the last decade from 671.7 kilograms 
in 2009–10 to 8,776.5 kilograms in 2018–19. This reporting period the weight of ATS seized nationally 
decreased 22 per cent, from 11,205.2 kilograms to 8,776.5 kilograms in 2018–19 (see Figure 8). 
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FIGURE 8: National ATS seizures, by number and weight, 2009–10 to 2018–19
Tasmania reported the greatest percentage increase in the number of ATS seizures in 2018–19, while 
Victoria reported the greatest percentage increase in the weight of ATS seized. This reporting period 
New South Wales accounted for the greatest proportion of both the number (36 per cent) and weight  
of ATS seized nationally (51 per cent; see Table 3).
TABLE 3: Number, weight and percentage change of national ATS seizures, 2017–18 and 2018–19 
 
   Number             Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 12,582 13,865 10.2 8,315,935 4,448,119 -46.5
Victoria 2,364 2,360 -0.2 254,642 2,109,855 728.6
Queenslandb 8,440 10,000 18.5 944,919 1,601,445 69.5
South Australia 912 1,007 10.4 31,513 242,411 669.2
Western Australiac 11,295 9,439 -16.4 1,642,992 351,458 -78.6
Tasmania 613 743 21.2 3,913 7,722 97.3
Northern Territory 444 442 -0.5 7,014 4,815 -31.4
Australian Capital Territory 443 394 -11.1 4,337 10,724 147.3
Total 37,093 38,250 3.1 11,205,265 8,776,549 -21.7
a. Includes seizures by state/territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset. 
As a result, caution should be exercised in comparing data from previous reporting periods.
Of the 263 per cent increase in the number of national ATS seizures over the last decade  
(from 10,543 in 2009–10 to 38,250 in 2018–19), the increase was most marked for amphetamines27 
(320 per cent), followed by MDMA (114 per cent) and other ATS (85 per cent).    
27 Amphetamines include amphetamine, methylamphetamine, dexamphetamine and amphetamines not elsewhere classified.
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Over the last decade amphetamines accounted for the greatest proportion of the number of national 
ATS seizures, increasing from 72 per cent in 2009–10 to 84 per cent in 2018–19. This was followed  
by MDMA seizures (27 per cent in 2009–10 to 16 per cent in 2018–19) and other ATS (1 per cent in  
2009–10 and <1 per cent in 2018–19). 
  This reporting period, the number of national amphetamines seizures increased 3 per cent,  
from 31,204 in 2017–18 to 32,021 in 2018–19. The number of national MDMA seizures increased  
7 per cent, from 5,719 in 2017–18 to 6,103 in 2018–19, while the number of other ATS seizures 
decreased 26 per cent, from 170 in 2017–18 to 126 in 2018–19. 
Of the 1,206 per cent increase in the weight of national ATS seizures over the last decade (from  
671.7 kilograms in 2009–10 to 8,776.5 kilograms in 2018–19), the weight of amphetamines seized 
increased 1,387 per cent, with the weight of MDMA seized increasing 1,244 per cent and the weight  
of other ATS increasing 982 per cent.
Over the last decade amphetamines accounted for the greatest proportion of the weight of ATS  
seized nationally, increasing from 44 per cent in 2009–10 to 50 per cent 2018–19, followed by other  
ATS (decreasing from 39 per cent in 2009–10 to 32 per cent in 2018–19) and MDMA (remaining  
relatively stable at 17 per cent in 2009–10 and 18 per cent in 2018–19). 
  The weight of amphetamines seized decreased 13 per cent this reporting period, from  
5,064.9 kilograms in 2017–18 to 4,418.0 kilograms in 2018–19. The weight of MDMA seized 
decreased 23 per cent this reporting period, from 2,033.0 kilograms in 2017–18 to 1,560.0 kilograms 
in 2018–19, with the weight of other ATS seized decreasing 32 per cent this reporting period, from 
4,107.2 kilograms in 2017–18 to 2,798.4 kilograms in 2018–19. 
The form of national ATS seizures (by number) changed markedly over the last decade, from a  
relatively equal number of seizures of all forms of ATS earlier in the decade to predominantly  
seizures of crystalline ATS from 2013–14 onwards. 
  The number of national seizures of ATS in crystalline form increased 1,045 per cent from 2009–10  
to 2018–19, with the weight seized increasing 3,100 per cent over the same period. 
Proportionally, in 2009–10, national ATS seizures in crystalline, powder, tablet and other forms  
were broadly similar (ranging between 22 and 29 per cent). In 2018–19, seizures in crystalline form 
accounted for 69 per cent of the number of national ATS seizures, followed by other28 (18 per cent), 
powder (10 per cent) and tablet (3 per cent). 
By weight, the form of national ATS seizures fluctuated over the last decade, though the proportion of 
national seizures in crystalline form increased from 19 per cent in 2009–10 to 47 per cent in 2018–19.
  Seizures in crystalline form accounted for the greatest proportion of the weight of ATS seized 
nationally in 2018–19 (47 per cent), followed by powder (41 per cent), other (11 per cent) and  
tablet (<1 per cent).
ARRESTS
The number of national ATS arrests increased 232 per cent over the last decade, from 13,982 in 2009–10 
to 46,437 in 2018–19—an increase of 4 per cent from the 44,887 arrests in 2017–18. Consumer arrests 
continue to account for the greatest proportion of arrests, accounting for 88 per cent of national ATS 
arrests in 2018–19 (see Figure 9).
28 In relation to ATS drug form, the category of ‘other’ reflects drug forms other than crystalline, powder or tablet and includes seizures  
for which the drug form was not known or inadequately described.
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Amphetamines continue to account for the greatest proportion of national ATS arrests, accounting for 
87 per cent in 2018–19, followed by MDMA (13 per cent) and other ATS (<1 per cent). The number of 
national amphetamines arrests increased 4 per cent this reporting period, from 39,065 in 2017–18 to 
40,487 in 2018–19. The number of MDMA arrests increased 3 per cent this reporting period, from  
5,739 in 2017–18 to 5,890 in 2018–19. The number of other ATS arrests decreased 28 per cent,  
from 83 in 2017–18 to 60 in 2018–19.
FIGURE 9: Number of national ATS arrests, 2009–10 to 2018–19
Tasmania reported the greatest percentage increase in the number of ATS arrests in 2018–19. This 
reporting period Queensland accounted for the greatest proportion of national ATS (28 per cent;  
see Table 4). 
TABLE 4: Number and percentage change of national ATS arrests, 2017–18 and 2018–19
                          Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 9,784 10,355 5.8
Victoria 10,153 10,598 4.4
Queensland 11,511 12,926 12.3
South Australia 5,852 4,390 -25.0
Western Australia 6,631 7,031 6.0
Tasmania 551 718 30.3
Northern Territory 217 270 24.4
Australian Capital Territory 188 149 -20.7
Total 44,887 46,437 3.5
a. The arrest data for each state and territory include Australian Federal Police data.
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NATIONAL IMPACT
The weight of global ATS seizures increased from 2016 to 2017, with methylamphetamine accounting 
for the greatest proportion of the weight of ATS seized. Over the same period, the weight of 
methylamphetamine seized globally increased, the weight of amphetamine seized decreased and 
the weight of ecstasy seized remained stable. The number and weight of methylamphetamine and 
amphetamine seized globally by WCO agencies increased in 2018, while number and weight of  
MDMA seized decreased.
Several indicators of ATS supply and demand in Australia suggest that the markets for both 
methylamphetamine and MDMA are expanding.
Indicators of demand for amphetamines include surveys of people who regularly use drugs, police  
detainees and wastewater analysis.
  Data from surveys of people who regularly inject drugs point to an increase in methylamphetamine 
use in 2019. While heroin remains the drug of choice within this population, weekly or more  
frequent methylamphetamine use in the past six months in 2019 was higher than heroin for the 
second consecutive year.
  According to a national study of people who regularly inject drugs and of people who regularly  
use ecstasy and other stimulants, the availability of crystal methylamphetamine increased in 2019.
  According to a national study of police detainees, both the proportion of detainees testing positive  
to amphetamines—the majority of which continues to be methylamphetamine—and the proportion 
of detainees self-reporting recent methylamphetamine use increased. 
  According to historical national studies of secondary students, amphetamine use among secondary 
school students is low and declining.
  The NWDMP identified that, of the substances monitored by the program with available dose data, 
methylamphetamine remains the most consumed illicit drug, with regional consumption exceeding 
capital city consumption. The population-weighted average consumption of methylamphetamine 
increased in both capital city and regional sites.
Indicators of ATS (excluding MDMA) supply include border detection, seizure, arrest, price, purity and 
clandestine laboratory data. Compared to 2017–18, in 2018–19:
  The number of ATS (excluding MDMA) detections at the Australian border decreased, while the 
weight detected increased to record levels.
  The number of national ATS seizures increased, while the weight of ATS seized nationally decreased.
  Amphetamines accounted for the greatest proportion of the number and weight of national ATS 
seizures in 2018–19.
  The number of national ATS arrests increased, with amphetamines accounting for the greatest 
proportion of national ATS arrests in 2018–19.
  The national median price for a street deal of crystal methylamphetamine decreased.
  The annual median purity of analysed amphetamine samples fluctuated, while the annual median 
purity of analysed methylamphetamine samples increased in all states except South Australia.
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  While methylamphetamine manufactured from ephedrine/pseudoephedrine (Eph/PSE) remains 
prominent in the Australian market, drug profiling data indicates the proportion of methylamphetamine 
manufactured using P2P has increased. The proportion of mixed/unclassified seizures has also 
increased, suggesting the use of new routes of methylamphetamine manufacture.
  Methylamphetamine remains the main drug produced in clandestine laboratories detected nationally.
Indicators of MDMA demand include surveys of people who regularly use drugs, police detainees and 
wastewater analysis.
  According to a national study of people who regularly use ecstasy and other stimulants, ecstasy  
remains the drug of choice within this user population, with the median days of use in the past six 
months remaining stable. For first time since the program began in 2003, recent use of capsules 
overtook recent use of ecstasy pills.
  The same survey reported that the availability of ecstasy increased for all forms of the drug  
(powder, capsules and crystal) except pills.
  According to a national study of police detainees, the proportion of detainees testing positive  
to MDMA increased, while the proportion of detainees self-reporting MDMA use decreased.
  According to a national study of secondary students, the majority of secondary students surveyed  
had never used ecstasy, with use increasing with age. 
  The NWDMP indicates that average MDMA consumption is higher in regional sites than capital  
city sites. The population-weighted average consumption of MDMA decreased in capital city sites  
and increased in regional sites over the life of the program.
Indicators of MDMA supply include border detections, seizure, arrest, price, purity and clandestine 
laboratory data. Compared to 2017–18, in 2018–19:
  Both the number and weight of MDMA detections at the Australian border increased. The weight  
of MDMA detected in 2018–19 is the highest recorded in the last decade.
  The number of national MDMA seizures increased this reporting period, while the weight of  
MDMA seized nationally decreased.
  The number of national MDMA arrests decreased.
  The national median price for a single MDMA tablet/capsule decreased.
  The annual median purity of analysed phenethylamine samples—the majority of which related  
to MDMA—increased in all states except South Australia. 
  The number of MDMA laboratory detections decreased.
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  Cannabis continues to be one of the largest illicit drug markets globally and remained the most  
seized drug in the world in 2017.
 – There was a small increase in the weight of cannabis herb seized in 2017, counterbalanced  
by a decrease in the weight of cannabis resin seized.
  Indicators of cannabis demand and supply in Australia provide a mixed picture, but overall point  
to a large and relatively stable market.
 – While the number of cannabis detections at the border decreased this reporting period,  
the weight of cannabis detected at the Australian border increased in 2018–19 and is the  
highest weight recorded in the last decade.
 – The number and weight of national cannabis seizures and the number of national cannabis  
arrests all decreased in 2018–19, but remain high.
 – According to the National Wastewater Drug Monitoring Program, the population-weighted 
average consumption of cannabis decreased in both capital city and regional sites from  
August 2018 to August 2019.
KEY POINTS 
CANNABIS
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MAIN FORMS
Cannabis is derived from plants within the Cannabis genus, in particular the two species Cannabis  
sativa and Cannabis indica.
  Cannabis plants can grow in a range of climates, as well as indoors through the use of  
hydroponic cultivation.
  The primary cannabinoid and main psychoactive ingredient in cannabis is delta-9-
tetrahydrocannabinol, commonly known as THC, which is concentrated in the leaves and  
flowering head of the plant.
  The three main forms of cannabis are herb, resin and oil.
 – Herbal cannabis comprises the dried flowers and leaves of the plant, is usually smoked,  
and is the least potent form.
 – Cannabis resin (‘hashish’) is produced from the compressed resin glands of the cannabis plant.  
Resin can be smoked or added to food.
 – Cannabis oil, the most potent form of cannabis, is obtained from the resin and generally  
applied to cannabis herb or tobacco and smoked (CIS 2015).
INTERNATIONAL TRENDS
Cannabis continues to be the most commonly used illicit drug worldwide. While reported cannabis 
use stabilised in many countries with established cannabis markets, an increase in consumption was 
recorded for emerging markets in many countries in Asia and Africa. Available indicators point to an 
increase in both indoor and outdoor cannabis cultivation between 2013 and 2017. Based on the  
number of countries reporting cannabis cultivation or related law enforcement activity, the United 
Nations Office on Drugs and Crime (UNODC) assessed that while outdoor cannabis cultivation is 
estimated to be more widespread globally, the increase in indoor cannabis cultivation is estimated  
to be three times that of outdoor cannabis cultivation during the same period (UNODC 2019a).
Based on UNODC data, cannabis remains the most seized drug worldwide. The combined weight of 
cannabis resin and cannabis herb seized globally decreased 3 per cent, from 6,453 tonnes in 2016 to 
6,272 tonnes in 2017. The weight of cannabis resin seized globally decreased 31 per cent, from  
1,683 tonnes in 2016 to 1,161 tonnes in 2017—ending the upward trend in cannabis resin seizures  
over the period 2011–16. In contrast, the weight of cannabis herb seized globally increased 7 per cent, 
from 4,770 tonnes in 2016 to 5,111 tonnes in 2017. Forty-nine per cent of the combined weight of 
cannabis herb and resin seized globally in 2017 was in the Americas, followed by 18 per cent in Asia,  
17 per cent in Africa, 15 per cent in Europe and less than 1 per cent in Oceania. Data for the number  
of seizures for both cannabis resin and cannabis herb were not available (UNODC 2019a; UNODC 2019b; 
UNODC 2019c).
Similar to previous years, the Americas continued to account for the greatest proportion of the weight 
of cannabis herb seized globally in 2017 (60 per cent). In contrast to previous years where the largest 
proportion of cannabis herb was seized in North America, South America accounted for the greatest 
proportion seized in 2017 (38 per cent). The Near and Middle East/South-West Asian region, and 
Western and Central Europe accounted for the greatest proportion of the weight of cannabis resin  
seized in 2017 (UNODC 2019a).
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According to the World Customs Organization (WCO), the number of cannabis seizures and the weight 
of cannabis seized globally by WCO agencies continued to decrease in 2018. The number of cannabis 
seizures decreased 7 per cent to 10,521 in 2018 and the weight of cannabis seized decreased  
19 per cent to 683,002.6 kilograms in 2018. Similar to 2017, herbal cannabis accounted for the greatest 
proportion of the number and weight of cannabis seized. In contrast, the number of cannabis resin 
seizures and the weight of cannabis resin seized continued to increase. Compared to 2017, the number 
of cannabis resin seizures increased by 20 per cent in 2018 and the weight of cannabis resin seized 
increased by 25 per cent (WCO 2019).
DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of cannabis detections at the Australian border increased 666 per cent over the last  
decade, from 1,454 in 2009–10 to 11,133 in 2018–19. The number of cannabis detections decreased  
36 per cent this reporting period from 17,383 in 2017–18.
The weight of cannabis detected increased 9,144 per cent over the last decade, from 19.6 kilograms in 
2009–10 to 1,811.7 kilograms in 2018–19, the highest weight recorded in the last decade. The weight  
of cannabis detected increased 212 per cent this reporting period from 580.2 kilograms in 2017–18  
(see Figure 10).
The 2018–19 cannabis detections included a single detection of 1,500 kilograms (see Appendix 2).  
In 2018–19, 32 of the 11,133 cannabis detections (<1 per cent) weighed one kilogram or more. With 
a combined weight of 1,618.7 kilograms, these 32 detections account for 89 per cent of the weight of 
cannabis detected in 2018–19.29
FIGURE 10: Number and weight of cannabis detections at the Australian border 2009–10 to 2018–19 
(Source: Department of Home Affairs)
29 See Appendix 2 for significant border detections of cannabis in 2018–19.
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IMPORTATION METHODS
In 2018–19, detections of cannabis at the Australian border occurred in the air cargo, air passenger/ 
crew, international mail and sea cargo streams. By number, the international mail stream accounted  
for the greatest proportion of cannabis detections (97 per cent), followed by air cargo (2 per cent),  
air passenger/crew (1 per cent) and sea cargo (<1 per cent). By weight, sea cargo accounted for the 
greatest proportion of detections (83 per cent), followed by international mail (11 per cent), air cargo  
(6 per cent) and air passenger/crew (<1 per cent).
EMBARKATION POINTS
In 2018–19, 49 countries were identified as embarkation points for cannabis detected at the Australian 
border, compared to 50 countries in 2017–18. By weight, the United States continued to be the primary 
embarkation point for cannabis detected in 2018–19. Other key embarkation points by weight this 
reporting period include Spain, the United Kingdom, China (including Hong Kong), France, Laos,  
Canada, the Netherlands, Taiwan and the Philippines.
DOMESTIC MARKET INDICATORS
No single dataset provides a comprehensive picture of illicit drugs, or the Australian illicit drug  
market. Each has benefits and limitations, and it is only through the layering of multiple data that we  
are able to enhance our understanding of the extent of the supply and demand trends in Australia’s  
illicit drug markets.
The National Wastewater Drug Monitoring Program (NWDMP) collects wastewater samples every  
two months in capital city sites and every four months in regional sites. Aimed at acquiring data on  
the population-scale use of substances causing potential harm, the program provides a measure of  
the consumption of 13 illicit and licit drugs. The NWDMP began measuring cannabis consumption in 
August 2018. According to data from the NWDMP for August 2018 to August 2019:
  Cannabis consumption was higher per capita in regional sites than capital city sites.
  The population-weighted average consumption of cannabis in capital city sites decreased.
  The population-weighted average consumption of cannabis in regional sites decreased 
(ACIC 2020).
The below data reflect drug use within sentinel groups. As such, they are not representative of all  
people who use drugs, or drug use in the general population. However, they provide valuable insight  
into patterns of drug use and market trends and can assist in the identification of emerging issues  
that require further monitoring.
The Illicit Drug Reporting System (IDRS) collects self-report information on drug use and related  
harms annually from individuals in Australian capital cities who regularly inject drugs. According to  
this national study:
  Over the last decade, the proportion of respondents reporting cannabis as their drug of choice 
remained relatively stable at 8 per cent as reported in 2010 and 2019. In 2018 this proportion  
was 7 per cent.
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  The proportion of respondents reporting the recent use30 of any form of cannabis remained relatively 
stable over the last decade, decreasing from 75 per cent in 2010 to 74 per cent in 2019. In 2018 this 
proportion was 73 per cent.
  The reported median number of days of cannabis use in the six months preceding interview 
decreased over the last decade, from 180 days in 2010 to 130 days in 2019. In 2018 the median 
number of days was 100 (Stafford & Burns 2011; Peacock et al. 2019a).
The Ecstasy and Related Drugs Reporting System (EDRS) collects self-report information on drug use  
and related harms annually from individuals in Australian capital cities who regularly use ecstasy and 
other stimulants. According to this national study:
  The proportion of respondents reporting cannabis as their drug of choice increased over the last 
decade, from 16 per cent in 2010 to 26 per cent in 2019. This proportion remained unchanged  
from 2018.
  The proportion of respondents reporting the recent use of cannabis increased over the last  
decade, from 80 per cent in 2010 to 85 per cent in 2019. In 2018 this proportion was 90 per cent.
  The reported median number of days of cannabis use in the six months preceding interview  
increased over the last decade, from 24 days in 2010 to 60 days in 2019. In 2018 the median  
number of days was 48 (Sindicich & Burns 2011; Peacock et al. 2019b).
The Drug Use Monitoring in Australia (DUMA) program collects criminal justice and drug use  
information on a quarterly basis from police detainees, comprising an interviewer-assisted self-report 
survey and the voluntary provision of a urine sample, which is tested to detect licit and illicit drug use.31 
According to DUMA program data:
  Over the last decade the proportion of detainees testing positive to cannabis and self-reporting 
cannabis use have remained relatively stable.
  The proportion of detainees testing positive to cannabis over the last decade ranged from a low  
of 43 per cent in 2014–15 to a high of 49 per cent in 2012–13 and 2018–19. In 2017–18 this 
proportion was 46 per cent.
  The self-reported recent use32 of cannabis among detainees over the last decade ranged from  
55 per cent in 2009–10 to 59 per cent in 2016–17 and 2018–19. In 2017–18, this proportion was  
57 per cent (see Figure 11).
30 In both the IDRS and EDRS studies, recent use refers to reported use in the six months preceding interview.
31 Detainees can participate in the survey without providing a urine sample. Cases with missing data are excluded from the relevant analysis.
32 Recent use in the DUMA program refers to self-reported use in the 12 months prior to arrest.
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FIGURE 11: National proportion of detainees testing positive for cannabis compared with  
self-reported recent use, 2009–10 to 2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
The Australian Secondary Students Alcohol and Drug (ASSAD) Survey collects self-report information  
on alcohol, tobacco, over-the-counter drugs and illicit substance use among Australian secondary  
school students (aged 12 to 17) and is conducted every three years. According to the 2017 ASSAD 
survey:
  The proportion of respondents reporting cannabis use at least once in their lifetime increased  
over the last decade, from 14 per cent in 2008 to 17 per cent in 2017. In 2014 this proportion  
was 16 per cent.
  The proportion of respondents reporting having used cannabis at least once in the past month  
also increased over the last decade, from 6 per cent in 2008 to 8 per cent in 2017. In 2014 this 
proportion was 7 per cent.
  Data collected between 1996 and 2017 indicates that cannabis is the most commonly used illicit 
substance among secondary students, with prevalence and frequency of use increasing in older 
students (Guerin & White 2018; Guerin & White 2019).
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CLANDESTINE LABORATORIES
The number of detections of cannabis oil extraction laboratories remained relatively stable this  
reporting period, increasing from 17 in 2017–18 to 18 in 2018–19. South Australia accounted for 
the majority of detections (12), followed by Victoria (5) and New South Wales (1) (see Clandestine 
Laboratories and Precursors chapter).
PRICE
At the street level, the price of cannabis is generally measured as a ‘deal’ (approximately 1 gram). 
Nationally, the price for 1 gram of hydroponic cannabis head remained relatively stable over the last 
decade, ranging between $20 and $100 in 2009–10 to between $10 and $100 in 2018–19. In 2017–18 
the reported price ranged from $20 to $50. The national median price for 1 gram of hydroponic  
cannabis head also remained relatively stable over the last decade ($25 in 2009–10 and $23.70 in  
2018–19). In 2017–18 the national median price was $25.
Nationally, the price for 1 ounce (28 grams) of hydroponic cannabis head remained relatively stable  
over the last decade, ranging between $250 and $500 in 2009–10 to between $200 and $500 in 
2018–19. In 2017–18 the reported price ranged between $200 and $450. The national median price  
for 1 ounce of hydroponic cannabis head decreased over the last decade, from $350 in 2009–10 to  
$302.50 in 2018–19, an increase from $280 in 2017–18.
Nationally, the price for a single mature hydroponic cannabis plant remained relatively stable over  
the last decade, ranging between $2,000 and $5,000 in 2009–10 to between $3,000 and $5,000 in  
2018–19. In 2017–18 the reported price ranged between $2,000 and $5,000.
The price range for 1 gram of resin decreased over the last decade, from between $40 and $50 in  
2009–10 (reported in New South Wales and Queensland) to between $25 and $50 in 2018–19  
(reported in Queensland and Tasmania). The 2018–19 price remained unchanged from 2017–18.
AVAILABILITY
User surveys indicate that the availability of hydroponic cannabis remained relatively stable this 
reporting period, while the reported availability of bush cannabis33 increased.
In a 2019 national study of people who regularly inject drugs, the proportion of respondents reporting 
hydroponic cannabis as ‘easy’ or ‘very easy’ to obtain decreased, from 89 per cent in 2018 to 88 per  
cent in 2019. In the same study the proportion of respondents reporting bush cannabis as easy or very 
easy to obtain increased, from 77 per cent in 2018 to 78 per cent in 2019. While showing an overall 
decrease in availability over the last decade, these figures are similar to the proportions reported in  
2010 for hydroponic cannabis (92 per cent) and bush cannabis (79 per cent; Stafford & Burns 2011; 
Peacock et al. 2019a). 
33 Bush cannabis refers to cannabis grown outdoors.
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In a 2019 national study of people who regularly use ecstasy and other stimulants, the proportion of 
respondents reporting hydroponic cannabis as easy or very easy to obtain increased, from 84 per cent  
in 2018 to 90 per cent in 2019. In the same study the proportion of respondents reporting bush cannabis 
as easy or very easy to obtain increased, from 75 per cent in 2018 to 78 per cent in 2019. These figures 
are similar to the proportions reported in 2010, with small increases reported for the availability of 
hydroponic cannabis (87 per cent) and bush cannabis (73 per cent; Sindicich & Burns 2011; Peacock  
et al. 2019b).
SEIZURES
The number of national cannabis seizures increased 26 per cent over the last decade, from 44,736 in 
2009–10 to 56,491 in 2018–19. The number of national cannabis seizures decreased 5 per cent this 
reporting period from 59,139 in 2017–18.
The weight of cannabis seized nationally increased 29 per cent over the last decade, from  
5,989.8 kilograms in 2009–10 to 7,740.8 kilograms in 2018–19. The weight of cannabis seized nationally 
decreased 11 per cent this reporting period from 8,655.9 kilograms in 2017–18 (see Figure 12).
FIGURE 12: National cannabis seizures, by number and weight, 2009–10 to 2018–19
The Australian Capital Territory reported the greatest percentage increase in both the number and 
weight of cannabis seized in 2018–19. This reporting period New South Wales accounted for the greatest 
proportion of the number (31 per cent) of national cannabis seizures, while Victoria accounted for the 
greatest proportion of the weight of cannabis seized nationally (41 per cent; see Table 5).
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TABLE 5: Number, weight and percentage change of national cannabis seizures, 2017–18 and 2018–19
Number       Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 17,720 17,261 -2.6 2,373,144 2,197,338 -7.4
Victoria 3,312 3,524 6.4 1,434,393 3,184,656 122.0
Queenslandb 16,543 16,955 2.5 2,558,050 1,105,706 -56.8
South Australia 366 116 -68.3 506,229 223,684 -55.8
Western Australiac 16,771 14,240 -15.1 1,254,008 392,922 -68.7
Tasmania 1,897 1,799 -5.2 213,959 220,887 3.2
Northern Territory 1,922 1,941 1.0 163,708 71,331 -56.4
Australian Capital Territory 608 655 7.7 152,507 344,362 125.8
Total 59,139 56,491 -4.5 8,655,998 7,740,886 -10.6
a. Includes seizures by state/territory police and the Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset. 
As a result, caution should be exercised in comparing data from previous reporting periods.
ARRESTS
Overall, the number of national cannabis arrests increased 24 percent over the last decade, from  
57,170 in 2009–10 to 71,151 in 2018–19, although since 2015–16 the number of arrests decreased.  
The number of national cannabis arrests decreased 2 per cent this reporting period from 72,381 in 
2017–18. Consumer arrests continue to account for the greatest proportion of arrests, accounting  
for 91 per cent of national cannabis arrests in 2018–19 (see Figure 13).
FIGURE 13: Number of national cannabis arrests, 2009–10 to 2018–19
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The Northern Territory reported the greatest percentage increase in cannabis arrests in 2018–19. 
Queensland accounted for the greatest proportion of national cannabis arrests this reporting period  
(31 per cent; see Table 6).
TABLE 6: Number and percentage change of national cannabis arrests, 2017–18 and 2018–19
                                                      Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 16,679 16,224 -2.7
Victoria 9,675 10,485 8.4
Queensland 21,126 21,780 3.1
South Australia 1,672 1,141 -31.8
South Australia (CENs) b 8,961 8,093 -9.7
Western Australia 9,342 8,917 -4.5
Western Australia (CIRs)c 1,763 1,546 -12.3
Tasmania 1,591 1,435 -9.8
Northern Territory 507 555 9.5
Northern Territory (DINs)d 675 732 8.4
Australian Capital Territory 338 188 -44.4
Australian Capital Territory (SCONs)e 52 55 5.8
Total 72,381 71,151 -1.7
a. The arrest data for each state and territory include Australian Federal Police data.
b. Cannabis Expiation Notices.
c. Cannabis Intervention Requirements.
d. Drug Infringement Notices.
e. Simple Cannabis Offence Notices.
NATIONAL IMPACT
Cannabis continues to be the most commonly used illicit drug worldwide, with increases in consumption 
reported in many countries in Asia and Africa between 2016 and 2017. While there was a small decrease 
in the weight of cannabis seized worldwide in 2017, it remains the most seized drug globally, with 
cannabis herb continuing to account for the greatest proportion of the weight of cannabis seized. The 
number of cannabis seizures and the weight of cannabis seized globally by WCO agencies continued to 
decrease in 2018, with herbal cannabis continuing to account for the greatest proportion of both the 
number and weight of cannabis seized.
Indicators of cannabis demand and supply in Australia provide a mixed picture, but overall point to a 
large, relatively stable market.
Indicators of cannabis demand include surveys of people who regularly use drugs, police detainees  
and wastewater analysis.
58Australian Criminal Intellegence Commission Illicit Drug Data Report 2018–19
CA
N
N
A
BIS
CA
N
N
A
BIS
  According to a national study of people who regularly inject drugs, both the reported recent use of 
cannabis and median days of use increased from 2018 to 2019.
  According to a national study of people who regularly use ecstasy and other stimulants, the reported 
recent use of cannabis decreased from 2018 to 2019, while the median days of use increased.
  According to a national study of police detainees, both the proportion of detainees testing positive 
for cannabis and self-reported cannabis use increased in 2018–19.
  According to a national study of secondary students, cannabis was the most commonly reported  
drug used by secondary school students in 2017, with the prevalence and frequency of use increasing 
in older students.
  The NWDMP indicates that cannabis consumption was higher per capita in regional sites than capital 
city sites. When comparing data for August 2018 to August 2019, the population-weighted average 
consumption of cannabis decreased in both capital city and regional sites.
Indicators of cannabis supply include border detection, seizure, arrest, price and clandestine laboratory 
data. Compared to 2017–18, in 2018–19:
  The number of cannabis detections at the Australian border decreased, while the weight detected 
increased to the highest weight recorded in the last decade (noting that a single detection accounted 
for 83 per cent of the weight detected in 2018–19).
  While the number and weight of national cannabis seizures and the number of national cannabis 
arrests decreased, they remain high.
  The national median price for 1 gram of hydroponic cannabis head decreased slightly.
  The number of detections of cannabis oil extraction laboratories remained relatively stable, 
increasing from 17 in 2017–18 to 18 in 2018–19.
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KEY POINTS 
HEROIN
  Global opium cultivation and heroin production decreased in 2018, with Afghanistan remaining  
the largest cultivator of illicit opium in the world.
 – Drug profiling of both border and domestic seizures indicates the vast majority of heroin  
seized in Australia originated in South-East Asia.
 – For the first time since 2013, forensic profiling in the first six months of 2019 identified  
heroin originating from South America, accounting for over 7 per cent of the bulk weight  
of analysed samples.
  The weight of opiates (including heroin and opium) seized globally reached record levels in 2017.
 – Opium accounted for the greatest proportion of the weight of opiates seized globally,  
while heroin accounted for the greatest proportion of global opiate border seizures.
  Overall, indicators of heroin supply and demand in Australia suggest the heroin market remains 
 small, but has experienced small growth in some areas.
 – The number of heroin detections at the Australian border decreased in 2018–19, while the  
weight detected increased.
 – While the weight of heroin seized nationally decreased this reporting period, the number  
of national heroin seizures increased in 2018–19 and is the second highest on record.
 – The number of national heroin and other opioid arrests increased in 2018–19 and is the  
second highest reported in the last decade.
 – According to the National Wastewater Drug Monitoring Program, the population-weighted 
average consumption of heroin increased in both capital city and regional sites from  
August 2018 to August 2019, however consumption is low relative to methylamphetamine.
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MAIN FORMS
Heroin (diacetylmorphine or diamorphine) is a derivative of morphine—an alkaloid contained  
in raw opium.
  Illicit cultivation of opium occurs on a large scale in three primary regions:
 – South-West Asia, known as the ‘Golden Crescent’, which encompasses large areas of  
Afghanistan and parts of Pakistan.
 – South-East Asia, known as the ‘Golden Triangle’, which encompasses the border regions  
of Myanmar, Thailand and Laos.
 – Latin America, primarily Mexico and Colombia.
  Of the four main ‘grades’ of heroin, grades 1 and 2 refer to heroin base, not commonly found  
in Australia. Grade 3 heroin is more refined than heroin base and less granular. Unsuitable for 
injection, it is most commonly heated and the vapours inhaled. Grade 4 powdered heroin is the  
most common grade used in developed countries. It is the purest form and is suitable for injection.
  In Australia, heroin is most commonly found either as a powder or a hard granular material,  
usually white or off-white in colour (though colour is not a reliable indicator of origin or purity).
  The most common route of administration for heroin is injection, followed by snorting,  
inhalation (through smoking), swallowing or as an additive to cannabis or tobacco (ADF 2019; 
EMCDDA 2017; UNODC 2016).
INTERNATIONAL TRENDS
The total area under opium cultivation worldwide decreased 17 per cent, from 418,000 hectares  
in 2017 to around 346,000 hectares in 2018. While global opium production decreased 25 per cent,  
from 10,500 tonnes in 2017 to 7,790 tonnes in 2018, it remains amongst the highest weights reported  
in the last two decades. Afghanistan remains the largest opium producing country in the world, 
accounting for 82 per cent of global illicit opium production in 2018. The decrease in global opium 
production in 2018 was primarily the result of decreases in Afghanistan34, where the area under  
opium poppy cultivation decreased by 20 per cent. Despite this decrease, the estimated area under 
cultivation in Afghanistan in 2018 is the second largest on record (UNODC 2018; UNODC 2019). 
Opium production in Myanmar also decreased in 2018 and is at its lowest reported level since  
2010—heroin originating from South East Asia, including Myanmar, dominates AFP border seizures.  
The area under opium cultivation in Myanmar has continued to decrease since 2014. The total area 
under opium cultivation decreased 11 per cent, from 37,300 hectares in 2018 to 33,100 hectares 
in 2019. Due to increases in average opium yield (11 per cent increase from 2018), the estimated 
production of opium in 2019 was 508 tonnes—a 2 per cent decrease from the 520 tonnes reported in 
2018. Estimated global heroin production decreased 25 per cent, from between 692 and 1,042 tonnes  
in 2017 to between 487 and 737 tonnes of heroin in 2018 (UNODC 2019; UNODC 2020).
34 A severe drought in Afghanistan impacted opium cultivation and production in 2018.
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According to the United Nations Office on Drugs and Crime (UNODC) 2019 World Drug Report, the 
weight of opiates (including heroin and opium) seized globally reached record levels in 2017. The  
weight of heroin seized globally increased 13 per cent, from 91 tonnes in 2016 to 103 tonnes in 2017, 
with the weight of opium seized globally increasing 5 per cent, from 658 tonnes in 2016 to 693 tonnes  
in 2017 (UNODC 2019).
The UNODC notes that most seizures of opiates occurred in, or close proximity to, the main opium 
production areas. In 2017, more than 90 per cent of global illicit opium production took place in Asia, 
which also accounted for 86 per cent of total weight of opiates (expressed in heroin equivalents) seized 
globally. Similar to 2016, in 2017 the Islamic Republic of Iran accounted for the greatest proportion of 
the weight of opiates seized globally (39 per cent), followed by Afghanistan (26 per cent) and Pakistan 
(14 per cent; UNODC 2018; UNODC 2019).
In 2017, the weight of heroin seized globally continued to increase in all regions except Oceania.  
Pakistan accounted for the greatest proportion of the weight of heroin seized globally in 2017  
(24 per cent), followed by the Islamic Republic of Iran (23 per cent) and Turkey (17 per cent;  
UNODC 2019).
According to the World Customs Organization (WCO), heroin continues to account for the greatest 
proportion of global opiate seizures at the border. Heroin was the only drug within the ‘opiates’  
category to report an increase in the number and weight of seizures in 2018, with other opiates 
reporting decreases. The number of heroin border seizures increased 12 per cent to 1,514 in 2018.  
While specific weights were not available, the weight of heroin seized increased 33 per cent in  
2018 (WCO 2019).
DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of heroin detections at the Australian border fluctuated greatly over the last decade, 
decreasing 26 per cent from 250 in 2009–10 to 184 in 2018–19 but the long-term trend was  
relatively stable. The number of heroin detections decreased 31 per cent this reporting period,  
from 265 in 2017–18.
The weight of heroin detected also fluctuated over the last decade, increasing 141 per cent from  
117.5 kilograms in 2009–10 to 283.4 kilograms in 2018–19. The weight of heroin detected increased  
49 per cent this reporting period, from 190.1 kilograms in 2017–18 (see Figure 14).
In 2018–19, 40 of the 184 heroin detections (22 per cent) weighed one kilogram or more. With a 
combined weight of 269.6 kilograms, these 40 detections accounted for 95 per cent of the weight  
of heroin detected in 2018–19.35
35 See Appendix 2 for significant border detections of heroin in 2018–19.
63 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
H
ERIO
N
H
ERO
IN
FIGURE 14: Number and weight of heroin detections at the Australian border, 2009–10 to 2018–19 
(Source: Department of Home Affairs)
IMPORTATION METHODS
In 2018–19, detections of heroin at the Australian border occurred in the air cargo, air passenger/crew, 
international mail and sea cargo streams. By number, the international mail stream accounted for the 
greatest proportion of heroin detections (81 per cent), followed by air cargo (17 per cent), air passenger/
crew (1 per cent) and sea cargo (1 per cent). By weight, the air cargo stream accounted for the greatest 
proportion of detections (68 per cent), followed by international mail (21 per cent), sea cargo (11 per cent) 
and air passenger/crew (<1 per cent).
EMBARKATION POINTS
In 2018–19, 21 countries were identified as embarkation points for heroin detected at the Australian 
border, compared to 24 countries in 2017–18. By weight, Malaysia was the primary embarkation point 
for heroin detected in 2018–19. Other key embarkation points by weight this reporting period include 
Thailand, Laos, Singapore, Iraq, South Africa, Pakistan, Mozambique, Indonesia and India.
DRUG PROFILING
The Australian Federal Police (AFP) Forensic Drug Intelligence (FDI) team operates a forensic drug profiling 
capability through the National Measurement Institute (NMI), which enables the identification of the 
regions of origin and manufacturing trends for samples of heroin submitted from seizures made at the 
Australian border36 and seizures provided to the AFP by international agencies for the purpose of chemical 
profiling.37 The capability also allows for comparisons within and between seizures to identify distinct 
batches of drugs, the origin of drugs, or to demonstrate links between groups involved in illicit drug 
manufacture or trafficking. 
36 This data may also include seizures destined for Australia which occurred offshore.
37 Data from these samples/seizures have not been included in these summary.
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The following data relate to seizures investigated by the AFP between 2009 and June 2019, from which 
samples were submitted to the NMI for routine analysis and profiling.38 
  Heroin originating from South-East Asia (SEA) continues to dominate AFP seizures (see Tables 7 and 8).
  For the first time since 2013, heroin originating from South America was seized during this reporting 
period (see Table 7). This seizure was made offshore (but destined for Australia) as part of Operation 
HOTH and accounted for 7 per cent of the total bulk weight analysed in the first six months of 2019.
  While there was an increase in the number of heroin seizures of South-West Asian (SWA) origin in  
the first six months of 2019, they were small seizures and accounted for less than one per cent of the 
total bulk weight for that period.
  Across the 2018 to June 2019 reporting period, there were a number of instances where geographical 
origin was unable to be determined. These are small seizures and account for less than one cent of  
the total bulk weight of samples analysed in that period.
TABLE 7: Geographical origin of heroin samples as a proportion of analysed AFP border seizures,  
2009–June 201939 (Source: Australian Federal Police, Forensic Drug Intelligence)
Year
South-East 
Asia 
%
South-West 
Asia 
%
South 
America 
%
Unclassified 
%
South-East Asia 
& Unclassified 
%
South-West Asia 
& Unclassified 
%
Jan–Jun 2019 73.3 13.3 6.7 6.7 – –
2018 92.3 – – 7.7 – –
2017 94.1 5.9 – – – –
2016 95.2 4.8 – – – –
2015 77.8 18.5 – 3.7 – –
2014 52.2 37.0 – 2.2 4.3 –
2013 74.6 18.2 5.5 – 1.8 –
2012 70.7 25.9 – 3.4 – –
2011 49.0 51.0 – – – –
2010 63.8 27.5 – 5.8 – 2.9
2009 53.9 42.6 – 3.4 – –
38 Improvements in information technology have brought about changes to how the data is collated and presented, and for this reason, care 
should be taken in comparing figures before 2010 to more recent data. For all reporting years, the data represent a snapshot across the 
applicable reporting period. These figures cannot reflect seizures that have not been submitted for forensic examination due to prioritisation 
of law enforcement resources or those that have passed through the border undetected. Certain seizures/samples, such as those containing 
swabs or trace material, have been omitted from the analysis as they are not amenable to chemical profiling. It is difficult to extrapolate 
the impact of any observed border trends on drugs reaching consumers i.e. street level seizures in Australia. Samples from selected state 
and territory jurisdictions are submitted for chemical profiling as part of the Enhanced National Intelligence Picture on Illicit Drugs (ENIPID) 
capability.
39 This data may also include seizures destined for Australia which occurred offshore.
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TABLE 8: Geographical origin of heroin samples as a proportion of total bulk weight of analysed  
AFP border seizures, 2009–June 201940 (Source: Australian Federal Police, Forensic Drug Intelligence)
Year
South-East 
Asia 
%
South-West 
Asia 
%
South 
America 
%
Unclassified 
%
South-East Asia 
& Unclassified 
%
South-West Asia 
& Unclassified 
%
Jan–Jun 2019 92.5 0.3 7.1 <0.1 – –
2018 99.9 – – <0.1 – –
2017 99.9 0.1 – – – –
2016 100.0 – – – – –
2015 97.4 1.8 – 0.8 – –
2014 89.9 7.8 – <0.01 0.2 –
2013 84.3 8.9 4.3 – 2.5 –
2012 98.4 1.3 – 0.3 – –
2011 39.4 60.6 – – – –
2010 47.9 50.6 – 1.5 – –
2009 70.1 27.4 – 2.7 – –
The Enhanced National Intelligence Picture on Illicit Drugs (ENIPID) capability extends forensic profiling 
to include state and territory seizures involving heroin, methylamphetamine and cocaine. This enables 
the identification of convergences between supply routes into different jurisdictions, links between 
different criminal groups, as well as comparison of trends between jurisdictions.41
Heroin samples submitted to the ENIPID capability in 2018 and the first six months of 2019 continue  
to reflect the situation at the border, highlighting the continued dominance of SEA heroin in the 
Australian market (see Appendix 3, Tables 3 and 4).42
  When compared to the AFP border data, an increase in the “Mixed/Unclassified” samples for the 
2018 period was noted, however this remained consistent with trends observed in the ENIPID  
data reported in previous years.
  A slight increase in SWA heroin was observed when compared to AFP border data for the 2018 
reporting period; however, when compared to 2017, there is a notable decrease in heroin ENIPID 
samples of SWA origin. 
40 This data may also include seizures destined for Australia which occurred offshore.
41 The Proceeds of Crime Act-funded ENIPID project officially concluded on 30 June 2016. Since then, the ENIPID capability has been 
integrated into core AFP Forensic Drug Intelligence duties to ensure its continued delivery through AFP Forensics.
42 Care should be taken when drawing any conclusions from this data due to the low number of heroin samples profiled during this period.
66Australian Criminal Intellegence Commission Illicit Drug Data Report 2018–19
H
ERIO
N
H
ERO
IN
DOMESTIC MARKET INDICATORS
No single dataset provides a comprehensive picture of illicit drugs, or the Australian illicit drug  
market. Each has benefits and limitations, and it is only through the layering of multiple data that  
we are able to enhance our understanding of the extent of the supply and demand trends in  
Australia’s illicit drug markets.
The National Wastewater Drug Monitoring Program (NWDMP) collects wastewater samples every  
two months in capital city sites and every four months in regional sites. Aimed at acquiring data on  
the population-scale use of substances causing potential harm, the program provides a measure of  
the consumption of 13 illicit and licit drugs, including heroin from August 2017. According to data  
from the NWDMP for August 2018 to August 2019:
  Heroin consumption fluctuated, but overall was higher per capita in capital city sites than  
regional sites.
  The population-weighted average consumption of heroin in both capital city and regional  
sites increased.
  Demand for heroin remains low compared to other illicit drugs, particularly methylamphetamine.
  The ACIC estimates that around 940 kilograms of heroin was consumed annually in Australia, an 
increase from the estimated 750 kilograms of heroin consumed in the previous year (ACIC 2020).
The below data reflect drug use within sentinel groups. As such, they are not representative of all  
people who use drugs, or drug use in the general population. However, they provide valuable insight  
into patterns of drug use and market trends and can assist in the identification of emerging issues  
that require further monitoring.
The Illicit Drug Reporting System (IDRS) collects self-report information on drug use and related  
harms annually from individuals in Australian capital cities who regularly inject drugs. According to  
this national study:
  The proportion of respondents reporting heroin as their drug of choice decreased over the last 
decade, from 54 per cent in 2010 to 45 per cent in 2019. In 2018 this proportion was 41 per cent.
  While heroin remains the most commonly reported drug of choice within this population, in  
2019 methylamphetamine was reported as the drug injected most often in the past month  
(42 per cent for methylamphetamine compared to 40 per cent for heroin).
  The reported recent use43 of heroin in this population decreased over the last decade, from  
64 per cent in 2010 to 54 per cent in 2018. In 2019 this proportion was 55 per cent, the first  
increase in recent use reported in the last decade.
  Over the last decade the reported median number of days of heroin use in the six months  
preceding interview increased, ranging from 60 days in 2013 to 90 days in 2015 and 2019, 
respectively. In 2018, the reported number of days was 74 (Stafford & Burns 2011; Peacock  
et al. 2019a).
43 In both the IDRS and EDRS studies, recent use refers to reported use in the six months preceding interview.
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The Ecstasy and Related Drugs Reporting System (EDRS) collects self-report information on drug  
use and related harms annually from individuals in Australian capital cities who regularly use ecstasy  
and other stimulants. According to this national study:
  The proportion of respondents reporting the recent use of heroin remained relatively stable  
over the last decade, with 4 per cent of this population reporting the recent use of heroin in  
2010, compared to 3 per cent reported in both 2018 and 2019 (Sindicich & Burns 2011;  
Peacock et al. 2019a).
The Australian Needle and Syringe Program Survey (ANSPS) collects self-report information and  
capillary blood samples44 annually to monitor blood borne viral infections and associated risk  
behaviour among individuals who inject drugs. According to the ANSPS National Data Reports:
  Methylamphetamine was the most commonly reported drug last injected since 2014. Notably,  
earlier in the decade heroin was the most commonly reported drug last injected (in 2009 heroin  
was 34 per cent and methylamphetamine was 24 per cent).
  The proportion of respondents reporting heroin as the drug last injected varied across the states  
and territories, but nationally decreased over the last decade, ranging from 34 per cent in 2009 to  
26 per cent in 2018. The proportion reported in 2018 is a decrease from the 30 per cent reported  
in 2017 (Iversen & Maher 2015; Heard et al. 2019).
The Drug Use Monitoring in Australia (DUMA) program collects criminal justice and drug use  
information on a quarterly basis from police detainees, comprising an interviewer-assisted self-report 
survey and the voluntary provision of a urine sample, which is tested to detect licit and illicit drug use.45 
According to DUMA program data:
  Over the last decade the proportion of detainees testing positive to heroin and self-reporting  
heroin use generally decreased.
  The proportion of detainees testing positive46 to heroin over the last decade ranged from a low  
of 5 per cent in 2018–19 to a high of 11 per cent in 2009–10 and 2010–11. In 2017–18 this  
proportion was 6 per cent. 
  The proportion of detainees self-reporting recent heroin use47 over the last decade ranged  
from 11 per cent in both 2014–15 and 2017–18 to 14 per cent in 2009–10, 2010–11 and  
2011–12. In 2018–19 this proportion was 13 per cent (see Figure 15).
44 Individuals participating in the survey are invited to provide a blood sample for HIV and HCV antibody testing.
45 Detainees can participate in the survey without providing a urine sample. Cases with missing data are excluded from the relevant analysis.
46 Heroin and its metabolite can be detected in urine for six hours after administration.
47 Recent use in the DUMA program refers to self-reported use in the 12 months prior to arrest.
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FIGURE 15: National proportion of detainees testing positive for heroin compared with self-reported 
recent use, 2009–10 to 2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
The Australian Secondary Students Alcohol and Drug (ASSAD) Survey collects self-report information  
on alcohol, tobacco, over-the-counter drugs and illicit substance use among Australian secondary  
school students (aged 12 to 17) and is conducted every three years. According to the 2017 ASSAD 
survey:
  1 per cent of respondents reported heroin use at least once in their lifetime.
  1 per cent of respondents reported having used heroin at least once in the past month  
(Guerin & White 2018).48
PRICE
At the street level the price of heroin is generally measured as a ‘taste/cap’ or in grams. Nationally,  
the price for one taste/cap of heroin (0.1 to 0.3 grams) increased over the last decade, ranging between 
$40 and $100 in 2009–10 to between $30 and $150 in 2018–19 (noting there is a large overlap in price 
ranges). The price range reported in 2018–19 remained unchanged from 2017–18. The national median 
price also increased over the last decade, from $52.50 in 2009–10 to $75 in 2018–19, a decrease from 
$90 in 2017–18.
48 Due to changes in the ASSAD questionnaire between 2014 and 2017, data specific to heroin consumption are not available for previous 
reporting periods, which previously focused on opiates. Reported opiate use in 2014 was 1.5 per cent for lifetime use and 0.6 per cent for 
past month use.
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The price for one gram of heroin remained relatively stable over the last decade, ranging between $200  
and $600 in 2009–10 to between $200 and $700 in 2018–19. The price range reported in 2018–19 
remained unchanged from 2017–18. The national median price increased slightly over the last decade,  
from $375 in 2009–10 to $400 in 2018–19.
No price data were available for a kilogram of heroin in 2009–10. This reporting period New South Wales 
and Victoria were the only jurisdictions to report a price for one kilogram of heroin, which ranged  
between $90,000 and $170,000, compared with a price range of $160,000 to $195,000 (reported by  
New South Wales and Victoria) in 2017–18.
PURITY
Since 2009–10, the annual median purity of analysed heroin samples ranged between 13 per cent and  
76 per cent (see Figure 16) across the states and territories. In 2018–19, the annual median purity ranged 
from 22 per cent in South Australia to 76 per cent in New South Wales. While annual median heroin purity 
generally trended upwards over the last decade, this was most marked in New South Wales. Heroin purity 
in Victoria, which is Australia’s primary heroin market, was low and relatively stable.
FIGURE 16: Annual median purity of heroin samples, 2009–10 to 2018–19
AVAILABILITY
User surveys indicate no change in the reported availability of heroin in 2019 compared to 2018. In a 2019 
survey of people who regularly inject drugs, the proportion of respondents reporting heroin as ‘easy’ or 
‘very easy’ to obtain remained unchanged at 89 per cent. This figure is similar to the proportion reported  
in 2010 (86 per cent; Stafford & Burns 2011; Peacock et al. 2019a).
SEIZURES
The number of national heroin seizures increased 32 per cent over the last decade, from 1,582 in  
2009–10 to 2,080 in 2018–19. The number of national heroin seizures remained high and relatively stable 
over the last four reporting periods, increasing 5 per cent this reporting period from 1,977 in 2017–18,  
with the 2,080 seizures in 2018–19 the second highest number on record.
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The weight of heroin seized nationally increased 165 per cent over the last decade, from 74.7 kilograms 
in 2009–10 to 197.7 kilograms in 2018–19. The weight seized nationally remained relatively stable over 
the last four reporting periods, decreasing 14 per cent this reporting period from 229.3 kilograms in 
2017–18 (see Figure 17).
FIGURE 17: National heroin seizures, by number and weight, 2009–10 to 2018–19
Tasmania reported the greatest percentage increase in the number of heroin seizures in 2018–19,  
while South Australia reported the greatest percentage increase in the weight of heroin seized.  
This reporting period New South Wales accounted for the greatest proportion of both the number  
(56 per cent) and weight (44 per cent) of heroin seized nationally (see Table 9).
TABLE 9: Number, weight and percentage change of national heroin seizures, 2017–18 and 2018–19
State/Territorya
Number Weight (grams)
2017–18 2018–19 % Change 2017–18 2018–19 % Change
New South Wales 1,015 1,170 15.3 160,692 86,633 -46.1
Victoria 329 310 -5.8 46,252 56,915 23.1
Queenslandb 186 198 6.5 20,205 25,026 23.9
South Australia 22 20 -9.1 569 15,408 2,607.9
Western Australiac 372 334 -10.2 1,432 13,656d 853.6
Tasmania 9 13 44.4 114 99 -13.2
Northern Territory 2 2 0.0 1 7 600.0
Australian Capital Territory 42 33 -21.4 41 53 29.3
Total 1,977 2,080 5.2 229,306 197,797 -13.7
a. Includes seizures by state/territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
d. The majority of the weight of heroin seized in Western Australia in 2018–19 relates to a single seizure.
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ARRESTS
The number of national heroin and other opioid arrests increased 13 per cent over the last decade,  
from 2,767 in 2009–10 to 3,129 in 2018–19. The number of arrests remained relatively stable for the  
last four reporting periods, increasing 3 per cent this reporting period from 3,029 in 2017–18, with the 
3,129 arrests in 2018–19 the second highest number reported in the last decade. Consumer arrests 
continue to account for the greatest proportion of arrests, accounting for 84 per cent of national  
heroin and other opioid arrests in 2018–19 (see Figure 18).
FIGURE 18: Number of national heroin and other opioid arrests, 2009–10 to 2018–19
Victoria reported the greatest percentage increase in the number of heroin and other opioid arrests in 
2018–19. This reporting period Victoria accounted for the greatest proportion of national heroin and 
other opioid arrests (47 per cent; see Table 10).
TABLE 10: Number and percentage change of national heroin and other opioid arrests, 2017–18 and 
2018–19
State/Territorya
Arrests
2017–18 2018–19 % change
New South Wales 887 907 2.3
Victoria 1,359 1,469 8.1
Queensland 325 330 1.5
South Australia 135 86 -36.3
Western Australia 265 285 7.5
Tasmania 32 33 3.1
Northern Territory 0 3 –
Australian Capital Territory 26 16 -38.5
Total 3,029 3,129 3.3 
a. The arrest data for each state and territory include Australian Federal Police data.
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NATIONAL IMPACT
In 2018, the total area under opium cultivation worldwide decreased 17 per cent and global opium 
production decreased 25 per cent—primarily due to declines in opium production in Afghanistan. 
Estimated global heroin production also decreased 25 per cent in 2018. The weight of heroin seized 
globally increased 13 per cent between 2016 and 2017, with Pakistan accounting for the greatest 
proportion of the weight of global seizures. The number and weight of heroin seized at the border  
by WCO agencies increased in 2018.
Indicators of heroin demand and supply in Australia provide a mixed picture. Overall, they suggest  
the heroin market remains small but has experienced small growth in some areas.
Indicators of heroin supply include surveys of drug users, police detainees and wastewater analysis.
  According to national study of regular injecting drug users in 2019, there was a notable increase  
in the reported median number of days of heroin use, with the reported recent use of heroin 
increasing for the first time in the last decade.
  According to the ANSPS, the proportion of respondents reporting heroin as the last drug  
injected decreased in 2018.
  According to a national study of police detainees, the proportion of detainees testing positive  
to heroin decreased in 2018–19, while self-reported heroin use increased.
  The NWDMP indicates that heroin consumption was higher per capita in capital city sites than 
regional sites. When comparing data for August 2018 and August 2019, the population-weighted 
average consumption of heroin increased in both capital city and regional sites.
Indicators of heroin demand include border detection, seizure, arrest, price and purity data.  
Compared to 2017–18, in 2018–19:
  The number of heroin detections at the Australian border decreased, while the weight  
detected increased.
  Forensic profiling indicates that South East Asia remains the predominant source of analysed  
heroin in Australia. Of note this reporting period is the identification of heroin originating  
from South America, which was last identified in 2013.
  The number of national heroin seizures increased to the second highest on record, while the  
weight of heroin seized nationally decreased.
  The number of national heroin and other opioids arrests increased.
  The national median price for one taste/cap of heroin decreased.
  The annual median purity of analysed heroin samples fluctuated.
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KEY POINTS 
COCAINE
  The total area under coca bush cultivation and the estimated weight of cocaine produced globally 
continued to increase in 2017, with the weight of cocaine seized worldwide in 2017 at record levels.
  Colombia produces the majority of the world’s cocaine and drug profiling of both border and 
domestic seizures indicates that the majority of cocaine seized in Australia originates in Colombia.
  Indicators of supply and demand point to a continued expansion of the cocaine market in Australia.
 – While the number of cocaine detections at the Australian border decreased in 2018–19, the 
weight detected increased and is the second highest on record.
 – There was a record number of national cocaine seizures and arrests in 2018–19. While the  
weight of cocaine seized nationally decreased this reporting period, it is the third highest  
weight on record.
 – According to the National Wastewater Drug Monitoring Program, the population-weighted 
average consumption of cocaine decreased in capital city sites and increased in regional sites  
from August 2018 to August 2019.
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MAIN FORMS
Cocaine (benzoylmethylecgonine) is a naturally occurring psychoactive alkaloid and stimulant found 
in specific varieties of the coca plant, in particular Erythroxylum coca (E. coca) and Erythroxylum 
novogranatense (E. novogranatense).
  E. coca and E. novogranatense are native to the Andes region of western South America.
 – E. coca is cultivated in the Plurinational State of Bolivia (Bolivia) and Peru.
 – E. novogranatense is cultivated in Colombia and Central America.
  The two most common forms of cocaine are hydrochloride salt and cocaine base.
 – Powdered hydrochloride is the most common form of cocaine available in Australia,  
which can be snorted, rubbed into the gums or dissolved in water and injected.
 – Cocaine base, often referred to as ‘crack’, has a rock crystal appearance and is readily  
converted into vapour with heat, making it suitable for inhalation. Crack cocaine is not  
commonly encountered in Australia (Baker et al. 2004; US DEA 1993).
INTERNATIONAL TRENDS
The total area under coca bush cultivation and the quantity of cocaine produced globally continued 
to increase, reaching record levels in 2017. The United Nations Office on Drugs and Crime (UNODC) 
estimates that the total global area under coca bush cultivation increased 15 per cent, from 213,000 
hectares in 2016 to 245,000 hectares in 2017. This contributed to a 25 per cent increase in the  
estimated weight of potential cocaine production worldwide, which, according to UNODC estimates, 
reached 1,976 tonnes (at 100 per cent purity) in 2017 (UNODC 2019a).
Similar to 2016, the three primary cocaine producing countries in 2017 were Colombia (which  
accounted for 70 per cent of global coca bush cultivation), Peru (20 per cent) and Bolivia (10 per cent). 
All three countries recorded increases in the area under coca bush cultivation in 2017. There was a 
31 per cent increase in the estimated quantity of cocaine manufactured in Colombia between 2016 
and 2017 (reaching 1,379 tonnes in 2017). While the total area of coca bush cultivation in Colombia 
increased between 2016 and 2017, the annual growth rate of the area under cultivation decreased  
from 52 per cent in 2016 to 17 per cent in 2017. Between 2017 and 2018 the area under coca  
cultivation in both Bolivia and Colombia decreased (by 6 per cent and 1 per cent respectively). 
Information from 2018 relating to the area under cultivation in Peru was unavailable at the time  
of publication (UNODC 2019a; UNODC 2019b; UNODC–SIMCI 2019).
Based on UNODC data, cocaine is the second most seized drug worldwide by weight. According to  
the 2019 World Drug Report, the weight of cocaine seized globally continued to increase in 2017.  
The weight of cocaine seized globally increased 13 per cent, from 1,129 tonnes in 2016 to a record  
1,275 tonnes in 2017, with increases in the weight of cocaine seized reported across all regions except 
Asia. Oceania (94 per cent) and Europe (53 per cent) reported considerable increases in the weight of 
cocaine seized in 2017 compared to 2016. Over the past decade, the weight of cocaine seized globally 
increased 74 per cent (UNODC 2018; UNODC 2019a).
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In 2017, global cocaine seizures remained concentrated in the Americas and Europe. The Americas 
accounted for the majority (90 per cent) of the weight of cocaine seized globally in 2017, of which 
Colombia accounted for 38 per cent. In Colombia, the weight of cocaine seized increased 20 per cent, 
from 362 tonnes in 2016 to 435 tonnes in 2017 (UNODC 2019a).
The number of cocaine seizures reported by World Customs Organization (WCO) agencies increased 
7 per cent, from 5,975 in 2017 to 8,236 in 2018. Powdered cocaine continued to account for the  
greatest proportion (96 per cent) of the number of global cocaine seizures in 2018, followed by coca 
leaves (2 per cent) and cocaine base (2 per cent). Compared to 2017 data, the total weight of cocaine 
seized globally in 2018 decreased 7 per cent to 191,751.8 kilograms (no data were available on the 
proportional weight of powdered cocaine, cocaine base and coca leaf seizures in 2018; WCO 2019).
DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of cocaine detections at the Australian border increased 826 per cent over the last  
decade, from 291 in 2009–10 to 2,695 in 2018–19. The number of cocaine detections decreased  
2 per cent this reporting period, from 2,741 in 2017–18.
The weight of cocaine detected fluctuated over the last decade, increasing 171 per cent from  
386.8 kilograms in 2009–10 to 1,049.6 kilograms in 2018–19, the second highest weight on record.  
The weight of cocaine detected increased 13 per cent this reporting period, from 926.5 kilograms  
in 2017–18.
In 2018–19, 89 of the 2,695 cocaine detections (3 per cent) weighed one kilogram or more. With a 
combined weight of 962.5 kilograms, these 89 detections account for 92 per cent of the weight of 
cocaine detected in 2018–19 (see Figure 19).49
FIGURE 19: Number and weight of cocaine detections at the Australian border, 2009–10 to 2018–19 
(Source: Department of Home Affairs)
49 See Appendix 2 for significant border detections of cocaine in 2018–19.
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IMPORTATION METHODS
In 2018–19, detections of cocaine at the Australian border occurred in the air cargo, air passenger/ 
crew, international mail and sea cargo streams. By number, the international mail stream accounted  
for the greatest proportion of cocaine detections (94 per cent), followed by air cargo (5 per cent),  
air passenger/crew (1 per cent) and sea cargo (<1 per cent). By weight, the sea cargo stream accounted  
for the greatest proportion of cocaine detections (72 per cent), followed by international mail  
(12 per cent), air cargo (12 per cent) and air passenger/crew (4 per cent).
EMBARKATION POINTS
Similar to 2017–18, 49 countries were identified as embarkation points for cocaine detected at  
the Australian border in 2018–19. By weight, South Africa remained the primary embarkation point  
for cocaine detected in 2018–19. Other key embarkation points by weight this reporting period  
include Mexico, the United States, Fiji, France, Canada, the Netherlands, Brazil, Belgium and the  
United Kingdom.
DRUG PROFILING
The Australian Federal Police (AFP) Forensic Drug Intelligence (FDI) team operates a forensic drug 
profiling capability through the National Measurement Institute (NMI), which is used to identify 
regions of origin and manufacturing trends for samples of cocaine submitted from seizures made at 
the Australian border50 and seizures provided to the AFP by international agencies for the purpose of 
chemical profiling. The capability also allows for comparisons within and between seizures to identify 
distinct batches of drugs, the origin of drugs, or to demonstrate links between groups involved in illicit 
drug manufacture or trafficking. The following data relate to seizures investigated by the AFP between 
2009 and June 2019, from which samples were submitted to the NMI for routine analysis and profiling.51
  Based on data from 2018 and the first six months of 2019, cocaine of Colombian origin continues  
to dominate the Australian market (see Tables 11 and 12).
  Though it decreased between 2017 and 2018, the proportion of samples comprising cocaine  
from more than one geographical location (mixed origin) increased in the first six months of 2019. 
These samples were predominantly of Colombian and unclassified origin.
  The proportion of cocaine samples with unclassified geographical origin continued to increase this 
reporting period—potentially as a result of cocaine manufacturing methodologies using coca leaf 
from more than one geographical region.
  For the third consecutive year, none of the cocaine samples analysed by the AFP between 2018 and 
June 2019 originated exclusively from Bolivia. However, 13 cocaine samples analysed between 2018 
and June 2019 returned chemical profiling results with a geographical origin of Peru or Bolivia and 
were attributed to the unclassified category.
50 These data may also include seizures destined for Australia which occurred offshore.
51 Profiling data relate to seizures investigated by the AFP between 2009 to June 2019, and from which samples were submitted to the 
NMI for routine analysis and profiling. Improvements in information technology have brought changes to how the data is collected and 
presented, and for this reason, care should be taken when comparing figures before 2010 to more recent data. For all reporting years, 
the data represents a snapshot across the applicable reporting period. These figures cannot reflect seizures that have not been submitted 
for forensic examination due to prioritisation of law enforcement resources or those that have passed through the border undetected. 
Certain seizures/samples, such as those containing swabs or trace material, have been omitted from the analysis as they are not amenable 
to chemical profiling. It is difficult to extrapolate the impact of any observed border trends on drugs reaching consumers i.e. street level 
seizures in Australia. Samples from selected state and territory jurisdictions are submitted for chemical profiling as part of the Enhanced 
National Intelligence Picture on Illicit Drugs (ENIPID) capability.
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TABLE 11: Geographical origin of coca leaf used to produce cocaine as a proportion of analysed  
AFP border seizures, 2009–June 201952 (Source: Australian Federal Police, Forensic Drug Intelligence)
Year Colombia % Peru % Bolivia % Mixed % Unclassified %
Jan–Jun 2019 65.0 2.5 – 15.0 17.5
2018 55.2 11.9 – 9.0 23.9
2017 59.6 11.9 – 13.8 14.7
2016 75.9 0.9 – 9.3 13.9
2015 53.6 13.1 2.4 5.9 25.0
2014 47.9 43.8 1.4 6.9 –
2013 64.1 28.2 – 5.1 2.6
2012 55.3 29.1 – 5.9 9.7
2011 55.9 35.3 – 5.9 2.9
2010 55.2 30.2 1.0 6.3 7.3
2009 44.9 32.7 2.0 10.2 10.2
TABLE 12: Geographical origin of coca leaf used to produce cocaine as a proportion of total bulk  
weight of analysed AFP border seizures, 2009–June 201953 (Source: Australian Federal Police,  
Forensic Drug Intelligence)
Year Colombia % Peru % Bolivia % Mixed % Unclassified %
Jan–Jun 2019a 69.6 2.2 – – 28.3
2018 56.0 13.3 – – 30.7
2017 63.6 3.6 – <0.1 32.8
2016 84.1 1.8 – – 14.1
2015 49.9 8.9 0.1 34.7 6.4
2014 67.2 31.8 0.9 0.1 –
2013 9.9 90.0 – – 0.1
2012 23.7 74.3 – 1.3 0.7
2011 51.3 44.2 – 4.4 0.1
2010 96.3 3.2 <0.1 – 0.4
2009 91.3 6.8 <0.1 – 1.9
a. Due to a change in sampling methodology for large illicit drug seizures made by the AFP, the geographical origin of seizures by weight cannot 
accurately be attributed for seizures with mixed profiling. The geographical origin of these seizures by weight has been assigned to the most 
prevalent chemical profiling determination.
52 These data may also include seizures destined for Australia which occurred offshore.
53 Ibid.
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The Enhanced National Intelligence Picture on Illicit Drugs (ENIPID) project extends this profiling to 
include state and territory seizures involving heroin, methylamphetamine and cocaine. This enables 
detection of convergences between supply routes into different jurisdictions, links between different 
criminal groups, as well as comparison of trends between jurisdictions.54
  ENIPID profiling data from 2018 and the first six months of 201955 show a considerable increase 
in mixed/unclassified cocaine samples, with a comparable split between Colombian and mixed/
unclassified samples in 2018 (see Appendix 3, Tables 5 and 6).
  Colombia remains the dominant source of cocaine in Australia.
  Cocaine samples of Peruvian origin have decreased and no cocaine samples submitted to the  
ENIPID project for this reporting period returned an exclusively Bolivian geographic origin.  
However, samples with a geographic origin of Peru or Bolivia were attributed to the mixed/
unclassified category.
DOMESTIC MARKET INDICATORS
No single dataset provides a comprehensive picture of illicit drugs or the Australian illicit drug  
market. Each has benefits and limitations, and it is only through the layering of multiple data that  
we are able to enhance our understanding of the extent of the supply and demand trends in  
Australia’s illicit drug markets.
The National Wastewater Drug Monitoring Program (NWDMP) collects wastewater samples every  
two months in capital city sites and every four months in regional sites. Aimed at acquiring data on  
the population-scale use of substances causing potential harm, the program provides a measure of  
the consumption of 13 illicit and licit drugs. According to data from the NWDMP for August 2018 to 
August 2019:
  Cocaine consumption was higher per capita in capital city sites than regional sites.
  The population-weighted average consumption of cocaine in capital city sites decreased.
  The population-weighted average consumption of cocaine in regional sites increased.
  The ACIC estimates that around 4.6 tonnes of cocaine was consumed annually in Australia, an 
increase from the estimated 4.1 tonnes of cocaine consumed in the previous year (ACIC 2020).
The below data reflect drug use within sentinel groups. As such, they are not representative of all  
people who use drugs, or drug use in the general population. However, they provide valuable insight  
into patterns of drug use and market trends and can assist in the identification of emerging issues  
that require further monitoring.
The Illicit Drug Reporting System (IDRS) collects self-report information on drug use and related  
harms annually from individuals in Australian capital cities who regularly inject drugs. According  
to this national study:
  The proportion of respondents reporting cocaine as their drug of choice remained relatively stable 
over the last decade, decreasing from 3 per cent in 2010 to 2 per cent in 2019. This proportion 
remained unchanged from 2018.
54 The Proceeds of Crime Act-funded ENIPID project officially concluded on 30 June 2016. Since then, the ENIPID capability has been 
integrated into core AFP FDI duties to ensure its continued delivery through AFP Forensics.
55 Care should be taken when drawing any conclusions from the ENIPID data for the first six months of 2019 due to the low number of  
cocaine samples profiled during this period.
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  The proportion of respondents reporting the recent use56 of cocaine decreased over the last  
decade, from 18 per cent in 2010 to 13 per cent in 2019. In 2018 this proportion was 14 per cent.
  Over the last decade the reported median number of days of cocaine use in the six months  
preceding interview decreased, from 5 days in 2010 to 3 days in 2019. The median number of  
days remained unchanged from 2018 (Stafford & Burns 2011; Peacock et al. 2019a).
The Ecstasy and Related Drugs Reporting System (EDRS) collects self-report information on drug use  
and related harms annually from individuals in Australian capital cities who regularly use ecstasy and 
other stimulants. According to this national study:
  The proportion of respondents reporting cocaine as their drug of choice decreased over the  
last decade, from 13 per cent in 2010 to 11 per cent in 2019. In 2018 this proportion was 
8 per cent.
  The proportion of respondents reporting the recent use of cocaine increased over the last  
decade, from 48 per cent in 2010 to 67 per cent in 2019. In 2018 this proportion was 59 per cent.
  The reported median number of days of cocaine use in the six months preceding interview  
remained relatively stable over the last decade, increasing from 3 days in 2010 to 4 days in 2019.  
In 2018, the median number of days was 3 (Sindicich & Burns 2011; Peacock et al. 2019b).
The Australian Needle and Syringe Program Survey (ANSPS) collects self-report information and  
capillary blood samples57 annually to monitor blood borne viral infections and associated risk  
behaviour among individuals who inject drugs. According to the ANSPS National Data Report, the 
proportion of respondents reporting cocaine as the drug last injected remained relatively stable  
over the last decade, decreasing from 2 per cent in 2009 to 1 per cent in 2018 (Iversen & Maher 2015; 
Heard et al. 2019).
The Drug Use Monitoring in Australia (DUMA) program collects criminal justice and drug use  
information on a quarterly basis from police detainees, comprising an interviewer-assisted self-report 
survey and the voluntary provision of a urine sample, which is tested to detect licit and illicit drug use.58 
According to DUMA program data:
  Over the last decade the proportion of detainees testing positive to cocaine remained relatively 
stable, while the proportion self-reporting cocaine use increased.
  The proportion of detainees testing positive to cocaine over the last decade ranged from a low  
of 1 per cent in 2014–15 to a high of 2 per cent in 2013–14, 2017–18 and 2018–19.
  The proportion of detainees self-reporting recent cocaine use59 over the last decade ranged from 
 11 per cent in 2011–12 to 17 per cent in 2016–17 and 2017–18. In 2018–19, this proportion was  
16 per cent (see Figure 20).
56 In both the IDRS and EDRS studies, recent use refers to reported use in the six months preceding interview.
57 Individuals participating in the survey are invited to provide a blood sample for HIV and HCV antibody testing.
58 Detainees can participate in the survey without providing a urine sample. Cases with missing data are excluded from the relevant analysis.
59 Recent use in the DUMA program refers to self-reported use in the 12 months prior to arrest.
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FIGURE 20: National proportion of detainees testing positive for cocaine compared with                  
self-reported recent use, 2009–10 to 2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
The Australian Secondary Students Alcohol and Drug (ASSAD) Survey collects self-report information  
on alcohol, tobacco, over-the-counter drugs and illicit substance use among Australian secondary  
school students (aged 12 to 17) and is conducted every three years. According to the 2017 ASSAD 
survey:
  The proportion of respondents who reported having used cocaine at least once in their lifetime 
remained stable over the last decade at 2 per cent.
  The proportion of respondents who reported having used cocaine at least once in the past month 
remained stable over the last decade at 1 per cent.
  Data collected between 1996 and 2017 indicate that most secondary students surveyed had never 
used cocaine. From 2011, the proportion of older students reporting cocaine use within their  
lifetime increased slightly, however, with the exception of opiates, use remains lower than that 
reported for other drugs measured by the survey (Guerin & White 2018; Guerin & White 2019).
PRICE
At the street level, the price of cocaine is generally measured as a ‘cap’ or in grams. Nationally, the  
price for 1 cap (0.2 grams) of cocaine increased over the last decade, ranging between $40 and $70 in 
2009–10 to between $40 and $200 in 2018–19. In 2017–18, the reported price ranged from $50 to $250.
Nationally, the price for 1 gram of cocaine increased over the last decade, ranging between $250 and 
$500 in 2009–10 to between $200 and $800 in 2018–19. The reported price range was between $200 
and $600 in 2017–18. The national median price for 1 gram of cocaine increased slightly over the last 
decade, from $325 in 2009–10 to $350 in 2018–19, a decrease from $375 in 2017–18.
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Nationally, the price for 1 kilogram of cocaine increased over the last decade, ranging between $135,000 
and $260,000 in 2009–10 to between $90,000 and $300,000 in 2018–19 (noting there is a large overlap 
in price ranges). In 2017–18, the reported price ranged from $100,000 to $300,000.
PURITY
Since 2009–10, the annual median purity of analysed cocaine samples ranged between 10 per cent 
and 79 per cent (see Figure 21). In 2018–19, the annual median purity ranged from 41 per cent in 
Queensland to 79 per cent in South Australia. Annual median cocaine purity fluctuated over the last 
decade, but overall, all states reported an increase. In 2018–19, with the exception of South Australia 
which reported an increase from 2017–18, all states reported a decrease in the annual median purity  
of cocaine.
FIGURE 21: Annual median purity of cocaine samples, 2009–10 to 2018–19
 
 
 
 
 
 
 
 
 
 
AVAILABILITY
User surveys provide a mixed picture of the reported availability of cocaine in 2018–19.
In a 2019 national study of people who regularly inject drugs, the proportion of respondents reporting 
cocaine as ‘easy’ or ‘very easy’ to obtain decreased, from 64 per cent in 2018 to 62 per cent in 2019.  
This is similar to the proportion reported in 2010 (63 per cent; Stafford & Burns 2011; Peacock et al. 
2019a).
In a 2019 national study of people who regularly use ecstasy and other stimulants, the proportion of 
respondents reporting cocaine as easy or very easy to obtain increased, from 62 per cent in 2018 to 
69 per cent in 2019. This is an increase from the 60 per cent reported in 2010 (Sindicich & Burns 2011; 
Peacock et al. 2019b).
SEIZURES
The number of national cocaine seizures increased 255 per cent over the last decade, from 1,517  
in 2009–10 to a record 5,378 in 2018–19, a 6 per cent increase from 5,096 in 2017–18 (the second  
highest number on record).
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The weight of cocaine seized nationally fluctuated over the last decade, increasing 315 per cent from 
394.8 kilograms in 2009–10 to 1,638.5 kilograms in 2018–19—the third highest weight on record. The 
weight seized nationally decreased in the last three reporting periods from a record 4,623.3 kilograms 
in 2016–17. The weight of cocaine seized nationally decreased 17 per cent this reporting period from 
1,970.7 kilograms in 2017–18 (see Figure 22).
FIGURE 22: National cocaine seizures, by number and weight, 2009–10 to 2018–19
Queensland reported the greatest percentage increase in the number of cocaine seizures in 2018–19, 
while the Australian Capital Territory reported the greatest percentage increase in the weight of cocaine 
seized. New South Wales continues to account for the greatest proportion of national cocaine seizures, 
accounting for 67 per cent of the number and 55 per cent of the weight of cocaine seized nationally in 
2018–19 (see Table 13).
TABLE 13: Number, weight and percentage change of national cocaine seizures, 2017–18 and 2018–19
Number           Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 3,327 3,621 8.8 1,414,761 898,696 -36.5
Victoria 407 378 -7.1 343,080 63,929 -81.4
Queenslandb 641 761 18.7 163,321 644,275 294.5
South Australia 38 20 -47.4 16,632 450 -97.3
Western Australiac 461 415 -10.0 31,197 24,958 -20.0
Tasmania 25 29 16.0 135 332 145.9
Northern Territory 45 27 -40.0 969 134 -86.2
Australian Capital Territory 152 127 -16.4 652 5,798 789.3
Total 5,096 5,378 5.5 1,970,747 1,638,572 -16.9
a. Includes seizures by state and territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
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ARRESTS
The number of national cocaine arrests increased 303 per cent over the last decade, from 1,244 in 
2009–10 to a record 5,016 in 2018–19, a 16 per cent increase from 4,325 in 2017–18 (the second  
highest number on record). Consumer arrests continue to account for the greatest proportion of  
arrests, accounting for 76 per cent of national cocaine arrests in 2018–19 (see Figure 23). The  
exception was the Northern Territory, where provider arrests (8) exceeded the number of consumer 
arrests (4) this reporting period.
FIGURE 23: Number of national cocaine arrests, 2009–10 to 2018–19
Tasmania reported the greatest percentage increase in the number of cocaine arrests in 2018–19, 
although it started from a low base. New South Wales continues to account for the greatest proportion 
of national cocaine arrests, accounting for 51 per cent in 2018–19 (see Table 14).
TABLE 14: Number and percentage change of national cocaine arrests, 2017–18 and 2018–19
Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 2,316 2,564 10.7
Victoria 765 998 30.5
Queensland 737 907 23.1
South Australia 164 163 -0.6
Western Australia 208 284 36.5
Tasmania 5 11 120.0
Northern Territory 26 20 -23.1
Australian Capital Territory 104 69 -33.7
Total 4,325 5,016 16.0
a. The arrest data for each state and territory include Australian Federal Police data.
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NATIONAL IMPACT
Cocaine remains among the most commonly consumed drugs worldwide. Globally, both the total  
area under coca bush cultivation and estimated cocaine production continued to increase in 2017.  
The weight of cocaine seized globally increased to record levels in 2017, with seizures concentrated  
in the Americas (particularly Colombia) and Europe.
Indicators of supply and demand suggest that the Australian cocaine market continues to expand.
Indicators of cocaine demand include surveys of people who regularly use drugs, police detainees  
and wastewater analysis.
  The NWDMP indicates that average cocaine consumption in capital city sites exceeds regional 
consumption. When comparing data for August 2018 to August 2019, the population-weighted 
average consumption of cocaine decreased in capital city sites and increased in regional sites. 
  According to a national study of people who regularly inject drugs, cocaine use remained low  
and relatively stable.
  According to a national study of people who regularly use ecstasy and other stimulants, both  
the reported recent use of cocaine and median days of use increased from 2018 to 2019.
  According to a national study of police detainees, the proportion of detainees testing positive  
to cocaine remained stable in 2018–19, while self-reported cocaine use decreased.
  According to a national study of secondary students, reported cocaine use remained stable in  
2017 and is low compared to other drugs.
Indicators of cocaine supply include border detection, seizure, arrest, price and purity data. Compared  
to 2017–18, in 2018–19:
  The number of cocaine detections at the Australian border decreased, while the weight of cocaine 
detected increased and is the second highest weight on record.
  Forensic profiling indicates that Colombia remains the predominant source of analysed cocaine  
in Australia.
  There was a record number of national cocaine seizures. While the weight of cocaine seized 
nationally decreased this reporting period, it remains high.
  The number of national cocaine arrests increased to record levels.
  The national median price for one gram of cocaine decreased slightly.
  With the exception of South Australia, all states reported a decrease in the annual median  
purity of cocaine.
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KEY POINTS 
OTHER DRUGS
Compared to other illicit drug markets in Australia, the illicit markets for substances within the other 
drugs category are relatively small. However these markets are diverse and dynamic, and include a  
range of drugs which merit ongoing monitoring in order to identify new trends, as well as emerging 
areas of potential harm.
Indicators of demand and supply for other drugs in Australia in 2018–19 provide a mixed picture:
  The number of detections of performance and image enhancing drugs at the Australian border 
remained relatively stable, while the number and weight of national steroid seizures decreased.
  The number of tryptamine detections at the Australian border increased and is the second highest  
on record. Both the number and weight of national hallucinogen seizures decreased, while there  
was a record number of national hallucinogen arrests.
  There was a record number of anaesthetic detections at the Australian border.
  Forensic profiling indicates other NPS accounted for the greatest proportion of the number of 
analysed border seizures this reporting period, while amphetamine-type substances accounted  
for the greatest proportion of the weight. 
  The weight of other and unknown NEC drugs seized remained relatively stable, while both the 
number of national other and unknown NEC drug seizures and arrests increased to record levels.
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OTHER DRUGS
Other drugs and substances—collectively referred to in this report as ‘other drugs’—are recognised  
as part of Australia’s illicit drug market. This chapter focuses on the main drugs and substances in  
this category:
  anabolic agents and selected hormones
  anaesthetics
  new psychoactive substances (NPS)60
  pharmaceuticals
  tryptamines
  other drugs not elsewhere classified (NEC).
ANABOLIC AGENTS AND OTHER SELECTED HORMONES
MAIN FORMS
The Australian Standard Classification of Drugs of Concern distinguishes four classes of substances as 
anabolic agents and selected hormones: anabolic-androgenic steroids (AAS); beta-2 agonists; peptide 
hormones, mimetics and analogues; and other anabolic agents and selected hormones. More generally, 
this group of substances is referred to as performance and image enhancing drugs (PIEDs; ABS 2011).
AAS, commonly referred to as steroids, are derivatives of testosterone—a naturally occurring male  
sex hormone.
  Anabolic refers to the muscle-building effects of the drug, while androgenic refers to their 
masculinising effects.
  AAS are most commonly administered orally (as liquid or tablets), injected intramuscularly,  
absorbed using suppositories or cream, gel or patches on the skin, or via nasal sprays (ADF 2019a).
Beta-2 agonists, induce both anabolic and catabolic (body fat reduction) effects.
  A common beta-2 agonist misused in Australia is clenbuterol.
  Beta-2 agonists are usually sold in tablet form (DEA 2017; Larance et al. 2005).
Although AAS remain the most prevalent substance in the PIEDs category, a number of other  
substances exist which manipulate or interfere with the body’s hormonal system. Key substances 
in this category include erythropoietin (EPO), human growth hormone (hGH) and human chorionic 
gonadotrophin (hCG; ADF 2019b; Larance et al. 2005).
60 NPS have been referred to as drug analogues and new psychoactive substances (DANPS) in previous Illicit Drug Data Reports.
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INTERNATIONAL TRENDS
In response to the significant increase in the global trade in anabolic steroids over the last two  
decades and the risk their use may pose to human health, ‘Operation Viribus’ was established to  
counter the international trafficking of doping materials and counterfeit medicine. This international 
operation involves 33 countries, the International Criminal Police Organization (INTERPOL), the Joint 
Research Centre (JRC), the European Anti-Fraud Office (OLAF) and the World Anti-Doping Agency 
(WADA). Key outcomes of the operation include the detection and dismantling of nine clandestine 
laboratories in Europe; the seizure of almost 24 tonnes of raw steroid powder; the dismantling of 
17 organised crime groups involved in illicit steroid (and other doping substances) production and 
trafficking; the seizure of 3.8 million illicit doping substances and counterfeit medicines (including  
doping substances, dietary supplements, medicines and sport and food supplements); and the  
arrest of 234 suspects (Europol 2019).
Operation Viribus identified a number of trends in international PIEDs trafficking, including the 
involvement of small-scale organised crime groups in establishing and operating clandestine  
laboratories which produce doping substances; the increased use of both social media and  
unregulated online pharmacies for the advertisement and sale of anabolic substances; the  
small-scale importation of steroids from Asia and eastern Europe by non-professional athletes,  
bikers and body-builders; and the continued large-scale (wholesale) importation of illicit steroids 
(Europol 2019).
According to the World Customs Organisation (WCO), the number of ‘metabolic agents’61 seizures 
decreased 57 per cent, from 3,341 in 2017 to 1,429 in 2018. While the specific weight seized is not 
available, WCO reported an increase in the weight of ‘metabolic agents’ seized in 2018 (WCO 2019).
DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of PIED detections at the Australian border increased 72 per cent over the last decade,  
from 2,696 in 2009–10 to 4,643 in 2018–19. The number of detections decreased 3 per cent this 
reporting period, from 4,790 in 2017–18 (see Figure 24).62
61 Metabolic agents includes medical products such as steroids and antidiabetic.
62 The Department of Home Affairs is unable to provide statistical data on the weight of drugs in this category due to differences in drug form 
and units of measurement, which include liquid, vials and tablets.
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FIGURE 24: Number of performance and image enhancing drug detections at the Australian border, 
2009–10 to 2018–19 (Source: Department of Home Affairs)
While steroid detections have accounted for the greatest proportion of the number of PIED detections 
over the last decade, the proportion decreased from 89 per cent in 2009–10 to 68 per cent in 2018–19 
(see Figure 25).
  Of the 4,643 PIED detections in 2018–19, 68 per cent were steroids and 32 per cent were hormones.
  The number of steroid border detections decreased 9 per cent this reporting period, from 3,462 in 
2017–18 to 3,155 in 2018–19.
  The number of hormone border detections increased 12 per cent this reporting period, from  
1,328 in 2017–18 to 1,488 in 2018–19.
  The number of clenbuterol detections at the Australian border decreased 23 per cent this  
reporting period, from 262 in 2017–18 to 203 in 2018–19.
FIGURE 25: Number of performance and image enhancing drug detections, by category, at the 
Australian border, 2009–10 to 2018–19 (Source: Department of Home Affairs)
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IMPORTATION METHODS
In 2018–19, detections of PIEDs at the Australian border occurred in the air cargo, air passenger/crew, 
international mail and sea cargo streams. The international mail stream accounted for 76 per cent of  
the number of PIED detections in 2018–19, followed by air cargo (20 per cent), air passenger/crew 
(4 per cent) and sea cargo (<1 per cent).
In 2018–19, detections of clenbuterol at the Australian border occurred in the air cargo, air passenger/
crew and international mail streams. The international mail stream accounted for 92 per cent of the 
number of clenbuterol detections in 2018–19, followed by air passenger/crew (6 per cent) and air  
cargo (2 per cent).
EMBARKATION POINTS
In 2018–19, 56 countries were identified as embarkation points for PIEDs detected at the Australian 
border, compared with 59 countries in 2017–18. By number, China (including Hong Kong) was the 
primary embarkation point for PIED detections in 2018–19. Other key embarkation points by number 
this reporting period include the United States (US), the United Kingdom (UK), India, Singapore,  
Thailand, Turkey, the Philippines, Poland and Greece.
In 2018–19, 22 countries were identified as embarkation points for clenbuterol detected at the 
Australian border, compared with 31 countries in 2017–18.
DOMESTIC MARKET INDICATORS
No single dataset provides a comprehensive picture of illicit drugs, or the Australian illicit drug  
market. Each has benefits and limitations, and it is only through the layering of multiple data that  
we are able to enhance our understanding of the extent of the supply and demand trends in  
Australia’s illicit drug markets.
The below data reflect drug use within sentinel groups. As such, they are not representative of all  
people who use drugs, or drug use in the general population. However, they provide valuable insight  
into patterns of drug use and market trends and can assist in the identification of emerging issues  
that require further monitoring.
The Illicit Drug Reporting System (IDRS) collects self-report information on drug use and related  
harms annually from individuals in Australian capital cities who regularly inject drugs. According to 
this national study, the recent use63 of steroids have remained consistently low since the IDRS program 
began in 2010, ranging between 1 and 3 per cent. This reporting period the proportion of respondents 
reporting recent steroid use decreased from 3 per cent in 2018 to zero in 2019 (Peacock et al. 2019a).
The Australian Needle and Syringe Program Survey (ANSPS) collects self-report information and capillary 
blood samples64 annually to monitor blood borne viral infections and associated risk behaviour among 
individuals who inject drugs. According to the ANSPS, the proportion of respondents reporting PIEDs  
as the drug last injected in the last decade fluctuated, from 2 per cent in 2009 to 7 per cent in 2012, 
2013 and 2014. This proportion decreased from 5 per cent in 2017 to 4 per cent in 2018 (Iversen & 
Maher 2015; Heard et al. 2019).
63 In the IDRS study, recent use refers to reported use in the six months preceding interview.
64 Individuals participating in the survey are invited to provide a blood sample for HIV and HCV antibody testing.
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The Australian Secondary Students Alcohol and Drug Survey (ASSAD) collects self-report information  
on alcohol, tobacco, over-the-counter drugs and illicit substance use among Australian secondary  
school students (aged 12 to 17) and is conducted every three years. According to the 2017 ASSAD 
survey:
  The proportion of respondents who reported having used non-prescribed PIEDs at least once in  
their lifetime increased, from 2 per cent in 2014 to 3 per cent in 2017.
  The proportion of respondents who reported having used non-prescribed PIEDs at least once in  
the past month remained stable at 1 per cent in 2017 (Guerin & White 2018).
PRICE
National law enforcement data on the price of PIEDs are limited. Victoria, Queensland and Western 
Australia were the only jurisdictions to provide price data for PIEDs in 2018–19. The price for a single  
10 millilitre vial of testosterone enanthate remained unchanged this reporting period and ranged 
between $100 and $230. 
Queensland and Western Australia were the only jurisdictions to report a price for a single  
10 millilitre vial of trenbolone acetate. The price ranged between $150 and $240 in 2018–19,  
compared with a price of $240 (reported by Queensland) in 2017–18. Queensland and Western  
Australia reported a price range of between $340 and $1,400 for ten 10 millilitre vials of trenbolone 
acetate in 2018–19, compared with a price of $1,400 (reported by Queensland) in 2017–18. 
Queensland provided price data for several other types and quantities of PIEDs this reporting  
period—see Statistics chapter.
SEIZURES 
The number of national steroid seizures increased 192 per cent over the last decade, from 134 in  
2009–10 to 391 in 2018–19. The number of steroid seizures increased in the first half of the decade, 
peaking in 2014–15 at 529, then decreased in subsequent years. This reporting period the number  
of seizures decreased 13 per cent, from 448 in 2017–18.
The weight of steroids seized nationally increased 282 per cent over the last decade, from  
5.5 kilograms in 2009–10 to 21.2 kilograms in 2018–19. The weight of steroids seized fluctuated  
over the decade, peaking at 320.4 kilograms in 2014–15. The weight of steroids seized nationally 
decreased 72 per cent this reporting period, from 75.7 kilograms in 2017–18 (see Figure 26). 
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FIGURE 26: National steroid seizures, by number and weight, 2009–10 to 2018–19
The Australian Capital Territory reported the greatest percentage increase in the number of steroid 
seizures in 2018–19, while Victoria reported the greatest percentage increase in the weight of steroids 
seized. This reporting period New South Wales accounted for the greatest proportion of both the 
number (58 per cent) and weight (46 per cent) of steroids seized nationally (see Table 15).
TABLE 15: Number, weight and percentage change of national steroid seizures, 2017–18 and 2018–19
 Number               Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 270 227 -15.9 58,857 9,876 -83.2
Victoria 9 5 -44.4 845 5,206 516.1
Queenslandb 73 68 -6.8 10,557 3,505 -66.8
South Australia 0 0 — 0 0 —
Western Australiac 49 29 -40.8 2,034 582 -71.4
Tasmania 0 0 — 0 0 —
Northern Territory 30 32 6.7 1,909 1,756 -8.0
Australian Capital Territory 17 30 76.5 1,527 367 -76.0
Total 448 391 -12.7 75,729 21,292 -71.9
a. Includes seizures by state and territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
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ARRESTS
The number of national steroid arrests increased 303 per cent over the last decade, from 314 in 
2009–10 to 1,264 in 2018–19. The number of steroid arrests increased 5 per cent this reporting period, 
from 1,201 in 2017–18. Consumer arrests continue to account for the greatest proportion of arrests, 
accounting for 81 per cent of national steroid arrests in 2018–19 (see Figure 27).
FIGURE 27: Number of national steroid arrests, 2009–10 to 2018–19
The Northern Territory reported the greatest percentage increase in the number of steroid arrests in 
2018–19. Queensland accounted for the greatest proportion of national steroid arrests this reporting 
period (51 per cent; see Table 16).
TABLE 16: Number and percentage change of national steroid arrests, 2017–18 and 2018–19
Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 178 181 1.7
Victoria 102 153 50.0
Queensland 670 641 -4.3
South Australia 7 3 -57.1
Western Australia 211 247 17.1
Tasmania 19 15 -21.1
Northern Territory 10 20 100.0
Australian Capital Territory 4 4 0.0
Total 1,201 1,264 5.2
a. The arrest data for each state and territory include Australian Federal Police data.
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TRYPTAMINES
MAIN FORMS 
Tryptamines are hallucinogenic substances which act upon the central nervous system, producing 
altered states of perception, sensation, cognition and consciousness, often accompanied by visual or 
auditory hallucinations. Some are found naturally in a variety of flowering plants, leaves, seeds and some 
spore-forming plants, while others are synthetically produced. The following section covers lysergic acid 
diethylamide (LSD) and psilocybin-containing mushrooms, the two most common tryptamines used in 
Australia (ADF 2019c; EMCDDA 2018; UNODC 2016).
LYSERGIC ACID DIETHYLAMIDE (LSD) 
LSD, commonly referred to as ‘acid’, is a semi-synthetic hallucinogen derived from lysergic acid,  
a chemical found in a fungus which grows on certain types of grain.
  In pure form, LSD is a white, water-soluble and odourless powder.
  LSD is most commonly consumed orally, ingested on LSD-impregnated paper blotters (tabs65), 
miniature tablets (microdots) or gelatine sheets (window panes).
  In liquid form, LSD can be administered by intravenous or intramuscular injection, or through 
consumption of LSD-impregnated sugar cubes (ADF 2019c; UNODC 2016).
PSILOCYBIN-CONTAINING MUSHROOMS
Psilocybin is the primary psychoactive and hallucinogenic chemical present in certain species of 
mushroom within the Psilocybe genus, commonly referred to as ‘magic mushrooms’.
  Approximately 20 species of psilocybin-containing mushrooms are found in Australia. In addition  
to variation in the psilocybin content across species of mushroom, their potency is affected by their 
origin, growing conditions, harvest period and form.
  Hallucinogenic mushrooms are consumed as fresh fungi, preserved (dried, cooked and/or frozen)  
or as dry powders or capsules. These forms can be consumed orally (raw, cooked or brewed into  
a beverage), smoked or injected intravenously (EMCDDA 2018; UNODC 2016).
INTERNATIONAL TRENDS
The weight of tryptamines seized globally fluctuates each year and the types of substances which 
comprise these seizures also varies. Between 2011 and 2015, LSD and phencyclidine (PCP) accounted for 
the greatest proportion of the weight of hallucinogens seized globally. Since 2016, dimethyltryptamine 
(DMT) has dominated hallucinogen seizures. In 2016 and 2017, DMT was seized across multiple regions 
of the world and in 2017 it was the most commonly seized hallucinogen (by weight) in the Americas, 
Europe and Asia (UNODC 2019).
While WCO data for the specific number and weight of LSD seizures in 2018 were not reported, the  
WCO noted small increases in both the number and weight of LSD seized in 2018 (WCO 2019).
65 Small squares of absorbent paper generally decorated with artwork or designs and impregnated with LSD.
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DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of tryptamine detections at the Australian border increased 2,324 per cent over the last 
decade, from 49 in 2009–10 to 1,188 in 2018–19, the second highest number on record. The number  
of detections increased 27 per cent this reporting period, from 935 in 2017–18 (see Figure 28). 
FIGURE 28: Number of tryptamine detections at the Australian border, 2009–10 to 2018–19  
(Source: Department of Home Affairs)
Similar to 2017–18, the majority of tryptamine detections in 2018–19 were LSD.
  LSD accounted for 4 per cent of the number of tryptamine detections in 2009–10, increasing to 
82 per cent in 2018–19, while psilocybin accounted for 96 per cent of the number of tryptamine 
detections in 2009–10, decreasing to 10 per cent in 2018–19. Other tryptamines increased from  
zero detections in 2009–10 and accounted for 8 per cent of tryptamine detections in 2018–19.
  Of the 1,188 detections in 2018–19, 974 were LSD, a 30 per cent increase from the 749 detections  
in 2017–18. Over the last decade the number of LSD detections increased 48,600 per cent, from  
2 detections in 2009–10.
  Of the 1,188 detections in 2018–19, 114 were psilocybin. The number of psilocybin detections 
increased 48 per cent this reporting period, from 77 detections in 2017–18. Over the last decade  
the number of psilocybin detections increased 143 per cent, from 47 detections in 2009–10.
  The remaining 100 detections in 2018–19 were reported as ‘other’. The number of other tryptamine 
detections decreased 8 per cent, from 109 detections in 2017–18. Over the last decade the number 
of other tryptamine detections increased from zero in 2009–10.
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IMPORTATION METHODS
In 2018–19, detections of tryptamines occurred in the air cargo, air passenger/crew and international 
mail streams. By number, the international mail stream accounted for the greatest proportion of 
tryptamine detections (99 per cent), followed by air passenger/crew (1 per cent) and air cargo  
(<1 per cent).
In 2018–19, detections of LSD occurred in the air cargo, air passenger/crew and international mail 
streams. By number, the international mail stream accounted for the greatest proportion of LSD 
detections (99 per cent), followed by air passenger/crew (1 per cent) and air cargo (<1 per cent).
In 2018–19, detections of psilocybin occurred in the international mail stream only. 
EMBARKATION POINTS
By number, the Netherlands remained the primary embarkation point for tryptamine detections at  
the Australian border in 2018–19. Other key embarkation points by number this reporting period  
include Poland, Canada, the UK, Germany, Spain, the US, Belgium, France and Russia.
By number, the Netherlands was the primary embarkation point for psilocybin detections at the 
Australian border in 2018–19. Other key embarkation points by number this reporting period include 
Canada, the US, the UK, Poland, Spain, Germany, France, Austria and the Philippines.
DOMESTIC MARKET INDICATORS
The Ecstasy and Related Drugs Reporting System (EDRS) collects self-report information on drug use  
and related harms annually from individuals in Australian capital cities who regularly use ecstasy and 
other stimulants. According to this national study:
  The proportion of respondents reporting recent LSD use66 increased over the last decade,  
from 38 per cent in 2010 to 47 per cent in 2019. In 2018 this proportion was 51 per cent.
  The reported median number of days of LSD use in the past six months remained stable at 
3 days over the last decade, with the exception of 2014 and 2015 where the median number  
of days of use in the preceding six months was 2.
  The proportion of respondents reporting recent use of hallucinogenic mushrooms increased  
over the last decade, from 18 per cent in 2010 to 27 per cent in 2019. In 2018 this proportion  
was 26 per cent.
  The proportion of respondents reporting recent use of DMT increased over the last decade,  
from 7 per cent in 2010 to 16 per cent in 2019. This proportion was 18 per cent in 2018.
  The reported median number of days of DMT use in the six months preceding interview remained 
stable at 2 days between 2018 and 2019 (Sindicich & Burns 2011; Peacock et al. 2018; Peacock  
et al. 2019b). 
According to the ASSAD survey, the proportion of respondents who reported having used any 
hallucinogen67 at least once in their lifetime remained stable at 3 per cent from 2008 to 2011,  
increasing to 4 per cent in 2017. Over the decade, the reported use of any hallucinogen at least  
once in the past month remained stable at 1 per cent (Guerin & White 2018; Guerin & White 2019).
66 In the EDRS study, recent use refers to reported use in the six months preceding interview.
67 In the 2017 ASSAD survey, ‘hallucinogen’ refers to LSD or psilocybin-containing mushrooms (‘magic mushrooms’).
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PRICE
Nationally, the price range per tab of LSD increased over the last decade, ranging between $20 and  
$35 in 2009–10 to between $15 and $50 in 2018–19. The price reported in 2017–18 ranged from  
$5 to $50. The national median price per tab of LSD increased over the last decade, from $25 in  
2009–10 to $30 in 2018–19, an increase from $25 in 2017–18. Similar to 2017–18, Queensland  
was the only jurisdiction in 2018–19 to report price data for a single 20 millilitre vial of LSD,  
which remained unchanged at $800. 
South Australia was the only jurisdiction to report price data for 1 gram of psilocybin in 2018–19.  
The price for 1 gram of psilocybin was $15 in 2018–19, compared with a price range of $10 to $15 
(reported by South Australia) in 2017–18.
AVAILABILITY
A national study of people who regularly use ecstasy and other stimulants reported that over the  
last decade the proportion of respondents reporting LSD as ‘easy’ or ‘very easy’ to obtain decreased, 
from 70 per cent in 2010 to 57 per cent in 2019. This proportion was 61 per cent in 2018 (Peacock 
et al. 2019b).
SEIZURES 
The number of national hallucinogen seizures increased 168 per cent over the last decade, from  
215 in 2009–10 to 576 in 2018–19. This reporting period the number of national hallucinogen  
seizures remained relatively stable, decreasing 1 per cent from 584 in 2017–18. 
Over the last decade, the weight of hallucinogens seized nationally increased 63 per cent,  
from 11.7 kilograms in 2009–10 to 19.1 kilograms in 2018–19. This reporting period the weight  
of hallucinogens seized nationally decreased 43 per cent, from 33.5 kilograms in 2017–18  
(see Figure 29). 
FIGURE 29: National hallucinogen seizures, by number and weight, 2009–10 to 2018–19
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New South Wales reported the greatest percentage increase in the number of hallucinogen seizures  
in 2018–19, while all jurisdictions reported decreases in the weight of hallucinogens seized.  
New South Wales accounted for the greatest proportion of the number of national hallucinogen  
seizures this reporting period (63 per cent), while Victoria accounted for the greatest proportion  
of the weight of hallucinogens seized nationally (42 per cent; see Table 17).
TABLE 17: Number, weight and percentage change of national hallucinogen seizures, 2017–18  
and 2018–19
 Number              Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 328 364 11.0 6,365 5,755 -9.6
Victoria 92 77 -16.3 15,832 7,959 -49.7
Queenslandb 33 34 3.0 3,763 3,316 -11.9
South Australia 6 3 -50.0 2,340 23 -99.0
Western Australiac 74 60 -18.9 3,328 870 -73.9
Tasmania 14 8 -42.9 190 96 -49.5
Northern Territory 17 8 -52.9 17 8 -52.9
Australian Capital Territory 20 22 10.0 1,711 1,088 -36.4
Total 584 576 -1.4 33,546 19,115 -43.0
a. Includes seizures by state and territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018–19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
c. The 2018–19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods.
ARRESTS
The number of national hallucinogen arrests increased 101 per cent over the last decade, from  
512 in 2009–10 to a record 1,029 in 2018–19. The number of national hallucinogen arrests increased  
3 per cent this reporting period, from 995 in 2017–18. Consumer arrests continue to account for  
the greatest proportion of arrests, accounting for 81 per cent of national hallucinogen arrests in  
2018–19 (see Figure 30).
101 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
O
TH
ER D
RU
G
S
FIGURE 30: Number of national hallucinogen arrests, 2009–10 to 2018–19
Queensland reported the greatest percentage increase in the number of hallucinogen arrests this 
reporting period and accounted for the greatest proportion of national hallucinogen arrests in  
2018–19 (38 per cent; see Table 18).
TABLE 18: Number and percentage change of national hallucinogen arrests, 2017–18 and 2018–19
Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 237 237 0.0
Victoria 139 158 13.7
Queensland 333 389 16.8
South Australia 56 21 -62.5
Western Australia 183 193 5.5
Tasmania 25 16 -36.0
Northern Territory 9 6 -33.3
Australian Capital Territory 13 9 -30.8
Total 995 1,029 3.4
a. The arrest data for each state and territory include Australian Federal Police data.
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ANAESTHETICS
MAIN FORMS 
While anaesthetics and their precursors have many legitimate uses in the medical, veterinary,  
plastics and chemical industries, they are also diverted for illicit use. This section covers ketamine, 
gamma-hydroxybutyrate (GHB) and related substances, the most prevalent anaesthetics used illicitly  
in Australia (ADF 2019d; WHO 2014).
KETAMINE 
Ketamine is a central nervous system depressant used as an anaesthetic and analgesic in medical  
and veterinary settings.
  Ketamine is commonly found in three forms—liquid, powder and tablet.
  It is most commonly snorted, swallowed or injected. It can also be combined with other 
substances, such as cannabis or tobacco, and smoked (ADF 2019d; DrugWise 2017; UNODC  
2017a; UNODC 2016).
GAMMA-HYDROXYBUTYRATE (GHB) AND RELATED SUBSTANCES
GHB is a naturally occurring substance found in the central nervous system and may also be  
synthetically produced.
  GHB is commonly consumed as a water soluble salt and appears as a colourless and odourless  
liquid solution usually sold in small bottles or vials.
  Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are analogues and precursors of GHB  
which, upon ingestion, metabolise into GHB in the body, producing identical effects (ADF 2019d; 
DrugWise 2017; UNODC 2016; WHO 2014).
INTERNATIONAL TRENDS
Based on seizure data and other information reported by member states, the United Nations Office 
on Drugs and Crime (UNODC) assesses that ketamine trafficking appears to be spreading to regions 
outside of Asia, a primary region associated with illicit ketamine. While 89 per cent of the weight of 
ketamine seized globally between 2013 and 2017 occurred in Asia, the amount seized outside of Asia 
tripled between 2015 and 2017. Over the period 2015–17, the weight of ketamine seizures in Africa, 
the Americas and Oceania in particular increased. Nonetheless, the weight of ketamine seized globally 
continued to decrease since 2015 (when it peaked at 23 tonnes), totalling 12 tonnes in 2017. The 
UNODC also notes that global seizures of GHB increased over the past 15 years, particularly since  
2015, and reached record levels (over 3 tonnes) in 2017. Over the period 2013–17, the Americas, 
Oceania and Europe accounted for the majority (98 per cent) of the weight of global GHB seizures  
and the largest quantities (by weight and by region) were seized in the US, Australia and Norway 
respectively (UNODC 2019). 
According to the WCO, the number of seizures of ‘ketamine and phencyclidine-type substances’ within 
the NPS category increased in 2018, while the weight of seizures decreased. WCO data for GHB seizures 
were not available in 2018. While the specific number and weight of GBL seizures were not available, 
WCO agencies reported a decrease in number of GBL seizures and an increase in the weight of GBL 
seized in 2018 (WCO 2019).
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DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of detections of anaesthetics (including GHB, GBL and ketamine) at the Australian border 
increased 1,934 per cent over the last decade, from 67 in 2009–10 to a record 1,363 in 2018–19. The 
number of anaesthetic detections increased 48 per cent this reporting period, from 919 in 2017–18  
(see Figure 31). 
FIGURE 31: Number of anaesthetic detections at the Australian border, 2009–10 to 2018–19  
(Source: Department of Home Affairs)
Similar to 2017–18, the majority of anaesthetic detections in 2018–19 were ketamine.
  Ketamine accounted for 33 per cent of the number of anaesthetic detections in 2009–10,  
increasing to 61 per cent in 2018–19, while GBL accounted for 66 per cent in 2009–10, decreasing  
to 33 per cent in 2018–19. The number of GHB detections increased from 1 per cent in 2009–10 to  
7 per cent in 2018–19.
  Of the 1,363 anaesthetics detections in 2018–19, 828 were ketamine, a 37 per cent increase from  
the 606 detections in 2017–18. Over the last decade the number of ketamine detections increased 
3,664 per cent, from 22 in 2009–10. 
  Of the 1,363 anaesthetic detections in 2018–19, a record 445 were GBL, representing a 154 per cent 
increase from the 175 detections in 2017–18. Over the last decade the number of GBL detections 
increased 911 per cent, from 44 in 2009–10.
  The remaining 90 detections in 2018–19 were GHB, the highest number on record and a 73 per cent 
increase from the 52 detections in 2017–18. Over the last decade the number of GHB detections 
increased 8,900 per cent, from 1 in 2009–10.
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IMPORTATION METHODS
In 2018–19, detections of anaesthetics occurred in the air cargo, air passenger/crew, international  
mail and sea cargo streams. By number, the international mail stream accounted for the greatest 
proportion of anaesthetic detections (84 per cent), followed by air cargo (16 per cent), air passenger/
crew (<1 per cent) and sea cargo (<1 per cent).
  In 2018–19, detections of ketamine occurred in the air cargo, air passenger/crew and international 
mail streams. By number, the international mail stream accounted for the greatest proportion of 
ketamine detections (94 per cent), followed by air cargo (5 per cent) and air passenger/crew  
(<1 per cent).
  In 2018–19, detections of GHB occurred in the air cargo and international mail streams. By number, 
the international mail stream accounted for 99 per cent of GHB detections at the Australian border, 
followed by air cargo (1 per cent).
  In 2018–19, detections of GBL occurred in the air cargo, air passenger/crew, international mail 
and sea cargo streams. By number, the international mail stream accounted for 62 per cent of GBL 
detections at the Australian border, followed by air cargo (38 per cent), air passenger/crew  
(<1 per cent) and sea cargo (<1 per cent).
EMBARKATION POINTS
By number, the Netherlands remained the primary embarkation point for ketamine detections at the 
Australian border in 2018–19. Other key embarkation points this reporting period included the UK,  
Italy, Germany, India, France, Belgium, China (including Hong Kong), Malaysia and Canada.
By number, China (including Hong Kong) remained the primary embarkation point for GHB and GBL 
detections at the Australian border in 2018–19. Other key embarkation points this reporting period 
included the Netherlands, the UK, Lithuania, Germany, the US, the Republic of Korea, Poland,  
Belgium and Singapore.
DOMESTIC MARKET INDICATORS
According to the EDRS study:
  The proportion of respondents reporting recent ketamine use fluctuated over the last decade, 
increasing from 12 per cent in 2010 to 41 per cent in 2019. In 2018, this proportion was 35 per cent.
  The proportion of respondents reporting recent GHB/GBL use decreased over the last decade,  
from 6 per cent in 2010 to 5 per cent in 2019. In 2018, this proportion was 6 per cent.
  The reported median number of days of ketamine use in the past six months remained relatively 
stable at 2 days in the first half of the decade (2009 to 2015), increasing to 3 in 2016, 2017 and  
2018 and to 4 in 2019 (Sindicich & Burns 2011; Peacock et al. 2019b).
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CLANDESTINE LABORATORIES
Over the last decade, the proportion of clandestine laboratories detected nationally manufacturing  
GHB/GBL increased from zero in 2009–10 to 5 per cent in 2018–19. The number of laboratories detected 
nationally manufacturing GHB/GBL decreased 18 per cent this reporting period, from 22 in 2017–18 to 
18 in 2018–19 (see Clandestine Laboratories and Precursors chapter).
PRICE
The price for 1 gram of ketamine powder increased over the last decade, ranging between $50 and  
$180 in 2009–10 (reported by New South Wales and South Australia) to between $120 and $320 in 
2018–19. The price reported in 2017–18 ranged from $100 to $250. The national median price for  
1 gram of ketamine powder increased from $170 in 2017–18 to $190 in 2018–19.
Nationally, the price for 1–1.5 millilitres of GHB/GBL increased over the last decade, ranging between  
$3 and $6 in 2009–10 to between $2 and $15 in 2018–19. The price reported in 2017–18 ranged from  
$3 to $10. The national median price for 1–1.5 millilitres of GHB/GBL increased from $5.75 in 2017–18  
to $7 in 2018–19. 
Nationally, the price for 1 litre of GHB/GBL remained relatively stable over the last decade, ranging 
between $2,000 and $3,000 in 2009–10 to between $1,500 and $3,000 in 2018–19. The price reported 
in 2017–18 ranged from $600 to $3,500. The national median price for 1 litre of GHB/GBL increased  
from $2,025 in 2017–18 to $2,625 in 2018–19.
AVAILABILITY
In a national study of people who regularly use ecstasy and other stimulants, the proportion of 
respondents reporting ketamine as easy or very easy to obtain increased over the last decade, from  
33 per cent in 2010 to 53 per cent in 2019. In 2018 this proportion was 65 per cent. Data relating to  
the availability of GHB/GBL were unavailable for 2019 (Peacock et al. 2019b). 
PHARMACEUTICALS
MAIN FORMS
In Australia, the importation, manufacture, distribution and supply of pharmaceuticals is controlled 
under various pieces of legislation and regulations. Despite these controls, many pharmaceutical 
drugs continue to be diverted for non-medical use, including dependence, self-medication, improved 
performance, substitution or withdrawal from other drugs and to enhance or counter the effects  
of illicit drugs. Pharmaceutical drugs are obtained for non-medical purposes through a range of  
means, including:
  family and friends with legitimate prescriptions
  forged prescriptions
  over prescribing by health-care professionals
  online pharmacies
  theft from hospitals or pharmacies
  doctor shopping
  healthcare professionals self-prescribing or misappropriating medication (UNODC 2011).
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This section focuses on benzodiazepines and opioids, the pharmaceutical drugs most commonly used  
for non-medical reasons in Australia (AIHW 2017).
BENZODIAZEPINES
The term benzodiazepine covers a range of synthetic substances which act as central nervous system 
depressants. Benzodiazepines are most commonly found in tablet or capsule form, stamped with a  
brand name for oral ingestion and may also be injected (ADF 2019e; EMCDDA 2015; UNODC 2016).
OPIOIDS
Opioid is a generic term which covers both naturally occurring opiates extracted from the opium poppy, 
as well as semi or fully synthetic analogues. Most pharmaceutical opioids are produced and prescribed 
for pain relief (analgesics), as anaesthetics during surgery, or as therapeutic drugs to treat heroin and 
other opioid addictions. Common opioid-based medications in Australia include codeine, morphine, 
oxycodone, fentanyl, buprenorphine and tramadol, sold variously as tablets, capsules, liquid, lozenges, 
powder or skin patches (ADF 2019f; UNODC 2016).
INTERNATIONAL TRENDS
The weight of benzodiazepines seized globally decreased over 90 per cent, from 8 tonnes in 2016  
to 0.7 tonnes in 2017. The illicit trade in pharmaceutical opioids is supplied through diversion and  
illicit production—particularly for fentanyl-type substances. According to UNODC data, an average  
of 0.1 tonnes of pharmaceutical opioids was seized annually between 1998 and 2008. Between  
2009 and 2013, this increased to 6.3 tonnes per annum. Global pharmaceutical opioid seizures  
peaked in 2014, reaching 203 tonnes. The weight of pharmaceutical opioids seized globally increased  
72 per cent, from 87 tonnes in 2016 to 150 tonnes in 2017. While tramadol and codeine comprised  
the majority of the weight seized between 2013 and 2017, increases were reported in the weight  
of fentanyl seized in 2017 (a sixfold increase on 2016 seizures) and methadone (a fivefold increase)  
(UNODC 2018; UNODC 2019).
According to the WCO, the number of illicit medical products68 seized globally decreased 26 per cent, 
from 7,811 in 2017 to 5,799 in 2018. The weight of illicit medical products seized globally increased 
5 per cent to 562,219 kilograms in 2018. While specific figures are not available, both the number 
and weight of ‘nervous system agents’ within the medical products category (including sedative 
pharmaceuticals such as benzodiazepines) decreased in 2018 (WCO 2019).
A proportion of illicit medical products seizures were made during Operation Mirage from 
10 to 19 September 2018. Coordinated by the WCO, Operation Mirage was established to target and 
interdict counterfeit and illicit medicines, as well as other goods that could jeopardise human health 
and safety, entering the African continent. The operation resulted in the seizure of 232 cases of 
pharmaceutical goods and 9.5 kilograms of all types of goods (including both pharmaceutical and  
non-pharmaceuticals; WCO 2018; WCO 2019).
68 Medical products includes urogenital agents, metabolic agents, health supplements, nervous system agents, anti-infective agents, 
psychotherapeutic agents, respiratory system agents, musculoskeletal agents, dermatological agents and others.
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DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The importation of prescription pharmaceuticals by individuals is primarily done for personal use and 
without criminal intent. Pharmaceuticals continue to be purchased over the internet for a variety of 
reasons, including the anonymity afforded to purchasers, the ability to purchase without a prescription 
and lower costs. However, the importation of prescription pharmaceuticals can result in a greater risk 
of purchasing counterfeit drugs, which either have negative or no effects, or contain a different active 
ingredient than expected.
Pharmaceutical detections reported by the Department of Home Affairs only reflect detections of 
benzodiazepines and opioids (including morphine, buprenorphine, methadone and oxycodone).69  
Over the last decade the number of benzodiazepine and opioid pharmaceuticals detected at the 
Australian border fluctuated, increasing 98 per cent from 585 in 2009–10 to 1,156 in 2018–19, a  
19 per cent decrease from 1,425 in 2017–18 (see Figure 32). 
FIGURE 32: Number of pharmaceutical detections at the Australian border, 2009–10 to 2018–19 
(Source: Department of Home Affairs)
Similar to 2017–18, the majority (79 per cent) of pharmaceutical detections in 2018–19 were 
benzodiazepines.
  The number of benzodiazepine detections at the Australian border fluctuated over the last decade, 
increasing 57 per cent from 582 in 2009–10 to 912 in 2018–19. Benzodiazepine detections peaked  
at 2,772 in 2014–15. This reporting period the number of detections decreased 28 per cent, from 
1,260 in 2017–18.
  The number of opioid detections at the Australian border increased 8,033 per cent over the last 
decade, from 3 in 2009–10 to a record 244 in 2018–19. This reporting period the number of 
detections increased 48 per cent, from 165 in 2017–18.
69 Benzodiazepines and opioids statistics only represent a component of the larger pharmaceutical category. As such, caution must be  
used when comparing data.
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IMPORTATION METHODS
In 2018–19, detections of benzodiazepines at the Australian border occurred in the air cargo, air 
passenger/crew, international mail and sea cargo streams. By number, the international mail stream 
accounted for the greatest proportion of benzodiazepine detections (64 per cent), followed by air 
passenger/crew (30 per cent), air cargo (5 per cent), and sea cargo (1 per cent).
In 2018–19, detections of opioids at the Australian border occurred in the air cargo, air passenger/  
crew, international mail and sea cargo streams. By number, the international mail stream accounted  
for the greatest proportion of opioid detections (73 per cent), followed by air cargo (12 per cent),  
air passenger/crew (11 per cent) and sea cargo (5 per cent).
DOMESTIC MARKET INDICATORS
The National Wastewater Drug Monitoring Program (NWDMP) collects wastewater samples every  
two months in capital city sites and every four months in regional sites. Aimed at acquiring data on  
the population-scale use of substances causing potential harm, the program provides a measure of  
the consumption of 13 illicit and licit drugs. According to data from the NWDMP for August 2018 to 
August 2019:
  Fentanyl consumption was higher per capita in regional sites than capital city sites.
  The population-weighted average consumption of fentanyl in both capital city and regional sites 
decreased.
  Oxycodone consumption was higher per capita in regional sites than capital city sites.
  The population-weighted average consumption of oxycodone in capital city sites remained  
relatively stable and increased in regional sites (ACIC 2020).
According to the IDRS study:
  The proportion of respondents reporting recent non-prescribed use of methadone decreased  
over the last decade, from 25 per cent in 2010 to 15 per cent in 2019. In 2018 this proportion  
was 16 per cent. 
  The median number of days of any methadone use remained relatively stable at 180 days over  
the last decade.
  The proportion of respondents reporting recent non-prescribed use of buprenorphine decreased  
over the last decade, from 16 per cent in 2010 to 5 per cent in 2019. In 2018 this proportion was  
7 per cent.
  The median number of days of any buprenorphine use decreased over the last decade from  
38 days in 2010 to 22 in 2019. This figure was 24 days in 2018.
  The proportion of respondents reporting recent non-prescribed use of morphine decreased  
over the last decade, from 42 per cent in 2010 to 18 per cent in 2019. In 2018 this proportion  
was 22 per cent.
  The median number of days of any morphine use decreased over the last decade, from 20 days  
in 2010 to 15 in 2019. In 2018 the median number of days was 24.
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  The proportion of respondents reporting recent non-prescribed use of oxycodone decreased  
over the last decade, from 28 per cent in 2010 to 15 per cent in 2019, an increase from  
14 per cent in 2018.
  The median number of days of any oxycodone use fluctuated but overall decreased over the  
last decade, from 10 days in 2010 to 7 in 2019, an increase from 6 days in 2018.
  The proportion of respondents reporting recent non-prescribed use of fentanyl increased, from  
7 per cent in 2018 to 9 per cent in 2019.
  The median number of days of any fentanyl use increased from 3 days in 2018 to 5 days in 2019.
  The proportion of respondents reporting recent use of non-prescribed benzodiazepines  
decreased over the last decade, from 40 per cent in 2010 to 32 per cent in 2019, an increase  
from 30 per cent in 2018.
  The median number of days of non-prescribed benzodiazepine use decreased over the last  
decade, from 12 days in 2010 to 7 days in 2019.70
  The proportion of respondents reporting recent use of non-prescribed pharmaceutical  
stimulants71 decreased over the last decade, from 13 per cent in 2010 to 7 per cent in 2019.  
In 2018 this proportion was 9 per cent.
  The median number of days of non-prescribed pharmaceutical stimulant use remained  
relatively stable, increasing from 4 days in 2010 to 5 days in 2018 and 2019 (Stafford & Burns  
2011; Peacock at al. 2019a).
According to the EDRS study:
  The proportion of respondents reporting recent use of non-prescribed codeine decreased  
over the last decade, from 33 per cent in 2010 to 6 per cent in 2019. In 2018 this proportion  
was 11 per cent.
  The proportion of respondents reporting recent use of non-prescribed pharmaceutical opioids 
decreased, from 13 per cent in 2018 to 12 per cent in 2019. 
  The proportion of respondents reporting recent use of non-prescribed benzodiazepines increased 
over the last decade, from 26 per cent in 2010 to 41 per cent in 2018 and 2019.
  The recent use of non-prescribed pharmaceutical stimulants increased over the last decade,  
from 23 per cent in 2010 to 33 per cent in 2019, a decrease from 34 per cent in 2018 (Sindicich & 
Burns 2011; Peacock et al. 2018; Peacock et al. 2019b).
According to the ANSPS:
  The proportion of respondents reporting pharmaceutical opioids as the drug last injected  
decreased over the last decade, from 16 per cent in 2009 to 9 per cent in 2017 and 7 per cent  
in 2018 (Iversen & Maher 2015; Heard et al. 2019).
70 The median number of days of non-prescribed benzodiazepine use in 2018 was not reported.
71 In both IDRS and EDRS studies, pharmaceutical stimulants include dexamphetamine, methylphenidate and modafinil. 
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The Drug Use Monitoring in Australia (DUMA) program collects criminal justice and drug use  
information on a quarterly basis from police detainees, comprising an interviewer-assisted self-report 
survey and the voluntary provision of a urine sample, which is tested to detect licit and illicit drug use.72 
According to DUMA program data:
  The proportion of detainees testing positive to benzodiazepines over the last decade ranged from  
a low of 18 per cent in 2012–13 to a record 26 per cent in 2018–19. In 2017–18 this proportion was 
21 per cent.73
  The proportion of detainees self-reporting the recent use of benzodiazepines74 over the last decade 
ranged from 11 per cent in 2010–11 to a record 35 per cent in 2018–19. In 2017–18 this proportion 
was 33 per cent (see Figure 33).
  The proportion of detainees testing positive for any opiates75 over the last decade ranged from  
11 per cent in 2014–15, 2015–16 and 2017–18 to 16 per cent in 2009–10. In 2018–19 the  
proportion was 13 per cent.
  The self-reported recent use of any opiates over the last decade ranged from 8 per cent in  
2009–10 and 2012–13 to a record 22 per cent in 2017–18. In 2018–19 the proportion was  
19 per cent (see Figure 34).
FIGURE 33: National proportion of detainees testing positive for benzodiazepines, 2009–10 to  
2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
72 Detainees can participate in the survey without providing a urine sample. Cases with missing data are excluded from the relevant analysis.
73 Recent use in DUMA program refers to self-reported use in the 12 months prior to arrest.
74 Benzodiazepines and their metabolites can be detected in urine for 2 to 14 days after administration.
75 Opiates and their metabolites can be detected in urine on average 2 to 3 days after administration.
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FIGURE 34: National proportion of detainees testing positive for any opiate compared with self-reported  
use of opiates other than heroin, 2009–10 to 2018–19 (Source: Australian Institute of Criminology)
a. Urine was collected in the third and fourth quarter of 2013 and the first quarter of 2014.
b. Urine was collected in the third quarter of 2014 and the first and second quarter of 2015.
c. Urine was collected in the third quarter of 2015 and the first and second quarter of 2016.
d. Urine was collected in the third quarter of 2016 and the second quarter of 2017.
e. Urine was collected in the third quarter of 2017 in Adelaide, Brisbane and Perth; the fourth quarter of 2017 in Bankstown;  
and the first quarter of 2018 in Adelaide, Brisbane, Perth and Surry Hills.
f. Urine was collected in the third quarter of 2018 in Adelaide, Brisbane and Perth; the fourth quarter of 2018 in Bankstown;  
and the first quarter of 2019 in Adelaide, Brisbane, Perth and Surry Hills.
According to the 2017 ASSAD survey:
  The proportion of respondents reporting the non-medicinal76 use of tranquilisers77 at least once  
in their lifetime increased over the last decade, from 17 per cent in 2008 to 20 per cent in 2017.
  The proportion of respondents reporting the non-medicinal use of tranquilisers in the past month  
also increased over the last decade, from 4 per cent in 2008 to 6 per cent in 2017.
  In 2017, 6 per cent of respondents reported the non-medicinal use of other opiates78 at least  
once in their lifetime.
  In 2017, 2 per cent of respondents reported the non-medicinal use of other opiates in the  
past month (White & Williams 2016; Guerin & White 2018; Guerin & White 2019).
PRICE
Nationally, the price range for a single 100 milligram tablet of MS Contin increased over the last  
decade, ranging between $30 and $40 in 2009–10 (reported in New South Wales) to between 
$30 and $100 in 2017–18 and 2018–19 (reported by Queensland and Tasmania in both periods). 
76 In the 2017 ASSAD survey, ‘non-medicinal’ refers to use ‘without a doctor’s prescription’ or ‘other than for medical reasons’.
77 In the 2017 ASSAD survey, ‘tranquilisers’ includes sleeping tablets, tranquillisers, sedatives or benzodiazepines.
78 In the 2017 ASSAD survey, ‘other opiates’ includes methadone, morphine, oxycodone or pethidine.
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Nationally, the price range for a single OxyContin tablet increased over the last decade, ranging  
between $25 and $60 in 2009–10 (reported in New South Wales and South Australia) to between  
$10 and $100 in 2017–18 and 2018–19.
Nationally, the price for a single 100 microgram patch of fentanyl ranged between $25 and $250 in 
2018–19, compared with a price range of between $75 and $450 in 2017–18. Historical price data  
for fentanyl is unavailable.
National law enforcement price data for a single benzodiazepine tablet are limited. Queensland  
reported a price of $25 per tablet in 2009–10, compared with a price range of between $8 and $25 
in 2018–19 (reported in New South Wales and Queensland). In 2017–18, the reported price ranged 
between $5 and $25 (reported by New South Wales and Queensland). 
SEIZURES
The number of national other opioid seizures fluctuated over the last decade, decreasing 15 per cent 
from 315 in 2009–10 to 269 in 2018–19, a 5 per cent decrease from 284 in 2017–18.
The weight of other opioids seized nationally fluctuated over the last decade, increasing 253 per cent 
from 41.4 kilograms in 2009–10 to 146.2 kilograms in 2018–19, a 3 per cent decrease from the  
150.1 kilograms seized in 2017–18 (see Figure 35). 
FIGURE 35: National other opioid seizures, by number and weight, 2009–10 to 2018–19
The Australia Capital Territory reported the greatest percentage increase in the number of other opioid 
seizures in 2018–19, while Tasmania reported the greatest percentage increase in the weight of other 
opioids seized. This reporting period New South Wales accounted for the greatest proportion of both  
the number (66 per cent) and weight (64 per cent) of other opioids seized nationally (see Table 19).
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TABLE 19: Number, weight and percentage change of national other opioid seizures, 2017–18  
and 2018–19
 Number           Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 178 177 -0.6 101,283 92,962 -8.2
Victoria 46 22 -52.2 44,120 13,456 -69.5
Queenslandb 19 22 15.8 2,393 20,694 764.8
South Australia 2 2 0.0 11 1 -90.9
Western Australiac 18 13 -27.8 2,285 18,962 729.8
Tasmania 5 7 40.0 3 31 933.3
Northern Territory 0 0 — 0 0 —
Australian Capital Territory 16 26 62.5 27 123 355.6
Total 284 269 -5.3 150,122 146,229 -2.6
a. Includes seizures by state/territory police and AFP for which a valid seizure weight was recorded.
b. The 2018-19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
c. The 2018-19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
NEW PSYCHOACTIVE SUBSTANCES79
MAIN FORMS
New Psychoactive Substances (NPS) are substances that may be structurally or functionally similar  
to a parent compound which is a prohibited or scheduled drug and are referred to as analogues.
  There are three categories of analogue drugs: direct, structural and functional.
  NPS are often marketed and sold under a range of terms including ‘legal highs’80, ‘herbal highs’,  
‘bath salts’, ‘designer drugs’ and ‘research chemicals’ (UNODC 2017a; UNODC 2017b; UNODC  
2017c; Wermuth 2006).
Among the wide range of NPS available, this section covers three groups of NPS in more detail:  
synthetic cannabinoids, cathinones, in particular 4-methylmethcathinone (4-MMC) and NBOMe  
compounds. These substances are controlled and border controlled drugs for the purposes of the  
serious drug offences in the Criminal Code Act 1995 (Criminal Code).
SYNTHETIC CANNABINOIDS
Synthetic cannabinoids are a large and diverse group of substances which mimic the effect of  
delta-9-tetrahydrocannabinoil (THC)—the primary psychoactive component in cannabis.
  Commonly sold as smokable herbal mixtures which have been soaked in or sprayed with the  
synthetic compound, synthetic cannabinoids may also come in powder, crystal or tablet form  
(ADF 2019g; EMCDDA 2017; UNODC 2016).
79 The term ‘new’ does not necessarily refer to a new invention, as many NPS may have been synthesized years or decades ago, rather it 
reflects their recent emergence on the market.
80 Use of the term legal high may not reflect the true legal status of these substances under Australian legislation.
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4-MMC (4-METHYLMETHCATHINONE)
4-MMC, also known as mephedrone, is one of the most common cathinone-type substances  
available globally.
  Often sold as a white or brown powder, it is also available in crystal, capsule or tablet form  
and can be injected, smoked or swallowed (ADF 2019h).
NBOME COMPOUNDS
There are a number of different NBOMe compounds available, with differing effects. NBOMes  
are potent hallucinogenic drugs, with 25I, 25B and 25C the most commonly encountered  
NBOMe compounds.
  NBOMes are available in various forms including blotter paper (similar to LSD), liquid,  
powder or tablet and can be consumed orally (buccal or sublingual), snorted or injected 
(ADF 2019i; UNODC 2016; EMCDDA 2014; ACMD 2013).
INTERNATIONAL TRENDS
The illicit global trade in NPS—which the UNODC classifies as substances which are not under 
international control whose pharmacological effects mimic substances which are internationally 
controlled—is relatively small, but includes substances that are of global concern, particularly  
synthetic opioid NPS such as fentanyl analogues. The UNODC distinguishes between plant-based  
NPS and synthetic NPS. In 2017, kratom (Mitragyna speciosa), accounted for the greatest proportion  
of the weight of plant-based NPS seized globally, followed by khat (Catha edulis) and small quantities 
of the hallucinogen Datura stramonium. Synthetic cannabinoids, followed by ketamine, synthetic 
cathinones, tryptamines and phenethylamines accounted for greatest proportion of the weight  
of synthetic NPS seized globally in 2017. Of the 78 NPS which were reported to the UNODC early  
warning advisory for the first time (at the global level) in 2017, 29 per cent were synthetic opioid 
receptors agonists, 33 per cent were stimulants and 19 per cent were synthetic cannabinoids  
(ADF 2020; UNODC 2019).
According to the WCO, the number of NPS81 seizures globally reported by WCO agencies increased 
12 per cent in 2018 (the specific number of seizures was not reported). The number of seizures 
increased or remained relatively unchanged for all subcategories of NPS except for the subcategory 
‘other substances’. Other substances continued to account for the greatest proportion of the number 
of NPS seizures, followed by the subcategory ‘synthetic cathinones’ and ‘synthetic cannabinoids’. The 
total weight of NPS seized globally in 2018 decreased 53 per cent, from 19,280 kilograms in 2017 to 
8,980 kilograms in 2018—largely attributable to the 82 per cent decrease in the weight of synthetic 
cannabinoids seized in 2018 (WCO 2019). 
81 NPS includes synthetic cathinones, synthetic cannabinoids, Lyrica (pregabalin), fentanyl, ketamine and phencyclidine-type substance  
and other substances.
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DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
The number of NPS border detections decreased 16 per cent this reporting period, from 687 in  
2017–18 to 575 in 2018–19. 
In 2018–19, detections of NPS occurred in the air cargo, air passenger/crew and international mail 
streams. By number, the international mail stream accounted for the greatest proportion of NPS 
detections (82 per cent), followed by air cargo (18 per cent) and air passenger/crew (<1 per cent).
DRUG PROFILING
There is a large number of NPS appearing on the Australian illicit drug market, with some only  
appearing sporadically. The Australian Federal Police (AFP) Forensic Drug Intelligence team, in 
consultation with the National Measurement Institute (NMI), has identified the following  
categories of NPS:
  amphetamine-type substances
  cathinone-type substances
  synthetic cannabinoids
  tryptamine-type substances
  other.82 
Among the many substances detected and reported since NPS profiling began in 2007–08, some  
have been more common than others in terms of the overall number of seizures and/or the weight of  
material seized (see Figure 36). The data below refer only to seizures made and examined by the AFP.
  In 2018–19, other NPS accounted for 39 per cent of the total number of analysed seizures, followed 
by amphetamine-type substances (28 per cent), tryptamine-type substances (28 per cent) and 
cathinone-type substances (6 per cent).
  There were no analysed seizures of synthetic cannabinoids in 2018–19.
Consistent with previous reporting periods, amphetamine-type substances continue to account  
for the greatest proportion of the weight of analysed seizures.
  In 2018–19, amphetamine-type substances accounted for 99 per cent of the weight of  
analysed seizures.
 – The majority of the weight of amphetamine-type substances analysed this reporting  
period comprised two seizures of t-boc-MDMA (26.3 kilograms) and 
p-tosyl-methylamphetamine (3.7 kilograms).
  Cathinone-type substances, tryptamine-type substances and other NPS accounted for 
1 per cent of the weight of analysed seizures.
 – Of the tryptamine-type substances, N,N-dimethyltryptamine was the most commonly  
seized substance by weight in 2018–19, with psilocin/psilocybin found in one seizure.
82 Other NPS include 2C-group substances, synthetic opiates and ketamine analogues.
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FIGURE 36: Number and weight of seizures selected for further analysis and found to contain novel 
substances and drug analogues, 2009–10 to 2018–19  (Source: Australian Federal Police, Forensic  
Drug Intelligence)
DOMESTIC MARKET INDICATORS
According to data from the NWDMP:
  The NPS mephedrone and methylone were the least consumed substances monitored by the 
program. Both drugs were detected at a small number of sites, below the levels at which they  
could be reliably quantified.
  The number of mephedrone detections increased, from 30 in August 2018 to 38 in August 2019.
  The number of sites where mephedrone was detected increased, from 8 in August 2018 to  
12 in August 2019.
  The number of methylone detections increased, from 21 in August 2018 to 24 in August 2019.
  The number of sites where methylone was detected increased, from 6 in August 2018 to 8 in  
August 2019 (ACIC 2020).
According to the IDRS study:
  The recent use of NPS remained stable between 2018 and 2019 at 11 per cent. Substances  
mimicking the effects of cannabis were the most commonly reported NPS used (6 per cent) in 2019. 
Historical data for recent use of NPS are unavailable (Peacock at al. 2019a).
According to the EDRS study:
  The proportion of respondents reporting the recent use of NPS remained relatively stable over  
the last decade, decreasing from 32 per cent in 2010 to 31 per cent in 2018 and 30 per cent in 2019. 
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  The median number of days of reported NPS use remained low (2 days or less) for different  
NPS forms used over the last decade. 
  The following trends were observed in the proportions of respondents reporting recent use  
of other substances within the NPS group: 
 – Recent use of any 2C substance83 remained stable at 6 per cent in 2010 and 2019. In 2013,  
this increased to 20 per cent. The recent use of any 2C substance decreased this reporting  
period, from 8 per cent in 2018.
 – Recent use of NBOMes remained stable at 2 per cent this reporting period. Historical data  
for NBOMes were unavailable.
 – Recent use of mephedrone decreased over the last decade, from 16 per cent in 2010 to  
1 per cent in 2019. The recent use of mephedrone increased this reporting period, from  
less than 1 per cent in 2018. 
 – Recent use of synthetic cannabinoids remained stable at 3 per cent this reporting period. 
Historical data for synthetic cannabinoids were unavailable (Peacock et al. 2019b).
According to the 2017 ASSAD survey, the proportion of respondents reporting the use of synthetic 
cannabis at least once in their lifetime remained relatively stable at 2 per cent in 2017 (White &  
Williams 2016; Guerin & White 2018).
PRICE
National law enforcement price data for NPS are limited. Queensland was the only jurisdiction to  
report price data for 3 grams of synthetic cannabinoids in 2018–19, which ranged between $100  
and $250 in 2018–19 compared to a price range of between $50 and $95 (reported by Queensland  
and South Australia) in 2017–18. 
OTHER AND UNKNOWN NOT ELSEWHERE     
CLASSIFIED DRUGS
Data for national other and unknown not elsewhere classified (NEC) drug seizures and arrests capture 
those drugs and substances outside the specific drug categories contained in the Illicit Drug Data Report. 
This category contains a range of substances including precursors, anaesthetics, NPS, pharmaceuticals 
and drugs not elsewhere classified. Substances in this category are likely to change between reporting 
periods. Data limitations are further discussed in the Statistics chapter of this report.
SEIZURES 
The number of national other and unknown NEC drug seizures increased 95 per cent over the last 
decade, from 4,628 in 2009–10 to a record 9,039 in 2018–19, a 10 per cent increase from 8,206 in 
2017–18. 
The weight of national other and unknown NEC drug seizures increased 1,134 per cent over the last 
decade, from 661 kilograms in 2009–10 to 8,158.6 kilograms in 2018–19, a 2 per cent decrease from 
8,281.0 kilograms in 2017–18 (see Figure 37).
83 2C substances are synthetic phenethylamines with psychedelic effects.
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FIGURE 37: National other and unknown not elsewhere classified drug seizures, by number and 
weight, 2009–10 to 2018–19
Victoria reported the greatest percentage increase in both the number and weight of other and 
unknown NEC drugs seized in 2018–19. This reporting period New South Wales accounted for the 
greatest proportion of both the number (53 per cent) and weight (64 per cent) of other and unknown 
NEC drugs seized nationally (see Table 20).
TABLE 20: Number, weight and percentage change of national other and unknown not elsewhere 
classified drug seizures, 2017–18 and 2018–19
Number           Weight (grams)
State/Territorya 2017–18 2018–19 % change 2017–18 2018–19 % change
New South Wales 4,115 4,760 15.7 5,443,178 5,185,287 -4.7
Victoria 519 789 52.0 901,134 2,629,915 191.8
Queenslandb 960 1,042 8.5 1,552,100 145,104 -90.7
South Australia 34 23 -32.4 61,659 11,216 -81.8
Western Australiac 2,009 1,812 -9.8 232,139 109,560 -52.8
Tasmania 187 186 -0.5 2,544 3,666 44.1
Northern Territory 211 225 6.6 86,240 69,583 -19.3
Australian Capital Territory 171 202 18.1 2,006 4,276 113.2
Total 8,206 9,039 10.2 8,281,000 8,158,607 -1.5
a. Includes seizures by state and territory police and Australian Federal Police for which a valid seizure weight was recorded.
b. The 2018-19 data provided by the Queensland Police Service reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
c. The 2018-19 data provided by the Western Australia Police Force reflects improvements made to the quality of the drug seizure dataset.  
As a result, caution should be exercised in comparing data from previous reporting periods. 
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ARRESTS
The number of other and unknown NEC drug arrests increased 174 per cent over the last decade,  
from 9,263 in 2009–10 to a record 25,351 in 2018–19, an 18 per cent increase from 21,545 in  
2017–18. Consumer arrests continue to account for the greatest proportion of arrests, accounting  
for 87 per cent of national other and unknown NEC drug arrests in 2018–19 (see Figure 38).
FIGURE 38: Number of national other and unknown not elsewhere classified drug arrests,  
by number and weight, 2009–10 to 2018–19
South Australia reported the greatest percentage increase in the number of other and unknown NEC 
drug arrests in 2018–19. Queensland accounted for the greatest proportion of national other and 
unknown NEC drug arrests this reporting period (29 per cent), followed by Victoria (28 per cent;  
see Table 21).
TABLE 21: Number and percentage change of national other and unknown not elsewhere classified 
drug arrests, 2017–18 and 2018–19
Arrests
State/Territorya 2017–18 2018–19 % change
New South Wales 2,806 3,123 11.3
Victoria 6,085 7,078 16.3
Queensland 5,962 7,319 22.8
South Australia 620 1,781 187.3
Western Australia 5,489 5,432 -1.0
Tasmania 472 510 8.1
Northern Territory 87 102 17.2
Australian Capital Territory 24 6 -75.0
Total 21,545 25,351 17.7
a. The arrest data for each state and territory include Australian Federal Police data.
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NATIONAL IMPACT
The illicit markets in Australia for substances within the other drugs category are comparatively small, 
however they include a range of drugs which merit ongoing monitoring in order to identify new trends 
as well as emerging areas of potential harm. 
ANABOLIC AGENTS AND OTHER SELECTED HORMONES
Demand and supply indicators for anabolic agents and other selected hormones in Australia provide  
a mixed picture. Overall, they suggest the market remained small and relatively stable in 2018–19.
Indicators of demand for anabolic agents and other selected hormones include surveys of secondary 
school students and of people who regularly inject drugs.
  According to the 2017 ASSAD survey, the proportion of respondents who reported having used  
non-prescribed PIEDs at least once in their lifetime increased, while reported non-prescribed  
PIED use at least once in the past month remained stable.
  Data from the ANSPS indicate that reported PIED use decreased in 2018. 
  According to a national study of people who regularly inject drugs, the proportion of people  
reporting recent use of steroids decreased in 2019.
Indictors of supply include border detections, price, seizure and arrest data. Compared to 2017–18,  
in 2018–19:
  The number of PIEDs detected at the Australian border decreased, with steroids continuing  
to account for the greatest proportion of PIED detections.
 – The number of steroid border detections decreased this reporting period, while hormone  
border detections increased. The number of clenbuterol border detections also decreased.
  The number and weight of national steroids seizures decreased, while the number of national  
steroid arrests increased.
TRYPTAMINES
Despite fluctuations, supply and demand indicators for tryptamines in Australia suggest the  
market for these substances remains relatively stable.
Indicators of demand for tryptamines include surveys people who regularly use ecstasy and  
other stimulants.
  According to a national study of people who regularly use ecstasy and other stimulants, LSD  
use and availability decreased in 2019, with the median number of days of use remaining stable.  
The same study reported an increase in the use of hallucinogenic mushrooms.
Indicators of tryptamine supply include border detections, price, seizure and arrest data. Compared  
to 2017–18, in 2018–19:
  The number of tryptamine detections at the Australian border increased and is the second highest 
number on record. LSD continued to account for the greatest proportion of tryptamine detections.
  The national median price for a single tab of LSD increased.
  The number and weight of national hallucinogen seizures decreased.
  The number of national hallucinogen arrests increased to the highest number on record.
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ANAESTHETICS
Available indicators of supply and demand for the illicit use of anaesthetics in Australia suggest  
the market remains relatively stable. 
According to a national study of people who regularly use ecstasy and other stimulants, the recent  
use of ketamine increased between 2018 and 2019 whereas the reported recent use of GHB and GBL 
both decreased.
Indicators of supply of anaesthetics include border detections, national clandestine laboratory 
detections and price data. Compared to 2017–18, in 2018–19:
  The number of border detections of GHB, GBL and ketamine increased to record high levels,  
with ketamine continuing to account for the greatest proportion of detections.
  The number of laboratories detected nationally manufacturing GHB/GBL decreased this  
reporting period.
  The national median price for 1 gram of ketamine powder increased and the national median  
price for 1–1.5 millimetres and 1 litre of GHB/GBL also increased.
PHARMACEUTICALS
Indicators of pharmaceutical demand and supply in Australia provide a mixed picture, with marked 
variation across drug types.
Indicators of demand for pharmaceuticals include surveys of people who regularly use drugs, police 
detainees and wastewater analysis.
  For benzodiazepines:
 – According to a national study of police detainees, the proportion of detainees testing positive  
to benzodiazepines and self-reporting recent use of benzodiazepines increased in 2018–19.
 – According to a national study of people who regularly inject drugs, the proportion of people 
reporting recent use of non-prescribed benzodiazepines increased in 2019.
 – According to a national study of people who regularly use ecstasy and other stimulants, the 
proportion of people reporting recent use of non-prescribed benzodiazepines remained  
stable in 2019.
  For opiates:
 – According to a national study of police detainees, the proportion of detainees testing positive  
for any opiates increased in 2018–19, while the self-reported recent use of any opiates decreased.
 – The NWDMP reported higher consumption of the pharmaceutical opioids fentanyl and  
oxycodone in regional areas than in capital city sites.
 – When comparing data for August 2018 and August 2019, the population-weighted average 
consumption of fentanyl decreased in both capital city and regional sites. Over the same period, 
average consumption of oxycodone remained relatively stable in capital city sites and increased  
in regional sites.
 – According to a national study of people who regularly inject drugs, the proportion of people 
reporting recent use of pharmaceutical opioids decreased in 2019 for most drugs monitored,  
with the exception of fentanyl and oxycodone.
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 – According to a national study of people who regularly use ecstasy and other stimulants, the 
proportion of people reporting recent use of pharmaceutical opioids decreased in 2019.
 – Data from the ANSPS indicate that pharmaceutical opioid use among this population  
decreased in 2018.
  For pharmaceutical stimulants:
 – According to a national study of people who regularly inject drugs, the proportion of people 
reporting recent use of non-prescribed pharmaceutical stimulants decreased in 2019. 
 – According to a national study of people who regularly use ecstasy and other stimulants,  
the proportion of people reporting recent use of non-prescribed pharmaceutical stimulants 
decreased in 2019.
Indicators of the supply of illicit pharmaceuticals include border detections, seizure and arrest  
data. Compared to 2017–18, in 2018–19:
  The number of pharmaceuticals detected at the Australian border decreased.
  Benzodiazepines continued to account for the greatest proportion of pharmaceutical detections.
 – The number of benzodiazepine border detections decreased this reporting period, while  
opioid border detections increased to record levels. 
 – The number and weight of national other opioid seizures decreased. 
NEW PSYCHOACTIVE SUBSTANCES
Indicators of NPS demand and supply in Australia provide a mixed picture. Overall, they suggest  
the NPS market remained small and relatively stable.
Indicators of demand for NPS include surveys of people who regularly use drugs and  
wastewater analysis. 
  The NWDMP reports that the NPS mephedrone and methylone are the least consumed illicit  
drugs of those measured by the program. Both substances were detected in quantities below  
quantification levels.
  According to a national study of people who regularly inject drugs, the proportion of people  
reporting recent use of NPS remained stable in 2019.
  According to a national study of people who regularly use ecstasy and other stimulants, the  
proportion of people reporting recent use of NPS decreased for most related drugs in 2019.
Indicators of NPS supply include border detection data. Compared to 2017–18, in 2018–19:
  The number of NPS detected at the Australian border decreased.
  Forensic profiling of NPS seized at the Australian border and selected for further analysis indicates 
other NPS accounted for the greatest proportion of the number of NPS detected this reporting  
period, while amphetamine-type substances accounted for the greatest proportion of the weight  
of analysed samples.
OTHER AND UNKNOWN NEC
In 2018–19, the number of national other and unknown NEC drug seizures increased to the highest 
number on record, while the weight seized decreased. 
There was a record number of other and unknown NEC national drug arrests in 2018–19.
123 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
O
TH
ER D
RU
G
S
REFERENCES
Australian Bureau of Statistics (ABS) 2011, Australian Classification of Drugs of Concern, ABS, Canberra.
Australian Criminal Intelligence Commission (ACIC) 2020, National Wastewater Drug Monitoring 
Program – Report 9, Canberra, <https://www.acic.gov.au/publications/reports/national-wastewater-
drug-monitoring-program-reports>.
Advisory Council on the Misuse of Drugs (ACMD) 2013, ‘NBOMe’ compounds: A review of the evidence  
of use and harm, United Kingdom, viewed 11 November 2019, <https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/261786/NBOMe_compounds_report.pdf>.
Alcohol and Drug Foundation (ADF) 2019a, Drug Facts, Anabolic steroids, viewed 11 November 2019, 
<https://adf.org.au/drug-facts/steroids/>.
Alcohol and Drug Foundation (ADF) 2019b, Drug Facts, Performance & image enhancing drugs, viewed 
11 November 2019, <https://adf.org.au/drug-facts/pieds/>.
Alcohol and Drug Foundation (ADF) 2019c, Drug Facts, LSD, viewed 11 November 2019, <https://adf.org.
au/drug-facts/lsd/>.
Alcohol and Drug Foundation (ADF) 2019d, Drug Facts, Ketamine, viewed 11 November 2019, <https://
adf.org.au/drug-facts/ketamine/>.
Alcohol and Drug Foundation (ADF) 2019e, Drug Facts, Benzodiazepines, viewed 11 November 2019, 
<https://adf.org.au/drug-facts/benzodiazepines/>.
Alcohol and Drug Foundation (ADF) 2019f, Drug Facts, Opioids, viewed 28 November 2019, <https://adf.
org.au/drug-facts/opioids/>.
Alcohol and Drug Foundation (ADF) 2019g, Drug Facts, Synthetic cannabis, viewed 11 November 2019, 
<https://adf.org.au/drug-facts/synthetic-cannabis/>.
Alcohol and Drug Foundation (ADF) 2019h, Drug Facts, Mephedrone, viewed 11 November 2019, 
<https://adf.org.au/drug-facts/mephedrone/>.
Alcohol and Drug Foundation (ADF) 2019i, Drug Facts, NBOMes, viewed 11 November 2019, <https://
adf.org.au/drug-facts/nbomes/>.
Alcohol and Drug Foundation (ADF) 2020, Drug Facts, Khat, viewed 22 June 2020, <https://adf.org.au/
drug-facts/khat/>.
Australian Institute of Health and Welfare (AIHW) 2017, Non-medical use of pharmaceuticals: trends, 
harms and treatment, 2006-07 to 2015-16, Drug treatment series no.30. Cat. no. HSE 195. Canberra.
Drug Enforcement Administration (DEA) 2017, Drugs of Abuse: A DEA Resource Guide, <https://www.
dea.gov/documents/2017/06/15/drugs-abuse >.
DrugWise 2017, GHB/GBL, viewed 11 November 2019, <http://www.drugwise.org.uk/GHB/>.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2018, Hallucinogenic mushrooms 
drug profile, viewed 11 November 2019, <http://www.emcdda.europa.eu/publications/drug-profiles/
mushrooms>.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2017, European Drug Report 2017: 
Trends and Developments, EMCDDA, Lisbon.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2015, Benzodiazepines drug 
profile, viewed 11 November 2019, <http://www.emcdda.europa.eu/publications/drug-profiles/
benzodiazepine>.
124Australian Criminal Intellegence Commission Illicit Drug Data Report 2018–19
O
TH
ER D
RU
G
S
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2014, EMCDDA–Europol Joint 
Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)
phenethylamine), Joint Reports, Publications Office of the European Union, Luxembourg, <http://www.
emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf>.
European Union Agency for Law Enforcement Cooperation (Europol) 8 July 2019, Press release:  
Keeping sport safe and fair: 3.8 million doping substances and fake medicines seized worldwide, viewed 
18 November 2019, <https://www.europol.europa.eu/newsroom/news/keeping-sport-safe-and-fair-38-
million-doping-substances-and-fake-medicines-seized-worldwide>.
Guerin, N & White, V 2018, ASSAD 2017 Statistics and Trends, Australian secondary students’ use of 
tobacco, alcohol, over-the-counter drugs, and illicit substances, Cancer Council Victoria, Melbourne, 
viewed 22 October 2019, <https://www.health.gov.au/resources/publications/secondary-school-
students-use-of-tobacco-alcohol-and-other-drugs-in-2017>.
Guerin, N & White, V 2019, ASSAD 2017 Statistics & Trends: Trends in substance use among Australian 
secondary students 1996–2017, Cancer Council Victoria, Melbourne, viewed 22 October 2019, <https://
www.health.gov.au/sites/default/files/trends-in-substance-use-among-australian-secondary-school-
students-1996-2017.pdf>.
Heard, S, Iversen, J, Geddes, L & Maher, L 2019, Australian Needle Syringe Program Survey National  
Data Report 2017–2018: Prevalence of HIV, HCV and injecting and sexual behaviour among NPS 
attendees, Kirby Institute, University of New South Wales, Sydney.
Iversen, J & Maher, L 2015, Australian NSP survey 20 year national data report 1995–2014: Prevalence 
of HIV, HCV and injecting and sexual behaviour among Needle and Syringe Program attendees, Kirby 
Institute, University of New South Wales, Sydney.
Larance, B, Degenhardt, L, Dillon, P & Copeland, J 2005, Use of performance and image enhancing drugs 
among men: a review, NDARC Technical Report No. 232, National Drug and Alcohol Research Centre, 
University of New South Wales, Sydney, <https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/
resources/TR.232.pdf>.
Peacock, A, Gibbs, D, Karlsson, A, Uporova, J, Sutherland, R, Bruno, R, Dietze, P, Lenton, S, Alati, R, 
Degenhardt, L & Farrell, M 2018, Australian Drug Trends 2018: Key findings from the National Ecstasy 
and Related Drugs (EDRS) interviews, National Drug and Alcohol Research Centre, University of New 
South Wales, Sydney.
Peacock, A, Uporova, J, Karlsson, A, Gibbs, D, Swanton, R, Kelly, G, Price, O, Bruno, R, Dietze, P, Lenton, S, 
Salom, C, Degenhardt, L & Farrell, M 2019a, Key findings from the National Illicit Drug Reporting System 
(IDRS) interviews, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
Peacock, A, Karlsson, A, Uporova, J, Gibbs, D, Swanton, R, Kelly, G, Price, O, Bruno, R, Dietze, P, Lenton, S, 
Salom, C, Degenhardt, L & Farrell, M 2019b, Australian Drug Trends 2019: Key findings from the National 
Ecstasy and Related Drugs (EDRS) interviews, National Drug and Alcohol Research Centre, University of 
New South Wales, Sydney.
Sindicich, N & Burns, L 2011, Australian Trends in Ecstasy and related Drug Markets 2010: Findings from 
the Ecstasy and Related Drugs Reporting System (EDRS), Australian Drug Trend Series No. 64, National 
Drug and Alcohol Research Centre, University of New South Wales, Sydney.
Stafford, J & Burns, L 2011, Australian Drug Trends 2010: Findings from the Illicit Drug Reporting System 
(IDRS), Australian Drug Trends Series, No. 55, National Drug and Alcohol Research Centre, University of 
New South Wales, Sydney.
125 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
O
TH
ER D
RU
G
S
United Nations Office on Drugs and Crime (UNODC) 2011, The non-medical use of prescription drugs: 
Policy direction issues, Discussion paper, <https://www.unodc.org/documents/drug-prevention-and-
treatment/nonmedical-use-prescription-drugs.pdf>.
United Nations Office on Drugs and Crime (UNODC) 2016, Terminology and Information on Drugs,  
3rd edition, New York, United Nations.
United Nations Office on Drugs and Crime (UNODC) 2017a, World Drug Report 2017, Vienna.
United Nations Office on Drugs and Crime (UNODC) 2017b, UNODC Early Warning Advisory (EWA)  
on New Psychoactive Substances (NPS), viewed 11 November 2019, <https://www.unodc.org/LSS/ 
Page/NPS >.
United Nations Office on Drugs and Crime (UNODC) 2017c, 2017 Global Synthetic Drugs Assessment, 
Austria, <https://www.unodc.org/documents/scientific/Global_Synthetic_Drugs_Assessment_ 
2017.pdf>.
United Nations Office on Drugs and Crime (UNODC) 2018, World Drug Report 2018, Vienna.
United Nations Office on Drugs and Crime (UNODC) 2019, World Drug Report 2019, Vienna.
Wermuth, C 2006, Similarity in Drugs: Reflections on analogue design, Drug Discovery Today,  
Volume 11, Issues 7-8, April 2006, pp 348-354.
White, V & Williams, T 2016, Australian secondary school students’ use of tobacco, alcohol, and  
over-the-counter and illicit substances in 2014, Cancer council Victoria, Melbourne, viewed  
23 October 2019, <https://www.health.gov.au/resources/publications/secondary-school-students 
-use-of-tobacco-alcohol-and-other-drugs-in-2014>.
World Customs Organisation (WCO) 2018, Operation “MIRAGE”, Brussels, <http://www.wcoomd.org 
/-/media/wco/public/global/pdf/topics/enforcement-and-compliance/activities-and-programmes/ipr/
operations/mirage_private_sector.pdf?db=web>.
World Customs Organization (WCO) 2019, Illicit Trade Report 2018, Brussels.
World Health Organization (WHO) Secretariat 2014, Gamma-butyrolactone (GBL): Critical Review  
Report, <http://www.who.int/medicines/areas/quality_safety/4_3_Review.pdf>.
126Australian Criminal Intellegence Commission Illicit Drug Data Report 2018–19
O
TH
ER D
RU
G
S
KEY POINTS 
CLANDESTINE  
LABORATORIES  
AND PRECURSORS
  The trafficking of precursor chemicals used in illicit drug production is a global market in itself,  
with the range of chemicals used worldwide to produce illicit drugs—including amphetamine-type 
substances—increasing.
  Indicators of domestic illicit drug production provide a mixed picture.
 – The number of clandestine laboratories detected nationally decreased for the seventh  
consecutive reporting period in 2018–19, with the 308 detections this reporting period  
the lowest number of detections reported in the last decade.
 – The majority of laboratories detected nationally in 2018–19 continue to be addict-based  
(small scale) and located in residential areas.
 – While the proportion of clandestine laboratories manufacturing ATS (excluding MDMA)  
decreased over the last decade, they continue to account for the greatest proportion of  
national detections, with methylamphetamine the main drug produced.
 – The number of ATS (excluding MDMA) precursors detected at the Australian border continued  
to decrease in 2018–19. While the weight detected close to halved this reporting period from  
the record weight reported in 2017–18, the 2,621.3 kilograms detected this reporting period  
is the second highest weight on record.
 – Both the number and weight of MDMA precursors detected at the Australian border increased  
in 2018–19, but remain relatively low.
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MAIN FORMS
Clandestine laboratories—commonly referred to as clan labs—are used to covertly manufacture  
illicit drugs or their precursors. Clandestine laboratories range from crude, makeshift operations  
using simple processes, to highly sophisticated operations using technically advanced processes, 
equipment and facilities. Irrespective of their size or level of sophistication, the corrosive or  
hazardous nature of many of the chemicals used in clandestine laboratories pose significant risks  
to the community. Many of the chemicals are extremely volatile and in addition to contaminating  
the laboratory premises, also contaminate the surrounding environment, including soil, water and  
air (EMCDDA & Europol 2016; UNODC 2016).
Drug manufacture carried out in clandestine laboratories may involve any or all of the following 
processes:
  Extraction—the active chemical ingredients are extracted from a chemical preparation or plant,  
using a chemical solvent to produce a finished drug or a precursor chemical. Examples of extraction 
include the extraction of precursor chemicals from pharmaceutical preparations, or the extraction  
of morphine from opium.
  Conversion—a raw or unrefined drug product is changed into a more sought-after product by  
altering the chemical form. Examples include converting cocaine base into cocaine hydrochloride  
or methylamphetamine base into crystalline methylamphetamine hydrochloride.
  Synthesis—raw materials are combined and reacted under specific conditions to create the 
finished product through chemical reactions. Synthetic drugs such as methylamphetamine, 
3,4-methylenedioxymethylamphetamine (MDMA) and lysergic acid diethylamide (LSD) are  
created through this process.
  Tableting—the final product is converted into dosage units. An example is pressing MDMA  
powder into tablets.
There are three types of substances used in illicit drug manufacture:
  Precursors—considered the starting materials for illicit drug manufacture. Through chemical 
reactions, the precursor’s molecular structure is modified to produce a specific illicit drug.  
For example, precursors such as ephedrine (Eph) and pseudoephedrine (PSE) are converted  
to methylamphetamine.
  Reagents—substances used to cause a chemical reaction that modify the precursor’s molecular 
structure. For example, when the reagent acetic anhydride is mixed with the precursor  
phenyl-2-propanone (P2P), the resulting compound is methylamphetamine.
  Solvents—added to the chemical mixture to ensure effective mixing by dissolving precursors  
and reagents, diluting the reaction mixtures, and separating and purifying other chemicals.  
For example, acetone and hydrochloric acid are used in heroin production (UNODC 2014).
The method of illicit drug manufacture employed is influenced by a number of factors, including the 
skill of the person and the availability of precursors. In Australia, amphetamine-type stimulants (ATS), 
specifically methylamphetamine, is the predominant drug manufactured in detected clandestine 
laboratories. The manufacturing methods and precursors used to manufacture ATS vary.
  The predominant processes used in Australia for manufacturing methylamphetamine are 
comparatively simple, using readily available basic equipment and precursor chemicals, with 
pseudoephedrine and ephedrine the most common precursors used.
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  By comparison, MDMA manufacture is considered more complicated, requiring a greater  
knowledge of chemistry and use of precursor chemicals that are more difficult to obtain.
INTERNATIONAL TRENDS
Preventing the diversion of precursors, reagents and solvents for use in illicit drug manufacture is  
an effective and efficient way of limiting the supply of illicit drugs. As many of these substances have 
legitimate application within various branches of industry, controls must balance legitimate access  
with efforts to reduce diversion to the illicit market.
The trafficking of precursors, reagents and solvents used to produce illicit drugs is a global illicit market 
in itself and may involve diversion from licit channels and/or illicit manufacture. The illicit production of 
plant-based substances (primarily cocaine and heroin) rely on a number of known precursors, solvents 
and reagents used in common and well understood methods of production. In contrast, the illicit 
manufacture of synthetic drugs—in particular ATS—and the precursor chemicals used in its manufacture, 
is increasingly using a combination of old and newly developed techniques. The International Narcotics 
Control Board (INCB) identified two main developments in ATS manufacture and related global ATS 
precursor trafficking in 2018 and 2019:
  The increasing use and development of ‘designer’ precursors, namely substances that are close 
chemical relatives of controlled precursors. These can be converted into a precursor chemical  
and purposely developed to evade international controls. The INCB notes that while the trafficking 
of non-scheduled chemicals is not new, the sophistication, diversification and scale of illicit drug 
manufacturing (particularly of synthetic drugs) have outpaced international precursor control 
frameworks.
  The increasing use of P2P-based methods in the manufacture of ATS in regions where this method 
was not commonly used (for example in East and South East Asia where PSE/Eph-based methods 
have been more common historically; INCB 2019; INCB 2020).
This section will focus on ephedrines, potassium permanganate and acetic anhydride seizures reported 
by the INCB. These chemicals are under international control and are used in the manufacture of ATS, 
cocaine and heroin.
  Eph and PSE: 35 countries reported seizures in 2018, with the combined weight seized close to  
40 tonnes. Seizures occurred in all regions of the globe. East and South East Asia accounted for  
the majority of reported seizures in 2018, including China (26 tonnes of raw Eph and Eph 
preparations and 908 kilograms of PSE) and the Philippines (more than 11 tonnes of Eph).
  Potassium permanganate: 17 countries reported seizures in 2018, totalling over 80 tonnes. While 
seizures of over one tonne (per country) were reported in 2018 by the Plurinational State of Bolivia, 
Bosnia and Herzegovina, Chile, China, Colombia and the Bolivarian Republic of Venezuela, the INCB 
reports that over 27 tonnes of potassium permanganate was seized in Colombia during the first six 
months of 2019. 
  Acetic anhydride: 21 countries reported seizures in 2018, totalling 188,000 litres. China, Georgia, the 
Islamic Republic of Iran, the Netherlands, Pakistan and Turkey each reported seizures of more than 
10,000 litres in 2018. The Islamic Republic of Iran alone reported seizures of 27,680 litres of acetic 
anhydride in 2018 (INCB 2020).
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DOMESTIC TRENDS
AUSTRALIAN BORDER SITUATION
As ATS are the most common illicit drugs manufactured in domestic clandestine laboratories in Australia, 
this chapter focuses on ATS (excluding MDMA) and MDMA precursor detection data.
The number of ATS (excluding MDMA) precursor detections at the Australian border fluctuated over the  
last decade, decreasing 49 per cent from 632 in 2009–10 to 325 in 2018–19. This reporting period the 
number of detections decreased 2 per cent, from 332 in 2017–18. The weight of ATS (excluding MDMA) 
precursors detected also fluctuated over the last decade, increasing 371 per cent from 556.3 kilograms  
in 2009–10 to 2,621.3 kilograms in 2018–19—the second highest weight on record. The weight detected  
this reporting period decreased 47 per cent, from a record 4,912.4 kilograms in 2017–18 (see Figure 39).84
FIGURE 39: Number and weight of ATS (excluding MDMA) precursor detections at the Australian border, 
2009–10 to 2018–19 (Source: Department of Home Affairs)
The number of MDMA precursor detections at the Australian border fluctuated over the last decade,  
but remain relatively low. A single detection of MDMA precursors was reported in both 2009–10 and  
2017–18, which increased to 2 detections in 2018–19. The weight of MDMA precursors detected also 
fluctuated over the last decade, increasing 290 per cent from 100 grams in 2009–10 to 390 grams in  
2018–19. This reporting period the weight detected increased 7,700 per cent, from 5.0 grams in  
2017–18 (see Figure 40). 
84 See Appendix 2 for significant ATS (excluding MDMA) precursor border detections in 2018–19.
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FIGURE 40: Number and weight/litresa of MDMA precursor detections at the Australian border, 
2009–10 to 2018–19 (Source: Department of Home Affairs)
a. Significant detections of MDMA precursors occur in both kilograms and litres. As this figure reflects two units of measurement, it is 
necessary to refer to ‘Significant Border Detections’ for individual reporting periods to determine the related unit of measurement.
IMPORTATION METHODS
In 2018–19, ATS (excluding MDMA) precursor border detections occurred in the air cargo, air passenger/
crew, international mail and sea cargo streams. By number, the international mail stream accounted  
for 41 per cent of ATS (excluding MDMA) precursor border detections, followed by air passenger/crew 
(28 per cent), air cargo (28 per cent) and sea cargo (3 per cent). By weight, sea cargo accounted for the 
greatest proportion of ATS (excluding MDMA) precursor border detections (79 per cent), followed by  
air cargo (18 per cent), international mail (3 per cent), and air passenger/crew (<1 per cent).
In 2018–19, the two MDMA precursor border detections occurred in the air cargo and air passenger/ 
crew streams.
EMBARKATION POINTS
By weight, China (including Hong Kong) was the primary embarkation point for ATS (excluding MDMA) 
precursor detections at the Australian border in 2018–19. Other key embarkation points by weight this 
reporting period include Malaysia, India, Taiwan, the United States (US), the United Kingdom, Italy, 
Canada, Indonesia and Singapore.
Vietnam was the primary embarkation point by weight for MDMA precursor detections in 2018–19, 
followed by the US.
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DOMESTIC MARKET INDICATORS
The number of clandestine laboratory detections is not indicative of production output, which is 
calculated using a number of variables including the size of reaction vessels, amount and type of 
precursors used, the skill of people involved and the method of manufacture.
CLANDESTINE LABORATORY DETECTIONS
The number of national clandestine laboratory detections in Australia decreased 56 per cent over the 
last decade, from 694 in 2009–10 to 308 in 2018–19—the lowest number of detections reported in the 
last decade. While the number of detections increased between 2009–10 and 2011–12, it decreased 
in every subsequent reporting period. This reporting period the number of clandestine laboratories 
detected nationally decreased 29 per cent, from 432 in 2017–18 (see Figure 41).
FIGURE 41: National clandestine laboratory detections, 2009–10 to 2018–19
All states and territories reported a decrease in the number of clandestine laboratories detected in 
2018–19, with the exception of the Australian Capital Territory, which reported an increase in the 
number of detections and the Northern Territory, which remained stable (see Table 22). Victoria 
accounted for the greatest proportion of national clandestine laboratory detections in 2018–19  
(30 per cent), followed by Queensland (26 per cent).
132Australian Criminal Intellegence Commission Illicit Drug Data Report 2018–19
CLA
N
D
ESTIN
E LA
BO
RATO
RIES A
N
D
 PRECU
RSO
RS
TABLE 22: Number of clandestine laboratory detections, by state and territory, 2009–10 to 2018–19
Year NSW Vic Qld SA WA Tas NT ACT Total
2009–10 82 113 297 71 118 1 12 0 694
2010–11 87 63 293 75 171 11 2 1 703
2011–12 90 99 379 58 160 15 7 1 809
2012–13 105 113 330 56 136 9 8 0 757
2013–14 98 114 340 80 96 5 11 0 744
2014–15 99 161 236 71 84 5 10 1 667
2015–16 83 144 234 69 40 1 3 1 575
2016–17 56 135 150 81 33 3 5 0 463
2017–18 86 98 141 78 25 2 2 0 432 
2018–19 59 91 81 58 14 1 2 2 308
SIZE AND PRODUCTION CAPACITY
State and territory police services are asked to provide an indication of the size and production capacity 
of detected laboratories using categories provided by the United Nations Office on Drugs and Crime in 
their data collection for the World Drug Report. Full definitions for the four categories—addict-based, 
other small scale, medium scale and industrial scale—are found in the Statistics chapter.
In 2018–19, clandestine laboratories detected in Australia ranged from addict-based laboratories, 
which typically use basic equipment and simple procedures, through to industrial scale laboratories, 
using oversized equipment. For those able to be categorised, the majority of detected laboratories in 
Australia continue to be addict-based, though the proportion of laboratories attributed to this category 
decreased, from 53 per cent in 2017–18 to 47 per cent in 2018–19. The proportion of laboratories 
categorised as other small scale increased this reporting period, from 26 per cent in 2017–18 to  
33 per cent in 2018–19, with the proportion of medium sized laboratories decreasing from 19 per cent 
in 2017–18 to 18 per cent in 2018–19. The proportion of industrial-scale laboratories remained relatively 
stable at 2 per cent this reporting period.
DRUG TYPES AND METHODS OF PRODUCTION
Over the last decade and of those able to be identified, clandestine laboratories manufacturing 
ATS (excluding MDMA) accounted for the greatest proportion of national detections, with 
methylamphetamine the main drug produced. The proportion of ATS (excluding MDMA) laboratory 
detections fluctuated over the decade, decreasing from 82 per cent in 2009–10 to 49 per cent in  
2018–19. In 2017–18 the proportion was 46 per cent.
  The number of national ATS (excluding MDMA) laboratory detections decreased 30 per cent  
this reporting period, from 233 in 2017–18 to 164 in 2018–19. Victoria accounted for the greatest 
proportion of national ATS (excluding MDMA) laboratories (26 per cent), followed by Queensland  
(25 per cent) and New South Wales (24 per cent). With the exception of Tasmania, all state and 
territories reporting clandestine laboratory detections in 2018–19 reported ATS (excluding MDMA) 
production (see Table 23).
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While fluctuating over the last decade, the proportion of MDMA laboratory detections remained stable  
at 2 per cent in 2009–10 and 2018–19. In 2017–18 the proportion was 4 per cent, the highest reported  
in the decade.
  The number of MDMA laboratory detections decreased 70 per cent this reporting period, from  
20 in 2017–18 to 6 in 2018–19. This reporting period MDMA laboratories were detected in  
New South Wales (4), Queensland (1) and Victoria (1).
Over the last decade the proportion of cannabis oil extraction laboratories increased, from less than  
1 per cent of national laboratory detections in 2009–10 to 5 per cent in 2018–19. In 2017–18, the 
proportion was 3 per cent.
  The number of cannabis oil extraction laboratory detections increased 6 per cent this reporting  
period, from 17 in 2017–18 to 18 detections 2018–19, the third highest number of detections since 
related reporting began in 2007–08. This reporting period cannabis oil extraction laboratories were 
detected in South Australia (12), Victoria (5) and New South Wales (1). The number of cannabis oil 
extraction laboratories detected in South Australia doubled this reporting period, from 6 in 2017–18  
to 12 in 2018–19.
TABLE 23: Number of clandestine laboratory detections, by drug production type and state and  
territory, 2018–19
State/
Territory
ATS 
(excluding 
MDMA) MDMA
Homebake 
heroin
Cannabis 
oil 
extraction
PSE 
extraction
GHB/ 
GBL Othera Unknownb Totalc
NSW 40 4 0 1 0 1 10 3 59
Vic 42 1 0 5 3 10 53 0 114
Qld 41 1 0 0 0 1 2 36 81
SA 31 0 0 12 1 6 1 11 62
WA 8 0 0 0 0 0 7 0 15
Tas 0 0 0 0 0 0 1 0 1
NT 1 0 0 0 0 0 0 0 1
ACT 1 0 0 0 0 0 1 0 2
Total 164 6 0 18 4 18 75 50 335
a. ‘Other’ refers to the detection of other illicit manufacture.
b. ‘Unknown’ includes seized substances which were unable to be identified or are awaiting analysis.
c. Total may exceed the number of clandestine laboratory detections due to multiple drug production types being identified in a single laboratory.
Over the last decade the proportion of gamma-hydroxybutyrate (GHB)/gamma-butyrolactone (GBL) 
laboratories increased, from zero detections in 2009–10 to 5 per cent of national clandestine laboratory 
detections in 2018–19. In 2017–18 this proportion was 4 per cent.
  The number of GHB/GBL laboratories decreased 18 per cent this reporting period, from a record  
22 detections in 2017–18 to 18 in 2018–19, the second highest number of GHB/GBL laboratory 
detections on record. This reporting period GHB/GBL laboratories were detected in Victoria (10),  
South Australia (6), New South Wales (1) and Queensland (1).
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While it fluctuated, over the last decade the proportion of clandestine laboratories extracting 
pseudoephedrine decreased, from 6 per cent of national laboratory detections in 2009–10 to  
1 per cent in 2018–19. In 2017–18 this proportion was less than 1 per cent.
  The number of pseudoephedrine laboratories doubled this reporting period, from 2 detections  
in 2017–18 to 4 in 2018–19. This reporting period pseudoephedrine extraction laboratories  
were detected in Victoria (3) and South Australia (1).
Over the last decade the proportion of homebake heroin laboratories decreased, accounting for  
less than one percent of national laboratory detections in 2009–10 to no detections reported in both 
2017–18 and 2018–19. There was a spike in detections in 2014–15, with homebake heroin laboratories 
accounting for 2 per cent of national laboratory detections in that reporting period.
Clandestine laboratories detected in Australia also manufacture a range of other illicit drugs, precursors 
and pre-precursors, as well as being used in extraction and recrystallization processes. The number of 
laboratories detected manufacturing other drugs increased 63 per cent this reporting period, from  
46 in 2017–18 to 75 in 2018–19.
  In 2018–19, this included laboratories manufacturing P2P, dimethyltryptamine (DMT), steroids, 
psilocybin and methylamine. Ephedrine, hypophosphorous acid, iodine, piperonal, mescaline,  
cocaine and heroin extraction laboratories were also detected in 2018–19.
The hypophosphorous method of production continues to be the predominant method of ATS  
(excluding MDMA) manufacture in Australia (see Table 24). Over the last decade, the proportion  
of ATS (excluding MDMA) laboratories detected nationally using the hypophosphorous method 
of production increased, from 52 per cent in 2009–10 to 59 per cent in 2018–19. The number of 
laboratories detected using this method of production decreased 7 per cent this reporting period,  
from 103 in 2017–18 to 96 in 2018–19. Other trends observed in ATS (excluding MDMA) laboratory 
detections nationally over the last decade include:
  The proportion of detections identified as using the red phosphorous method decreased, from  
11 per cent in 2009–10 to 7 per cent of detections in 2018–19. The number of laboratories  
detected decreased 42 per cent this reporting period, from 19 in 2017–18 to 11 in 2018–19.
  The proportion of detections identified as using the Nazi/Birch method decreased, from 23 per cent 
in 2009–10 to 6 per cent in 2018–19. The number of laboratories detected decreased 38 per cent  
this reporting period, from 16 in 2017–18 to 10 in 2018–19.
  The proportion of detections identified as using the P2P method remained relatively stable at  
2 per cent in 2009–10 and 3 per cent in 2018–19. The number of laboratories detected decreased  
73 per cent this reporting period, from 11 in 2017–18 to 3 in 2018–19.
  The proportion of detections identified as using other methods of ATS (excluding MDMA) production 
increased, from 11 per cent in 2009–10 to 27 per cent in 2018–19. The number of laboratories 
detected decreased 17 per cent this reporting period, from 53 in 2017–18 to 44 in 2018–19.
In 2018–19, New South Wales accounted for the greatest proportion of the number of hypophosphorous 
laboratories detected nationally (40 per cent). Queensland accounted for the greatest proportion of 
red phosphorous laboratory detections (36 per cent), while Victoria accounted for all P2P laboratory 
detections this reporting period. Western Australia accounted for the greatest proportion of Nazi/Birch 
laboratory detections in 2018–19 (60 per cent).
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TABLE 24: Method of ATS (excluding MDMA) production in clandestine laboratory detections,  
by state and territory, 2018–19
State/
Territory Hypophosphorous Red-phosphorus Nazi/Birch
Phenyl-2- 
propanone (P2P) Othera Totalb
NSW 38 2 0 0 0 40
Vic 30 3 4 3 2 42
Qld 13 4 0 0 24 41
SA 14 1 0 0 16 31
WA 1 0 6 0 1 8
Tas 0 0 0 0 0 0
NT 0 1 0 0 0 1
ACT 0 0 0 0 1 1
Total 96 11 10 3 44 164
a. ‘Other’ includes the detection of other ATS (excluding MDMA) production methods.
b. Total may not equal the number of ATS (excluding MDMA) clandestine laboratory detections as the method of production may not be 
identified or the detection is awaiting analysis.
SIGNIFICANT PRECURSOR SEIZURES
This section provides a snapshot of the identification and/or seizure of some significant quantities  
of precursors, reagents and solvents (by weight) this reporting period:
Ephedrine
  207.50 kilograms in South Australia
  5.50 kilograms in Victoria
  1.05 kilograms in New South Wales.
Hypophosphorous acid
  0.21 kilograms in Queensland
  0.16 kilograms in Queensland.
Iodine
  287.00 kilograms in South Australia
  250.00 kilograms in New South Wales
  250.00 kilograms in New South Wales
  25.00 kilograms in Victoria
  7.30 kilograms in South Australia
  0.49 kilograms in Queensland
  0.40 kilograms in Queensland
  0.33 kilograms in Queensland
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  0.24 kilograms in Queensland
  0.19 kilograms in Queensland
  0.10 kilograms in Queensland.
Pseudoephedrine
  5.00 kilograms in New South Wales
  9,360 tablets in New South Wales.
Red phosphorous
  0.01 kilograms in the Northern Territory.
Other
  138.69 kilograms of MDP2P/PMK in New South Wales
  108.00 kilograms of methyl-2-phenyl-aceto-acetate in Victoria
  100.00 kilograms of methylamine in Victoria
  89.94 kilograms of safrole in New South Wales
  13.00 kilograms of MDP2P/PMK in New South Wales
  10.00 kilograms of GABA in South Australia
  6.00 kilograms if GABA in South Australia
  5.00 kilograms of sodium 2-methyl-3-phenyl glycidate in Victoria
  3.00 kilograms of GABA in South Australia.
This section provides a snapshot of the identification and/or seizure of some significant quantities  
of precursors, reagents and solvents (by volume) this reporting period:
Benzaldehyde
  2.00 litres in Victoria.
Hypophosphorous acid
  220.00 litres in South Australia
  27.00 litres in Victoria
  23.00 litres in New South Wales
  3.05 litres in South Australia.
Piperonal
  0.20 litres in the Australian Capital Territory.
1,4-butanediol
  200.00 litres in Western Australia.85
Other
  1,000.00 litres of tetrahydrofuran in Victoria
  8.00 litres of benzaldehyde in South Australia.
85 This 200.0 litre seizure of 1,4 butanediol (1,4-BD) was the largest of several seizures of 1,4-BD in Western Australia this reporting period, 
which totalled 375.0 litres. 
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LOCATION AND CATEGORY
The majority of clandestine laboratories detected in Australia continue to be located in residential 
areas—though the proportion of clandestine laboratories detected in residential areas decreased  
this reporting period, from 71 per cent in 2017–18 to 69 per cent in 2018–19. Clandestine laboratories 
located in commercial and industrial areas accounted for the second largest proportion of national 
detections this reporting period (10 per cent, an increase from 4 per cent in 2017–18), followed by 
laboratories detected in vehicles (9 per cent, a decrease from 10 per cent in 2017–18), rural areas  
(5 per cent, a decrease from 7 per cent in 2017–18) and other locations (remained relatively stable  
at 5 per cent).
  Several jurisdictions (Queensland, Victoria, and South Australia) reported detections of  
laboratories in hotels/motels or other short-term rental accommodation in 2018–19.
Based on their operating status, there are four distinct categories of clandestine laboratories:
  Category A—active (chemicals and equipment in use)
  Category B—stored/used (equipment and chemicals)86
  Category C—stored/unused (equipment and chemicals)
  Category D—historical site.
Consistent with previous reporting periods, for those able to be categorised, Category C was the 
most common category for clandestine laboratories detected nationally, accounting for 44 per cent 
of laboratories in 2018–19, a decrease from 47 per cent in 2017–18. This was followed by Category B, 
which remained relatively stable at 33 per cent this reporting period (32 per cent in 2017–18),  
Category D which accounted for 12 per cent (a decrease from 13 per cent in 2017–18) and  
Category A, which accounted for 12 per cent (an increase from 8 per cent in 2017–18).
NATIONAL TABLET PRESS SEIZURES
The number of tablet presses seized nationally decreased 42 per cent this reporting period, from  
31 in 2017–18 to 18 in 2018–19. The 18 national tablet press seizures this reporting period comprised  
16 single station/simple presses and 2 rotary presses. In 2018–19, seizures were made in New South 
Wales (6), Victoria (6), South Australia (2), Queensland (1), Tasmania (1), the Northern Territory (1)  
and the Australian Capital Territory (1).
The number of encapsulators seized nationally doubled this reporting period, from 5 in 2017–18 to  
10 in 2018–19 and is the highest number reported since 2011–12 (13). The 10 encapsulators were  
seized in New South Wales (4), South Australia (3), Victoria (1), Western Australia (1) and the  
Northern Territory (1).
86 Laboratories which are fully assembled, but not active at the time of detection.
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NATIONAL IMPACT
The trafficking of precursor chemicals used to produce illicit drugs is a global market in itself, 
and the range of chemicals used worldwide in illicit drug production is increasing.
Indicators of domestic drug production provide a mixed picture. These include border detection,  
seizure, clandestine laboratory, tablet press and encapsulator data.
  In 2018–19, the number of ATS (excluding MDMA) precursors detected at the Australian border 
decreased slightly. While the weight detected close to halved this reporting period, it is the  
second highest weight on record.
  In 2018–19, both the number and weight of MDMA precursors detected at the Australian border 
increased—though the number and weight of detections are comparatively small.
  The number of clandestine laboratories detected nationally in 2018–19 decreased for the seventh 
consecutive reporting period. The 308 laboratories detected this reporting period is the lowest 
number of detections reported in the last decade.
  Clandestine laboratories in Australia manufacture and process a range of illicit drugs, precursors  
and pre-precursors.
 – In 2018–19, this included ATS (excluding MDMA), MDMA, GHB/GBL, DMT, P2P, steroids,  
psilocybin and methylamine, as well as ephedrine, hypophosphorous acid, iodine, piperonal, 
mescaline, cocaine and heroin extraction laboratories.
 – While decreasing over the last decade, clandestine laboratories manufacturing ATS (excluding 
MDMA) continue to account for the greatest proportion of national detections, with 
methylamphetamine the main drug produced in 2018–19.
  The hypophosphorous method of production remains the predominant method of ATS  
(excluding MDMA) production in Australia.
  Clandestine laboratories detected in Australia range from addict-based through to industrial  
scale laboratories.
 – The majority of laboratories detected nationally in 2018–19 continue to be addict-based and 
located in residential areas—though the proportion of other small scale and industrial-scale 
laboratories increased from 2017–18.
 – The majority of laboratories continue to relate to the detection of stored/unused equipment or 
chemicals (Category C). While active laboratories (Category A) were the least detected category 
this reporting period, the proportion of active laboratories detected increased in 2018–19.
  In 2018–19, 18 tablet presses and 10 encapsulators were seized nationally.
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INTRODUCTION
STATISTICS
The Australian Criminal Intelligence Commission (ACIC) uses the National Illicit Drug Reporting  
Format (NIDRF) system to process seizure, arrest and purity data for the Illicit Drug Data Report (IDDR). 
This allows for more accurate analysis of law enforcement data and assists in moving towards nationally 
standardised data holdings. The ACIC acknowledges the assistance of police statisticians and information 
managers in this process. 
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COUNTING METHODOLOGY
The following methodology was used to develop a count of arrests by drug type:
  where a person has been charged with multiple consumer or provider offences for a particular  
type of drug, that person is counted once only as a consumer or provider of that drug
  where consumer or provider charges for a particular drug type have been laid, the provider  
charge takes precedence and the person is counted only as a provider of that drug
  a person who has been charged in relation to multiple drug types is counted as a consumer  
or provider for each drug type
  a person is counted on each separate occasion that they are charged.
DATA SOURCES
ARREST AND SEIZURE DATA
The following agencies provided arrest and seizure data:
  Australian Federal Police (AFP)
  Australian Federal Police, ACT Policing
  New South Wales Police Force
  Northern Territory Police
  Queensland Police Service
  South Australia Police
  Tasmania Police
  Victoria Police
  Western Australia Police Force.
DRUG PURITY DATA
The following agencies and organisations provided drug purity data:
  Australian Federal Police
  ChemCentre Western Australia
  Forensic Science SA
  Forensic Science Service Tasmania
  Health System Information and Performance Reporting, New South Wales Ministry of Health.  
Sample analysis conducted by NSW Forensic & Analytical Science Service (FASS)
  New South Wales Police Force
  Queensland Health Forensic and Scientific Services
  Victoria Police.
The purity tables only represent purity figures for seizures of that drug type that have been analysed at a 
forensic laboratory. The number of ‘cases’ in the purity tables reflects the number of individual samples 
analysed (items), as distinct from the number of seizures/cases (which may have multiple items).
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The time between the date of seizure by police and the date of receipt at laboratories can vary from 
a few days to several months and, in isolated cases, years. The purity table represents those seizures 
analysed during 2018–19, not necessarily all seizures made during that period.
From 2017, the NSW FASS only tests for purity levels on samples submitted from seizures of a 
commercial quantity or greater.
South Australia tests for purity levels on cases when the total weight of drug-containing material within  
a case is >5 grams. All samples with total weight >2 grams are sent for quantitation (if none are >2 grams, 
then the largest sample is sent for quantitation). When the total weight of drug-containing material 
within a case is >100 grams, all samples regardless of their total weight are sent for quantitation.
Tasmania Police do not conduct purity determinations on exhibits unless it is specifically requested by 
the investigator and he/she has a good reason for doing so. Tasmania Police also do not conduct purity 
determinations on less than 0.5 grams. Legislation in Tasmania does not take into account the purity of 
the exhibit, so there are very few instances where purity determinations are of great value and hence 
not worth the significant effort required to determine the purity.
Drug seizures are not routinely tested for purity in the Northern Territory, unless specifically requested. 
The Misuse of Drugs Act (NT) provides for all of the preparation or mixture to be deemed as if all of the 
substance (preparation or mixture) is comprised of the dangerous drug found, irrespective of purity.
Due to legislative changes in the Australian Capital Territory, drug seizures are no longer routinely  
tested for purity.
DRUG PRICE DATA
Data on prices for illicit drugs were collected from each of the police jurisdictions and are based on 
information supplied by covert police units and police informants. Unless otherwise stated, police  
price information has been used.
LIMITATIONS OF THE DATA
OVERVIEW
Despite limitations in the current dataset, the ACIC’s IDDR provides the best collection of arrest and 
seizure statistics available in Australia. The NIDRF data processing system has enabled the ACIC to 
improve statistical quality and reliability.
DATASETS
Since the development and implementation of the NIDRF processing system, limitations with the 
administrative datasets used to compile the statistics have decreased. However, the following factors 
should be considered when using the data to develop assessments or conclusions:
  a lack of uniformity across all states and territories in the recording and storing of data on illicit  
drug arrests and seizures
  ongoing problems with quality control, resulting in the absence of essential information from  
some records
  differences in applying a uniform counting and data extraction methodology across all jurisdictions
  differences in definitions of consumer and provider offences across and within jurisdictions  
over time
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  differences in the way drugs and offences may be coded
  insufficient drug identification
  an inability to identify seizures resulting from joint operations, for example, those involving the  
AFP and a state or territory agency.
DRUG IDENTIFICATION AND CODING
Not all illicit drugs seized by law enforcement are scientifically analysed to establish the precise nature 
of the drug. In some cases, only seizures of a predetermined weight or those that are the subject of a 
‘not guilty’ plea are analysed. In some instances, an initial field test may be carried out to provide an 
indication as to the seized drug, but all other seizures are recorded at the discretion of the investigating 
officer and without further qualification.
Historically, a number of jurisdictional data systems did not differentiate between amphetamines and 
3,4-methylenedioxymethamphetamine (MDMA). This has restricted the ACIC’s ability to monitor and 
report on national trends in regards to seizures and arrests of specific ATS drug types. Similar problems 
continue to exist with the range of drugs recorded as ‘other drugs’. Monitoring and reporting on  
national trends of these drugs is therefore limited.
RECORDING AND STORAGE METHODS
The lack of consistency between law enforcement agencies in recording illicit drug arrests and seizures 
presents difficulties when data are aggregated and compared. Disparities exist in the level of detail 
recorded for each offence, the methods used to quantify the seizures, the way offence and seizure  
data are extracted, and the way counting rules and extraction programs are applied.
QUALITY CONTROL
Missing, incomplete and non-specific information relating to drug seizures makes it impossible to 
precisely calculate the total quantity of each drug type seized. Since 2001–02, the NIDRF system  
has allowed for increased scrutiny of large seizures that may not have been queried in the past.
CONSUMERS AND PROVIDERS
Offenders are classified as consumers or providers in order to differentiate between people who  
have been apprehended for trading in, as opposed to using, illicit drugs. Those charged with  
supply-type offences (importation, trafficking, selling, cultivation and manufacture) are classified 
providers. Those charged with user-type offences (processing or administering drugs for their  
own use) are classified as consumers.
In some cases, the jurisdictions allocate consumer and provider codes, and in others, the ACIC  
applies the codes based on the information on the type of offence committed. Further, there are  
some differences in the methodologies jurisdictions use for applying consumer and provider codes.  
In some states and territories, the quantity of the drug involved determines whether an offence is 
regarded as a consumer or a provider offence. Additionally, the threshold quantity that determines 
whether a person is to be charged as a provider varies over time, both within and between states  
and territories.
Offender data supplied may exclude law enforcement actions that are the subject of ongoing 
investigations.
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DETECTION DATA
Border detection data supplied may exclude detections that are the subject of ongoing investigations.
SEIZURE DATA
The seizure data presented in Table 35 include only those seizures for which a valid drug weight was 
recorded. Consequently, it undercounts both the number of seizures and the amount of drug seized  
for all drug types. Seizure data for ATS, cannabis and other drugs are most likely to be affected by 
the variety of measurement methods and these figures should be treated with caution when making 
comparisons between jurisdictions or over time. This table includes seizures by the AFP and state  
and territory police.
Seizure data supplied may exclude seizures that are the subject of ongoing investigations.
DRUG USE MONITORING IN AUSTRALIA (DUMA) PROGRAM
The DUMA program is an ongoing illicit drug use monitoring program that captures information  
on approximately 2,200 police detainees per year, across five locations throughout Australia. There  
are two core components: a self-report survey and voluntary provision of a urine sample which is 
subjected to urinalysis at an independent laboratory to detect the presence of licit and illicit drugs.  
The self-report survey captures a range of criminal justice, demographic, drug use, drug market 
participation and offending information. Urinalysis serves as an important objective method for 
corroborating self-reported drug use. Not all detainees who respond to the self-report survey  
agree to provide a urine sample when requested, although the urine compliance rate is high.
NATIONAL WASTEWATER DRUG MONITORING PROGRAM
Wastewater analysis is a technique for measuring population-scale consumption of substances. 
Following the recommendations of the National Ice Taskforce and National Ice Action Strategy,  
in 2016 the ACIC received funding under the Proceeds of Crime Act 2002 to deliver the National 
Wastewater Drug Monitoring Program (NWDMP) over three years. Since then, additional funding  
in the ACIC’s annual budgetary appropriation has allowed for the extension of the program.
The University of Queensland and University of South Australia have been commissioned to provide drug 
consumption data to the ACIC. A total of approximately fifty wastewater treatment sites nationally are 
assessed, bimonthly in the case of capital city sites and every four months for regional sites. The aim is to 
acquire data on the population-scale use of substances causing potential harm, either through addiction, 
health risks, or criminal and anti-social behaviour. Drugs monitored by the program include nicotine, 
alcohol, amphetamine, methylamphetamine, cocaine, MDMA, 3,4-methylendioxyamphetamine (MDA), 
heroin, oxycodone, fentanyl, cannabis, mephedrone and methylone.
The ACIC provides data from the NWDMP in the form of public reports three times per year. The reports 
present patterns of substance use across Australia, showing differences in levels between capital cities 
and regional centres within states and territories, and nationally. The collective national data are placed 
in an international context by comparing findings with European and other studies which conduct similar 
wastewater analyses. The public reports are accessible on the ACIC website <https://www.acic.gov.au/
publications/reports/national-wastewater-drug-monitoring-program-reports>.
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JURISDICTIONAL ISSUES
Comparing law enforcement data across states and territories is problematic. Figures reported in  
the IDDR may differ from those reported in other publications. Reasons for this include the date of 
extraction and the counting rules applied. For the information of agencies and individuals wishing to 
interpret the data, specific issues regarding jurisdictional data have been identified by the ACIC and  
the relevant jurisdiction. These issues have been summarised and are presented below.
AUSTRALIAN CAPITAL TERRITORY
ACT Policing provided the ACIC with seizure and offender data. Data are comparable with figures in  
the IDDR from 2002–03 onwards.
As reported by ACT Policing, Simple Cannabis Offence Notices (SCONs) data may not be a true 
representation of the number of SCONs issued for the period as offenders may be subsequently 
summonsed for non-payment and will therefore be included in consumer and provider arrests data.
Data are subject to change and reflect the available data at time of extraction. Totals reported in the 
IDDR may differ from those published in other reports, including annual reports and other publications.
AUSTRALIAN FEDERAL POLICE
The AFP provided national offender, seizure and purity data. This data was compiled in conjunction  
with the AFP’s Forensic Drug Intelligence team. Seizures resulting from joint operations with the 
Department of Home Affairs are represented within AFP figures. Totals may differ from those published 
in other reports, including annual reports and other publications, due to the data extraction being  
based on more recent data and on the AFP using different drug-grouping categories to the ACIC.
DEPARTMENT OF HOME AFFAIRS
Detections of illicit drugs by the Department of Home Affairs are handed to the AFP for investigation 
purposes, safe storage and destruction. Border detections are recorded on ‘DrugLab’, which is updated 
with confirmed seizure weight data from the AFP. At present, there is no provision for an automatic 
update of accurate weights to DrugLab. Data relating to the same border detections held by the AFP  
and DrugLab will differ slightly. This is because only unconfirmed seizure weights are initially recorded. 
The Department of Home Affairs detection figures are subject to change and reflect available data at 
time of extraction. As such, figures published in the IDDR may differ from those published in other 
reports, including Department of Home Affairs Annual Reports.
For operational reasons, the format of data presented in the IDDR may vary from year to year.
From 2010–11, the Department of Home Affairs was unable to provide importation data to populate 
country of embarkation charts for inclusion in the report. From 2011–12, dehydroepiandrosterone 
(DHEA) and steroid border detection data are reported as a combined figure.
The Department of Home Affairs advised that statistics relating to cannabis in 2014–15 were impacted 
by a number of food products containing hemp and cannabis seeds, such as ‘Hemp Force Powder’  
and tea.
From 2012–13, the Department of Home Affairs have provided benzodiazepine and opiate statistics 
which only represent a component of the larger pharmaceuticals category.
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NEW SOUTH WALES
The New South Wales Police Force provided the ACIC with offender, seizure and purity data, with  
the purity sample analysis conducted by NSW FASS.
From 2017, New South Wales FASS have made changes to their processes in response to legislative 
changes to the Drugs Misuse and Trafficking Act—amendment 2016. New South Wales Police Force  
is now able to take a subsample of a seizure and therefore not all seizures are sent to FASS for analysis. 
Around 50 per cent of samples are sent to FASS and they may or may not be weighted by New South 
Wales Police Force. The subsamples analysed by FASS are weighted, but purity tests will only be carried 
out on samples related to a commercial quantity or greater. This will impact the data provided for the 
IDDR and caution should be exercised in comparing data.
Prior to 2005–06, New South Wales Police Force data was extracted directly from the mainframe 
recording system (COPS). Since 2005–06, data has been extracted from COPS using a data warehousing 
application ‘Enterprise Data Warehouse’. Tests to verify the process of data extraction have been 
undertaken and the New South Wales Police Force is confident that the retrieval process is  
comparable with previous extracts from COPS.
To improve data quality, in 2015–16 the New South Wales Police Force changed the way in which 
pharmaceutical drugs are coded. As a result, caution should be exercised in comparing data across  
the reporting periods.
Data are subject to change and reflect the available data at time of extraction. Totals reported  
in the IDDR may differ from those published in other reports, including annual reports and  
other publications.
NORTHERN TERRITORY
Northern Territory Police provided the ACIC with seizure and offender data.
Data collection methods in the Northern Territory have been audited since the 2010–11 report.  
The change in data collection methodology has resulted in the provision of more detailed and  
accurate data.
Seizure data for the Northern Territory relate to suspected drug type only. The number of  
Drug Infringement Notices (DINs) may differ to those extracted from the Integrated Justice  
Information System.
Kava seizures in the Northern Territory may constitute a significant proportion of the number  
and weight of other and unknown NEC seizures within a given reporting period.
In the Northern Territory, it is often difficult to obtain accurate date of birth and address details  
from offenders; however, this lack of detail does not invalidate the data.
Data are subject to change and reflect the available data at time of extraction. Totals reported in the 
IDDR may differ from those published in other reports, including annual reports and other publications.
QUEENSLAND
The Queensland Police Service provided the ACIC with offender and seizure data. Queensland Health 
Forensic and Scientific Services provided purity data.
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The 2018–19 data reflects further improvements made to the quality of the Queensland Police  
Service drug seizure and offender dataset. As a result, caution should be exercised in comparing  
data from previous reporting periods.
Since 2001, a legislated minor drugs offence diversion program requires police to offer an eligible  
person the opportunity to participate in a drug diversion assessment program with an approved 
Queensland Health program provider, as an alternative to prosecution. Arrest data provided by  
the Queensland Police Service includes data for offenders participating in this diversion program.
Data are subject to change and reflect the available data at time of extraction. Totals reported  
in the IDDR may differ from those published in other reports, including annual reports and  
other publications.
SOUTH AUSTRALIA
South Australia Police provided the ACIC with offender and seizure data. Forensic Science  
South Australia provided the purity data.
South Australia Police implemented a new system for recording criminal statistics and other  
business data in November 2018.
From 2015–16, offender data provided by South Australia Police includes data for offenders  
participating in its Drug Diversion Program (excluding diversion records not related to a drug seizure).  
As a result, caution should be exercised in comparing data from previous reporting periods.
The Illicit Drug Diversion Initiative implemented changes which took effect on 1 April 2019. An  
adult can only be referred to the Drug Diversion Program no more than twice in a four year period  
and on a third detection, the adult is referred directly to court. This action has resulted in a reduction  
in drug diversions.
Data are subject to change and reflect the available data at time of extraction. Totals reported in the 
IDDR may differ from those published in other reports, including annual reports and other publications.
TASMANIA
Tasmania Police provided the ACIC with offender and seizure data. Forensic Science Service Tasmania 
provided the purity data.
It is important to note that the reported figures may differ from those reported in the Tasmania Police 
Annual Report and other publications due to the differing counting rules applied.
VICTORIA
Victoria Police provided the ACIC with offender, seizure and drug quantities data from Law  
Enforcement Assistance Program (LEAP). Drug purity data was provided by Victoria Police Forensics 
Department. Drug quantities and weights reported are estimates only and are not validated by  
forensic analysis.
Victorian clandestine laboratory detection figures are taken from the record of attendances by  
forensic analysts at suspected laboratories and validated by the Clandestine Laboratory Squad.
Data are subject to change and reflect the available data at time of extraction. Totals reported in the 
IDDR may differ from those published in other reports, including annual reports and other publications.
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WESTERN AUSTRALIA
The Western Australia Police Force provided the ACIC with seizure and offender data. ChemCentre 
provided the purity data. 
The 2018–19 data reflects further improvements made to the quality of the Western Australia Police 
Force drug seizure and offender dataset. A counting rule was developed to overcome a limitation of 
current recording practices, which would otherwise lead to double-counting of some drug seizures.  
This has generally resulted in a decrease in the number and weight of seizures compared with  
previous reporting periods. As a result, caution should be exercised in comparing data from  
previous reporting periods. 
Data are subject to change and reflect the available data at time of extraction. Totals reported in the 
IDDR may differ from those published in other reports, including the Western Australia Police Force 
Annual Report and other publications. 
Legislation changes for cannabis offences in Western Australia took effect from 1 August 2011 following 
amendments to the Misuse of Drugs Act 1981. The Cannabis Infringement Notice (CIN) was replaced 
by a Cannabis Intervention Requirement (CIR) which changes the way police should respond when 
dealing with a person in possession of cannabis. From 1 August 2011, any person who does not have a 
criminal history and is found to have 10 grams or less of cannabis will be offered 28 days to complete a 
Cannabis Intervention Session after which no charges will follow. People with previous cannabis-related 
convictions are ineligible for this option. Participation in a Cannabis Intervention Session is offered once 
to adult offenders, but twice to juveniles aged between 14 and 17 years, so that subsequent offending 
would result in charges being brought directly.
EXPLANATORY NOTES
The following explanatory notes relate to terms used in this report.
AMPHETAMINE-TYPE STIMULANTS (ATS)
Unless otherwise specified, ‘amphetamine-type stimulants’ (ATS) include amphetamine, 
methylamphetamine and phenethylamines.
ARRESTS
‘Arrest’ incorporates recorded law enforcement action against a person for suspected unlawful 
involvement in illicit drugs. It incorporates enforcement action by way of arrest and charge, 
summons, diversion program, cannabis expiation notice (South Australia), simple cannabis offence 
notice (Australian Capital Territory), drug infringement notice (Northern Territory), notice to appear 
(Queensland) and cannabis intervention requirement (Western Australia). Some charges may have  
been subsequently dropped or the defendant may have been found not guilty.
CANNABIS
‘Cannabis’ includes cannabis plant, leaf, resin, oil, seed and all other forms.
CATEGORIES FOR CLANDESTINE LABORATORIES
Since 2011–12, jurisdictions have been asked to distinguish detected clandestine laboratories into the 
following four categories, taken from the United Nations Office on Drugs and Crime Annual Report 
Questionnaire that is used to inform the World Drug Report.
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Addict-based labs (kitchen labs). Only basic equipment and simple procedures are used. Typically,  
those operating in such laboratories have a limited or non-existent knowledge of chemistry and simply 
follow instructions. Usually, there are no significant stores of precursors and the amount of drugs or 
other substances manufactured is for personal use. A typical manufacture cycle for ATS would yield  
less than 50 grams of the substance.
Other small scale labs. People operating in these laboratories have advanced chemical knowledge. 
More complex amphetamine-type stimulants may be manufactured. Laboratories may be of similar 
size to ‘addict-based labs’ but frequently employ non-improvised equipment. They may also include 
experimental laboratories. The amount manufactured is typically for personal use or for a limited 
number of close associates. Typical manufacture cycle for ATS would yield less than 500 grams of the 
substance.
Medium sized labs. Use commercially available standard equipment and glassware (in some cases, 
custom-made equipment). They are not very mobile, making it possible to recover precursor chemicals 
and equipment in many cases (production estimates are the most viable and reliable). The amount 
manufactured at such sites is primarily for illicit economic gain. A typical manufacture cycle for ATS 
would yield between 0.5 to 50 kilograms.
Industrial scale labs. Laboratories use oversized equipment and glassware that is either custom-made 
or purchased from industrial processing sources. Such industrial operations produce significant amounts 
of ATS in very short periods of time, only limited by access to precursors, reagents and consumables in 
adequate quantities and the logistics and manpower to handle large amounts of drugs or chemicals and 
process them into the next step. A typical manufacture cycle for ATS would yield 50 kilograms or more.
COCAINE
‘Cocaine’ includes cocaine, coca leaf and coca paste.
DETECTION
In the context of the border environment, the term ‘detection’ refers to the identification of illicit  
drugs by the Department of Home Affairs.
EMBARKATION POINT
‘Embarkation point’ describes the origin of the transport stage of importations. Embarkation is  
affected by air and sea transport connection patterns and the location of transport hubs, and may  
not necessarily reflect the true origin of drugs.
Australia may appear as an embarkation country due to an export-detection. In some instances,  
it may relate to detections on air passengers travelling domestically on an international flight.
HALLUCINOGENS
‘Hallucinogens’ includes tryptamines such as lysergic acid diethylamide (LSD) and  
psilocybin-containing mushrooms.
HEROIN AND OTHER OPIOIDS
‘Heroin and other opioids’ include opioid analgesics such as heroin, methadone and pethidine  
and opiate analgesics including codeine, morphine and opium.
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NATIONAL MEDIAN DRUG PRICES
Unless otherwise stated, national median drug prices are calculated using price data reported  
by four or more jurisdictions.
OTHER DRUGS
‘Other drugs’ include anabolic agents and selected hormones, tryptamines, anaesthetics, 
pharmaceuticals and drugs not elsewhere classified. Current reporting processes do not enable  
detailed identification of these drugs.
PERCENTAGES
Percentages reported in the text of this report have been rounded to whole numbers. As a  
consequence, they may differ slightly from figures reported in the tables of the report and figures 
reported in other publications.
PHENETHYLAMINES
Phenethylamines include 3,4-methylenedioxymethamphetamine (MDMA, commonly known as 
‘ecstasy’), 3,4-methylenedioxyethylamphetamine (MDEA), 3,4-methylenedioxyamphetamine (MDA), 
dimethoxyamphetamine (DMA) and paramethoxyamphetamine (PMA).
SEIZURE
‘Seizure’ is the confiscation by a law enforcement agency of a quantity of an illicit drug or a regulated 
drug being used or possessed unlawfully, whether or not an arrest is made in conjunction with that 
confiscation.
The amount of drug seized may be recorded by weight, volume or as a unit count—for example,  
number of tablets, plants or bags. The method of estimating the amount of drug seized varies between 
and within jurisdictions. For example, seizures of ATS in tablet form may be weighed or counted.
STEROIDS
‘Steroids’ include anabolic and androgenic steroids such as testosterone, nandrolone and stanazolol.
SYMBOLS AND ABBREVIATIONS
The following symbols and abbreviations are used in the tables:
gms grams
na not available
NEC not elsewhere classified
no. number
r revised figure
%  per cent
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W
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 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 
po
lic
e.
 T
ot
al
s m
ay
 d
iff
er
 fr
om
 th
os
e 
re
po
rt
ed
 in
 ju
ris
di
ct
io
na
l a
nn
ua
l r
ep
or
ts
 d
ue
 to
 th
e 
di
ffe
re
nt
 c
ou
nt
in
g 
ru
le
s a
pp
lie
d.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
8 
 TA
BL
E 
35
 (c
on
tin
ue
d)
: S
ei
zu
re
s—
dr
ug
 ty
pe
, b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 
 
N
SW
 
Vi
c 
Q
ld
 
SA
 
W
A 
Ta
s 
N
T 
AC
T 
To
ta
l 
Co
ca
in
e 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
3,
11
0 
27
7 
73
0 
18
 
39
5 
29
 
27
 
12
3 
4,
70
9 
W
ei
gh
t (
gm
s)
 
24
7,
27
8 
11
,8
47
 
11
,3
63
 
37
7 
8,
28
1 
33
2 
13
4 
5,
30
0 
28
4,
91
2 
AF
P 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
51
1 
10
1 
31
 
2 
20
 
0 
0 
4 
66
9 
W
ei
gh
t (
gm
s)
 
65
1,
41
8 
52
,0
82
 
63
2,
91
2 
73
 
16
,6
77
 
0 
0 
49
8 
1,
35
3,
66
0 
 
 
 
 
 
 
 
 
 
 
St
er
oi
ds
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
21
7 
0 
67
 
0 
29
 
0 
32
 
30
 
37
5 
W
ei
gh
t (
gm
s)
 
9,
40
9 
0 
3,
41
5 
0 
58
2 
0 
1,
75
6 
36
7 
15
,5
29
 
AF
P 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
10
 
5 
1 
0 
0 
0 
0 
0 
16
 
W
ei
gh
t (
gm
s)
 
46
7 
5,
20
6 
90
 
0 
0 
0 
0 
0 
5,
76
3 
 
 
 
 
 
 
 
 
 
 
Ha
llu
ci
no
ge
ns
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
20
9 
17
 
32
 
3 
45
 
8 
8 
19
 
34
1 
W
ei
gh
t (
gm
s)
 
48
0 
85
 
3,
01
5 
23
 
82
9 
96
 
8 
92
4 
5,
46
0 
AF
P 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
15
5 
60
 
2 
0 
15
 
0 
0 
3 
23
5 
W
ei
gh
t (
gm
s)
 
5,
27
5 
7,
87
4 
30
1 
0 
41
 
0 
0 
16
4 
13
,6
55
 
 
 
 
 
 
 
 
 
 
 
O
th
er
 a
nd
 u
nk
no
w
n 
dr
ug
s n
ec
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
3,
78
0 
34
8 
94
9 
17
 
1,
77
0 
18
6 
21
9 
19
6 
7,
46
5 
W
ei
gh
t (
gm
s)
 
2,
32
2,
60
4 
10
,4
74
 
40
,8
38
 
9,
62
3 
60
,2
23
 
3,
66
6 
64
,9
78
 
2,
17
6 
2,
51
4,
58
2 
AF
P 
 
 
 
 
 
 
 
 
 
Se
izu
re
s (
no
.) 
98
0 
44
1 
93
 
6 
42
 
0 
6 
6 
1,
57
4 
W
ei
gh
t (
gm
s)
 
2,
86
2,
68
3 
2,
61
9,
44
1 
10
4,
26
6 
1,
59
3 
49
,3
37
 
0 
4,
60
5 
2,
10
0 
5,
64
4,
02
5 
N
ot
e:
 In
cl
ud
es
 o
nl
y 
th
os
e 
se
izu
re
s f
or
 w
hi
ch
 a
 d
ru
g 
w
ei
gh
t w
as
 re
co
rd
ed
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 
po
lic
e.
 T
ot
al
s m
ay
 d
iff
er
 fr
om
 th
os
e 
re
po
rt
ed
 in
 ju
ris
di
ct
io
na
l a
nn
ua
l r
ep
or
ts
 d
ue
 to
 th
e 
di
ffe
re
nt
 c
ou
nt
in
g 
ru
le
s a
pp
lie
d.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
9 
PU
RI
TY
 T
AB
LE
S 
 TA
BL
E 
36
: A
m
ph
et
am
in
e 
pu
rit
y 
le
ve
ls
—
st
at
e 
an
d 
te
rr
ito
ry
, b
y 
qu
ar
te
r, 
20
18
–1
9 
 
Ju
ly
–S
ep
te
m
be
r 2
01
8 
 
O
ct
ob
er
–D
ec
em
be
r 2
01
8 
 
Ja
nu
ar
y–
M
ar
ch
 2
01
9 
 
Ap
ril
–J
un
e 
20
19
 
 
To
ta
l J
ul
y 
20
18
–J
un
e 
20
19
 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
 C
as
es
 
 M
ed
ia
n 
 M
in
  
 M
ax
 
 
   
Ca
se
s 
 M
ed
ia
n 
 M
in
  
 M
ax
 
 
   
Ca
se
s 
M
ed
ia
n 
 M
in
  
 M
ax
 
 
   
Ca
se
s 
M
ed
ia
n 
 M
in
  
M
ax
 
 
   
Ca
se
s 
 M
ed
ia
n 
  M
in
  
  M
ax
 
St
at
e/
te
rr
ito
ry
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
N
SW
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
5 
72
.0
 
69
.5
 
74
.0
 
 
1 
1.
0 
1.
0 
1.
0 
 
– 
– 
– 
– 
 
6 
71
.5
 
1.
0 
74
.0
 
>2
 g
m
s 
1 
10
.5
 
10
.5
 
10
.5
 
 
9 
71
.5
 
70
.0
 
75
.0
 
 
29
 
71
.0
 
14
.0
 
74
.0
 
 
– 
– 
– 
– 
 
39
 
71
.0
 
10
.5
 
75
.0
 
To
ta
l 
1 
10
.5
 
10
.5
 
10
.5
 
 
14
 
71
.7
 
69
.5
 
75
.0
 
 
30
 
71
.0
 
1.
0 
74
.0
 
 
– 
– 
– 
– 
 
45
 
71
.0
 
1.
0 
75
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
Vi
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
15
 
24
.0
 
0.
9 
80
.0
 
 
3 
2.
0 
1.
4 
3.
2 
 
3 
7.
8 
1.
7 
14
.4
 
 
2 
5.
6 
4.
2 
7.
1 
 
23
 
9.
4 
0.
9 
80
.0
 
>2
 g
m
s 
1 
2.
6 
2.
6 
2.
6 
 
– 
– 
– 
– 
 
4 
4.
9 
1.
6 
35
.4
 
 
– 
– 
– 
– 
 
5 
2.
6 
1.
6 
35
.4
 
To
ta
l 
16
 
21
.0
 
0.
9 
80
.0
 
 
3 
2.
0 
1.
4 
3.
2 
 
7 
7.
4 
1.
6 
35
.4
 
 
2 
5.
6 
4.
2 
7.
1 
 
28
 
7.
6 
0.
9 
80
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
Q
ld
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
8.
0 
8.
0 
8.
0 
 
1 
8.
0 
8.
0 
8.
0 
>2
 g
m
s 
1 
6.
6 
6.
6 
6.
6 
 
1 
5.
0 
5.
0 
5.
0 
 
2 
10
.4
 
10
.4
 
10
.5
 
 
– 
– 
– 
– 
 
4 
8.
5 
5.
0 
10
.5
 
To
ta
l 
1 
6.
6 
6.
6 
6.
6 
 
1 
5.
0 
5.
0 
5.
0 
 
2 
10
.4
 
10
.4
 
10
.5
 
 
1 
8.
0 
8.
0 
8.
0 
 
5 
8.
0 
5.
0 
10
.5
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
SA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
ot
e:
 F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
am
ph
et
am
in
e 
se
izu
re
s—
on
ly
 th
os
e 
th
at
 h
av
e 
be
en
 a
na
ly
se
d 
at
 a
 fo
re
ns
ic
 la
bo
ra
to
ry
. T
he
 p
er
io
d 
be
tw
ee
n 
th
e 
da
te
 o
f s
ei
zu
re
 b
y 
po
lic
e 
an
d 
th
e 
da
te
 o
f r
ec
ei
pt
 a
t t
he
 la
bo
ra
to
ry
 a
nd
 
su
bs
eq
ue
nt
 a
na
ly
sis
 c
an
 v
ar
y 
gr
ea
tly
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 p
ol
ic
e.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
10
 
TA
BL
E 
36
 (c
on
tin
ue
d)
: A
m
ph
et
am
in
e 
pu
rit
y 
le
ve
ls
—
st
at
e 
an
d 
te
rr
ito
ry
, b
y 
qu
ar
te
r, 
20
18
–1
9 
 
Ju
ly
–S
ep
te
m
be
r 2
01
8 
 
O
ct
ob
er
–D
ec
em
be
r 2
01
8 
 
Ja
nu
ar
y–
M
ar
ch
 2
01
9 
 
Ap
ril
–J
un
e 
20
19
 
 
To
ta
l J
ul
y 
20
18
–J
un
e 
20
19
 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Ca
se
s 
M
ed
ia
n 
 M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
 M
ed
ia
n 
 M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
St
at
e/
te
rr
ito
ry
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
W
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
2 
4.
0 
4.
0 
4.
0 
 
4 
32
.5
 
4.
0 
43
.0
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
6 
17
.0
 
4.
0 
43
.0
 
To
ta
l 
2 
4.
0 
4.
0 
4.
0 
 
4 
32
.5
 
4.
0 
43
.0
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
6 
17
.0
 
4.
0 
43
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
Ta
s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
 
– 
– 
 
– 
– 
 
– 
– 
 
– 
– 
– 
– 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
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– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AC
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
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gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
ot
e:
  F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
am
ph
et
am
in
e 
se
izu
re
s—
on
ly
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2 
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s 
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.0
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.0
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.5
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.5
 
 
32
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.2
 
56
.5
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.0
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.5
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.0
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.0
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4 
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.0
 
2.
0 
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.0
 
>2
 g
m
s 
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.5
 
1.
0 
80
.0
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77
.0
 
1.
0 
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.0
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0 
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.0
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0 
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.0
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6 
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0 
83
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10
4 
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.0
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83
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9 
77
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79
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– 
– 
– 
 
1 
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.6
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.6
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– 
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– 
– 
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.6
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.6
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.6
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9 
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.9
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80
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81
.9
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32
 
79
.5
 
1.
7 
81
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0.
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.0
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82
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29
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.0
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81
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22
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.0
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8 
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1 
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0.
1 
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88
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>2
 g
m
s 
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– 
– 
 
3 
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.9
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80
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5 
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.9
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80
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– 
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73
.0
 
 
31
5 
29
.5
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5 
72
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.0
 
4.
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36
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76
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.5
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.0
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s 
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36
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16
 
79
.0
 
77
.5
 
81
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53
 
77
.5
 
29
.0
 
82
.0
 
To
ta
l 
29
 
70
.5
 
30
.0
 
82
.0
 
 
8 
76
.2
 
29
.0
 
81
.5
 
 
48
 
77
.5
 
36
.5
 
83
.0
 
 
51
 
76
.5
 
43
.0
 
90
.5
 
 
13
6 
76
.2
 
29
.0
 
90
.5
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
1 
75
.9
 
75
.9
 
75
.9
 
 
– 
– 
– 
– 
 
1 
77
.7
 
77
.7
 
77
.7
 
 
– 
– 
– 
– 
 
2 
76
.8
 
75
.9
 
77
.7
 
>2
 g
m
s 
1 
49
.9
 
49
.9
 
49
.9
 
 
– 
– 
– 
– 
 
1 
75
.3
 
75
.3
 
75
.3
 
 
1 
39
.4
 
39
.4
 
39
.4
 
 
3 
49
.9
 
39
.4
 
75
.3
 
To
ta
l 
2 
62
.9
 
49
.9
 
75
.9
 
 
– 
– 
– 
– 
 
2 
76
.5
 
75
.3
 
77
.7
 
 
1 
39
.4
 
39
.4
 
39
.4
 
 
5 
75
.3
 
39
.4
 
77
.7
 
Vi
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
21
1 
55
.2
 
7.
2 
95
.3
 
 
12
8 
19
.3
 
7.
4 
85
.5
 
 
12
0 
24
.4
 
1.
1 
86
.7
 
 
32
 
55
.2
 
14
.5
 
82
.6
 
 
49
1 
28
.2
 
1.
1 
95
.3
 
>2
 g
m
s 
59
 
20
.7
 
7.
0 
86
.3
 
 
40
 
36
.5
 
11
.3
 
89
.0
 
 
50
 
68
.3
 
4.
0 
91
.0
 
 
30
 
19
.0
 
6.
0 
85
.0
 
 
17
9 
24
.3
 
4.
0 
91
.0
 
To
ta
l 
27
0 
38
.0
 
7.
0 
95
.3
 
 
16
8 
20
.3
 
7.
4 
89
.0
 
 
17
0 
31
.9
 
1.
1 
91
.0
 
 
62
 
23
.3
 
6.
0 
85
.0
 
 
67
0 
26
.0
 
1.
1 
95
.3
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
2 
73
.7
 
70
.8
 
76
.6
 
 
– 
– 
– 
– 
 
1 
72
.9
 
72
.9
 
72
.9
 
 
– 
– 
– 
– 
 
3 
72
.9
 
70
.8
 
76
.6
 
>2
 g
m
s 
3 
57
.0
 
55
.8
 
60
.0
 
 
5 
76
.8
 
72
.5
 
79
.5
 
 
7 
74
.7
 
56
.5
 
80
.8
 
 
3 
70
.7
 
38
.9
 
78
.2
 
 
18
 
74
.7
 
38
.9
 
80
.8
 
To
ta
l 
5 
60
.0
 
55
.8
 
76
.6
 
 
5 
76
.8
 
72
.5
 
79
.5
 
 
8 
74
.7
 
56
.5
 
80
.8
 
 
3 
70
.7
 
38
.9
 
78
.2
 
 
21
 
74
.7
 
38
.9
 
80
.8
 
Q
ld
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
18
 
10
.0
 
4.
2 
63
.1
 
 
15
 
22
.3
 
10
.1
 
73
.8
 
 
17
 
45
.7
 
31
.7
 
72
.5
 
 
22
 
66
.8
 
4.
3 
72
.2
 
 
72
 
32
.2
 
4.
2 
73
.8
 
>2
 g
m
s 
3 
61
.2
 
12
.8
 
68
.9
 
 
6 
35
.6
 
9.
2 
69
.7
 
 
8 
27
.5
 
4.
7 
72
.7
 
 
10
 
46
.0
 
15
.5
 
70
.7
 
 
27
 
44
.4
 
4.
7 
72
.7
 
To
ta
l 
21
 
13
.8
 
4.
2 
68
.9
 
 
21
 
23
.7
 
9.
2 
73
.8
 
 
25
 
44
.5
 
4.
7 
72
.7
 
 
32
 
62
.6
 
4.
3 
72
.2
 
 
99
 
32
.9
 
4.
2 
73
.8
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
1 
53
.3
 
53
.3
 
53
.3
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
53
.3
 
53
.3
 
53
.3
 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
75
.6
 
75
.6
 
75
.6
 
 
1 
75
.6
 
75
.6
 
75
.6
 
To
ta
l 
– 
– 
– 
– 
 
1 
53
.3
 
53
.3
 
53
.3
 
 
– 
– 
– 
– 
 
1 
75
.6
 
75
.6
 
75
.6
 
 
2 
64
.4
 
53
.3
 
75
.6
 
SA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
7 
35
.6
 
15
.3
 
69
.9
 
 
– 
– 
– 
– 
 
7 
19
.1
 
18
.1
 
23
.4
 
 
1 
33
.2
 
33
.2
 
33
.2
 
 
15
 
19
.6
 
15
.3
 
69
.9
 
>2
 g
m
s 
1 
31
.3
 
31
.3
 
31
.3
 
 
3 
32
.0
 
30
.7
 
65
.0
 
 
69
 
22
.0
 
16
.4
 
37
.2
 
 
4 
36
.9
 
34
.0
 
73
.7
 
 
77
 
22
.1
 
16
.4
 
73
.7
 
To
ta
l 
8 
35
.4
 
15
.3
 
69
.9
 
 
3 
32
.0
 
30
.7
 
65
.0
 
 
76
 
22
.0
 
16
.4
 
37
.2
 
 
5 
36
.6
 
33
.2
 
73
.7 s
 
 
92
 
22
.1
 
15
.3
 
73
.7
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
ot
e:
 F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
he
ro
in
 se
izu
re
s—
on
ly
 th
os
e 
th
at
 h
av
e 
be
en
 a
na
ly
se
d 
at
 a
 fo
re
ns
ic
 la
bo
ra
to
ry
. T
he
 p
er
io
d 
be
tw
ee
n 
th
e 
da
te
 o
f s
ei
zu
re
 b
y 
po
lic
e 
an
d 
th
e 
da
te
 o
f r
ec
ei
pt
 a
t t
he
 la
bo
ra
to
ry
 a
nd
 su
bs
eq
ue
nt
 
an
al
ys
is 
ca
n 
va
ry
 g
re
at
ly
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 p
ol
ic
e.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
16
 
TA
BL
E 
39
 (c
on
tin
ue
d)
: H
er
oi
n 
pu
rit
y 
le
ve
ls
—
st
at
e 
an
d 
te
rr
ito
ry
, b
y 
qu
ar
te
r, 
20
18
–1
9 
 
Ju
ly
–S
ep
te
m
be
r 2
01
8 
 
O
ct
ob
er
–D
ec
em
be
r 2
01
8 
 
Ja
nu
ar
y–
M
ar
ch
 2
01
9 
 
Ap
ril
–J
un
e 
20
19
 
 
To
ta
l J
ul
y 
20
18
–J
un
e 
20
19
 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
St
at
e/
te
rr
ito
ry
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
W
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
1 
59
.0
 
59
.0
 
59
.0
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
59
.0
 
59
.0
 
59
.0
 
>2
 g
m
s 
1 
60
.0
 
60
.0
 
60
.0
 
 
15
 
73
.0
 
37
.0
 
80
.0
 
 
5 
63
.0
 
18
.0
 
81
.0
 
 
41
 
75
.0
 
22
.0
 
82
.0
 
 
62
 
74
.5
 
18
.0
 
82
.0
 
To
ta
l 
2 
59
.5
 
59
.0
 
60
.0
 
 
15
 
73
.0
 
37
.0
 
80
.0
 
 
5 
63
.0
 
18
.0
 
81
.0
 
 
41
 
75
.0
 
22
.0
 
82
.0
 
 
63
 
74
.0
 
18
.0
 
82
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
61
.0
 
61
.0
 
61
.0
 
 
– 
– 
– 
– 
 
1 
61
.0
 
61
.0
 
61
.0
 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
61
.0
 
61
.0
 
61
.0
 
 
– 
– 
– 
– 
 
1 
61
.0
 
61
.0
 
61
.0
 
Ta
s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AC
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
ot
e:
 F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
he
ro
in
 se
izu
re
s—
on
ly
 th
os
e 
th
at
 h
av
e 
be
en
 a
na
ly
se
d 
at
 a
 fo
re
ns
ic
 la
bo
ra
to
ry
. T
he
 p
er
io
d 
be
tw
ee
n 
th
e 
da
te
 o
f s
ei
zu
re
 b
y 
po
lic
e 
an
d 
th
e 
da
te
 o
f r
ec
ei
pt
 a
t t
he
 la
bo
ra
to
ry
 a
nd
 su
bs
eq
ue
nt
 
an
al
ys
is 
ca
n 
va
ry
 g
re
at
ly
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 p
ol
ic
e.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
17
 
TA
BL
E 
40
: C
oc
ai
ne
 p
ur
ity
 le
ve
ls
—
st
at
e 
an
d 
te
rr
ito
ry
, b
y 
qu
ar
te
r, 
20
18
–1
9 
 
Ju
ly
–S
ep
te
m
be
r 2
01
8 
 
O
ct
ob
er
–D
ec
em
be
r 2
01
8 
 
Ja
nu
ar
y–
M
ar
ch
 2
01
9 
 
Ap
ril
–J
un
e 
20
19
 
 
To
ta
l J
ul
y 
20
18
–J
un
e 
20
19
 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
St
at
e/
te
rr
ito
ry
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
  (
no
.) 
  (
%
) 
(%
) 
(%
) 
N
SW
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
40
 
38
.5
 
6.
5 
84
.5
 
 
19
 
41
.5
 
11
.0
 
79
.0
 
 
28
 
41
.7
 
24
.5
 
88
.5
 
 
16
 
46
.0
 
18
.5
 
85
.5
 
 
10
3 
39
.5
 
6.
5 
88
.5
 
>2
 g
m
s 
60
 
71
.2
 
11
.0
 
88
.0
 
 
45
 
49
.5
 
6.
5 
89
.0
 
 
75
 
64
.5
 
1.
5 
88
.5
 
 
44
 
63
.0
 
1.
0 
92
.0
 
 
22
4 
64
.0
 
1.
0 
92
.0
 
To
ta
l 
10
0 
59
.5
 
6.
5 
88
.0
 
 
64
 
49
.5
 
6.
5 
89
.0
 
 
10
3 
56
.0
 
1.
5 
88
.5
 
 
60
 
63
.0
 
1.
0 
92
.0
 
 
32
7 
57
.0
 
1.
0 
92
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
1 
79
.6
 
79
.6
 
79
.6
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
79
.6
 
79
.6
 
79
.6
 
>2
 g
m
s 
10
 
75
.7
 
23
.5
 
85
.6
 
 
3 
85
.4
 
85
.3
 
85
.4
 
 
10
 
78
.7
 
27
.4
 
82
.4
 
 
9 
66
.6
 
26
.8
 
84
.4
 
 
32
 
77
.2
 
23
.5
 
85
.6
 
To
ta
l 
10
 
75
.7
 
23
.5
 
85
.6
 
 
4 
85
.3
 
79
.6
 
85
.4
 
 
10
 
78
.7
 
27
.4
 
82
.4
 
 
9 
66
.6
 
26
.8
 
84
.4
 
 
33
 
77
.5
 
23
.5
 
85
.6
 
Vi
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
24
2 
50
.9
 
0.
5 
96
.5
 
 
12
4 
41
.2
 
3.
6 
93
.5
 
 
10
0 
48
.6
 
8.
5 
10
0 
 
33
 
65
.9
 
5.
0 
86
.0
 
 
49
9 
50
.3
 
0.
5 
10
0 
>2
 g
m
s 
89
 
63
.3
 
9.
6 
91
.6
 
 
54
 
43
.0
 
0.
7 
85
.0
 
 
37
 
73
.0
 
6.
7 
88
.0
 
 
30
 
79
.0
 
17
.0
 
87
.5
 
 
21
0 
64
.9
 
0.
7 
91
.6
 
To
ta
l 
33
1 
54
.2
 
0.
5 
96
.5
 
 
17
8 
42
.0
 
0.
7 
93
.5
 
 
13
7 
52
.3
 
6.
7 
10
0 
 
63
 
71
.1
 
5.
0 
87
.5
 
 
70
9 
54
.1
 
0.
5 
10
0 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
1 
37
.5
 
37
.5
 
37
.5
 
 
2 
50
.3
 
30
.1
 
70
.5
 
 
– 
– 
– 
– 
 
3 
37
.5
 
30
.1
 
70
.5
 
>2
 g
m
s 
2 
62
.3
 
41
.2
 
83
.5
 
 
5 
60
.9
 
48
.5
 
85
.6
 
 
4 
73
.4
 
67
.5
 
79
.8
 
 
3 
82
.6
 
69
.7
 
83
.7
 
 
14
 
68
.9
 
41
.2
 
85
.6
 
To
ta
l 
2 
62
.3
 
41
.2
 
83
.5
 
 
6 
55
.1
 
37
.5
 
85
.6
 
 
6 
69
.3
 
30
.1
 
79
.8
 
 
3 
82
.6
 
69
.7
 
83
.7
 
 
17
 
68
.2
 
30
.1
 
85
.6
 
Q
ld
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
89
 
32
.9
 
6.
8 
76
.5
 
 
54
 
38
.0
 
1.
1 
79
.0
 
 
71
 
37
.2
 
8.
7 
77
.9
 
 
77
 
30
.3
 
1.
4 
76
.9
 
 
29
1 
36
.2
 
1.
1 
79
.0
 
>2
 g
m
s 
42
 
41
.0
 
3.
1 
72
.3
 
 
40
 
51
.3
 
5.
5 
78
.0
 
 
40
 
53
.8
 
0.
6 
75
.5
 
 
58
 
58
.6
 
5.
8 
77
.4
 
 
18
0 
49
.5
 
0.
6 
78
.0
 
To
ta
l 
13
1 
38
.4
 
3.
1 
76
.5
 
 
94
 
39
.7
 
1.
1 
79
.0
 
 
11
1 
42
.2
 
0.
6 
77
.9
 
 
13
5 
41
.6
 
1.
4 
77
.4
 
 
47
1 
40
.6
 
0.
6 
79
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
1 
37
.8
 
37
.8
 
37
.8
 
 
1 
65
.9
 
65
.9
 
65
.9
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
2 
51
.8
 
37
.8
 
65
.9
 
>2
 g
m
s 
3 
53
.1
 
52
.2
 
79
.5
 
 
5 
65
.4
 
53
.4
 
84
.8
 
 
10
 
72
.0
 
47
.7
 
85
.3
 
 
3 
80
.1
 
77
.9
 
80
.5
 
 
21
 
76
.5
 
47
.7
 
85
.3
 
To
ta
l 
4 
52
.6
 
37
.8
 
79
.5
 
 
6 
65
.6
 
53
.4
 
84
.8
 
 
10
 
72
.0
 
47
.7
 
85
.3
 
 
3 
80
.1
 
77
.9
 
80
.5
 
 
23
 
67
.5
 
37
.8
 
85
.3
 
SA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
7 
49
.2
 
0.
8 
64
.6
 
 
5 
72
.4
 
26
.3
 
84
.1
 
 
– 
– 
– 
– 
 
35
 
81
.4
 
66
.8
 
82
.9
 
 
47
 
81
.3
 
0.
8 
84
.1
 
>2
 g
m
s 
9 
48
.2
 
0.
7 
78
.5
 
 
11
 
75
.8
 
44
.7
 
76
.8
 
 
6 
57
.2
 
25
.1
 
81
.9
 
 
15
 
81
.3
 
28
.8
 
84
.4
 
 
41
 
75
.8
 
0.
7 
84
.4
 
To
ta
l 
16
 
48
.7
 
0.
7 
78
.5
 
 
16
 
75
.8
 
26
.3
 
84
.1
 
 
6 
57
.2
 
25
.1
 
81
.9
 
 
50
 
81
.4
 
28
.8
 
84
.4
 
 
88
 
78
.9
 
0.
7 
84
.4
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
1 
69
.9
 
69
.9
 
69
.9
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
69
.9
 
69
.9
 
69
.9
 
To
ta
l 
– 
– 
– 
– 
 
1 
69
.9
 
69
.9
 
69
.9
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
69
.9
 
69
.9
 
69
.9
 
N
ot
e:
 F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
co
ca
in
e 
se
izu
re
s—
on
ly
 th
os
e 
th
at
 h
av
e 
be
en
 a
na
ly
se
d 
at
 a
 fo
re
ns
ic
 la
bo
ra
to
ry
. T
he
 p
er
io
d 
be
tw
ee
n 
th
e 
da
te
 o
f s
ei
zu
re
 b
y 
po
lic
e 
an
d 
th
e 
da
te
 o
f r
ec
ei
pt
 a
t t
he
 la
bo
ra
to
ry
 a
nd
 su
bs
eq
ue
nt
 
an
al
ys
is 
ca
n 
va
ry
 g
re
at
ly
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 p
ol
ic
e.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
18
 
TA
BL
E 
40
 (c
on
tin
ue
d)
: C
oc
ai
ne
 p
ur
ity
 le
ve
ls
—
st
at
e 
an
d 
te
rr
ito
ry
, b
y 
qu
ar
te
r, 
20
18
–1
9 
 
Ju
ly
–S
ep
te
m
be
r 2
01
8 
 
O
ct
ob
er
–D
ec
em
be
r 2
01
8 
 
Ja
nu
ar
y–
M
ar
ch
 2
01
9 
 
Ap
ril
–J
un
e 
20
19
 
 
To
ta
l J
ul
y 
20
18
–J
un
e 
20
19
 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Pu
rit
y 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
 
Ca
se
s 
M
ed
ia
n 
M
in
  
M
ax
 
St
at
e/
te
rr
ito
ry
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
 
(n
o.
) 
(%
) 
(%
) 
(%
) 
W
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
1 
63
.0
 
63
.0
 
63
.0
 
 
4 
39
.5
 
32
.0
 
95
.0
 
 
4 
58
.0
 
33
.0
 
83
.0
 
 
25
 
50
.0
 
45
.0
 
86
.0
 
 
34
 
50
.0
 
32
.0
 
95
.0
 
>2
 g
m
s 
25
 
76
.0
 
39
.0
 
88
.0
 
 
17
 
41
.0
 
0.
3 
83
.0
 
 
10
 
50
.0
 
39
.0
 
81
.0
 
 
44
 
52
.0
 
0.
3 
83
.0
 
 
96
 
54
.0
 
0.
3 
88
.0
 
To
ta
l 
26
 
75
.0
 
39
.0
 
88
.0
 
 
21
 
41
.0
 
0.
3 
95
.0
 
 
14
 
50
.0
 
33
.0
 
83
.0
 
 
69
 
51
.0
 
0.
3 
86
.0
 
 
13
0 
53
.0
 
0.
3 
95
.0
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
1 
36
.0
 
36
.0
 
36
.0
 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
1 
36
.0
 
36
.0
 
36
.0
 
>2
 g
m
s 
5 
65
.9
 
38
.4
 
82
.9
 
 
1 
59
.5
 
59
.5
 
59
.5
 
 
2 
39
.4
 
30
.2
 
48
.7
 
 
– 
– 
– 
– 
 
8 
58
.7
 
30
.2
 
82
.9
 
To
ta
l 
6 
61
.9
 
36
.0
 
82
.9
 
 
1 
59
.5
 
59
.5
 
59
.5
 
 
2 
39
.4
 
30
.2
 
48
.7
 
 
– 
– 
– 
– 
 
9 
58
.0
 
30
.2
 
82
.9
 
Ta
s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
AC
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
at
e 
po
lic
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
>2
 g
m
s 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
To
ta
l 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
 
na
 
na
 
na
 
na
 
AF
P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<=
2 
gm
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
>2
 g
m
s 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
To
ta
l 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
N
ot
e:
 F
ig
ur
es
 d
o 
no
t r
ep
re
se
nt
 th
e 
pu
rit
y 
le
ve
ls 
of
 a
ll 
co
ca
in
e 
se
izu
re
s—
on
ly
 th
os
e 
th
at
 h
av
e 
be
en
 a
na
ly
se
d 
at
 a
 fo
re
ns
ic
 la
bo
ra
to
ry
. T
he
 p
er
io
d 
be
tw
ee
n 
th
e 
da
te
 o
f s
ei
zu
re
 b
y 
po
lic
e 
an
d 
th
e 
da
te
 o
f r
ec
ei
pt
 a
t t
he
 la
bo
ra
to
ry
 a
nd
 su
bs
eq
ue
nt
 
an
al
ys
is 
ca
n 
va
ry
 g
re
at
ly
. N
o 
ad
ju
st
m
en
t h
as
 b
ee
n 
m
ad
e 
to
 a
cc
ou
nt
 fo
r d
ou
bl
e 
co
un
tin
g 
da
ta
 fr
om
 jo
in
t o
pe
ra
tio
ns
 b
et
w
ee
n 
th
e 
Au
st
ra
lia
n 
Fe
de
ra
l P
ol
ic
e 
an
d 
st
at
e/
te
rr
ito
ry
 p
ol
ic
e.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
19
 
PR
IC
E 
TA
BL
ES
  
TA
BL
E 
41
: A
m
ph
et
am
in
e 
pr
ic
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
) 
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
a 
W
A 
Ta
s 
N
Tb
 
AC
T 
1 
st
re
et
 d
ea
l (
0.
1 
gr
am
) 
na
 
na
 
50
–1
00
 
na
 
na
 
40
–5
0 
na
 
na
 
0.
7 
gr
am
 
na
 
na
 
na
 
na
 
na
 
30
0 
na
 
na
 
1 
w
ei
gh
t g
ra
m
 
na
 
20
0 
25
0–
55
0 
na
 
na
 
30
0–
60
0 
na
 
na
 
2 
gr
am
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
3 
gr
am
s  
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
8 
ba
ll 
(3
.5
 g
ra
m
s;
 i.
e.
 1
/8
 o
un
ce
) 
na
 
na
 
55
0–
2,
50
0 
na
 
na
 
60
0–
1,
20
0 
na
 
na
 
1/
4 
ou
nc
e 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
vi
al
 (1
/2
 o
un
ce
) 
na
 
na
 
na
 
na
 
na
 
3,
50
0 
na
 
na
 
1 
ou
nc
e 
(s
tr
ee
t d
ea
l) 
na
 
na
 
4,
10
0–
10
,0
00
 
na
 
na
 
7,
00
0 
na
 
na
 
1 
ou
nc
e 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
po
un
d 
 
na
 
na
 
45
,0
00
–9
0,
00
0 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
na
 
na
 
70
,0
00
–1
20
,0
00
 
na
 
na
 
na
 
na
 
na
 
a.
 S
ou
th
 A
us
tr
al
ia
 P
ol
ic
e 
ha
s n
ot
 p
ro
vi
de
d 
pr
ic
es
 fo
r a
m
ph
et
am
in
e 
as
 th
is 
is 
be
lie
ve
d 
to
 n
o 
lo
ng
er
 h
av
e 
a 
m
ar
ke
t i
n 
So
ut
h 
Au
st
ra
lia
. 
b.
 P
ric
es
 re
po
rt
ed
 fo
r t
he
 N
or
th
er
n 
Te
rr
ito
ry
 re
fle
ct
 u
rb
an
 p
ric
in
g.
 It
 is
 n
ot
 u
nc
om
m
on
 fo
r p
ric
es
 in
 re
m
ot
e 
co
m
m
un
iti
es
 to
 b
e 
co
ns
id
er
ab
ly
 h
ig
he
r t
ha
n 
th
os
e 
re
po
rt
ed
 in
 u
rb
an
 lo
ca
tio
ns
. 
    TA
BL
E 
42
: M
DM
A 
pr
ic
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
) 
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
 
W
A 
Ta
s 
N
Ta
 
AC
T 
1 
ta
bl
et
/c
ap
su
le
 
20
–3
0 
na
 
9–
25
 
20
–3
0 
25
–5
0 
20
–3
0 
30
–5
0 
10
–4
0 
2–
24
 ta
bl
et
s/
ca
ps
ul
es
 (p
er
 ta
b)
 
20
–3
0 
na
 
20
–3
6 
15
–2
0 
15
–5
0 
18
–2
5 
na
 
na
 
25
–9
9 
ta
bl
et
s/
ca
ps
ul
es
 (p
er
 ta
b)
 
10
–1
8 
na
 
15
–2
0 
na
 
na
 
10
–2
0 
20
–4
0 
na
 
10
0–
99
9 
ta
bl
et
s/
ca
ps
ul
es
 (p
er
 ta
b)
 
9–
12
 
7b
 
13
–2
0 
na
 
9–
15
 
10
–1
8 
na
 
na
 
1 
00
0+
 ta
bl
et
s/
ca
ps
ul
es
 (p
er
 ta
b)
 
6–
7 
na
 
8–
18
 
na
 
na
 
8–
9 
na
 
na
 
1 
gr
am
 
13
0–
28
0 
10
0–
20
0 
15
0–
30
0 
15
0–
25
0 
20
0–
35
0 
20
0 
15
0–
20
0 
na
 
8 
ba
ll 
(3
.5
 g
ra
m
s;
 i.
e.
 1
/8
 o
un
ce
) 
na
 
30
0–
40
0 
80
0 
na
 
1,
20
0 
na
 
70
0 
na
 
1/
2 
ou
nc
e 
na
 
na
 
na
 
90
0–
1,
00
0 
1,
80
0 
na
 
na
 
1,
00
0 
1 
ki
lo
gr
am
 
35
,0
00
–4
0,
00
0 
na
 
60
,0
00
 
na
 
na
 
na
 
na
 
na
 
a.
 P
ric
es
 re
po
rt
ed
 fo
r t
he
 N
or
th
er
n 
Te
rr
ito
ry
 re
fle
ct
 u
rb
an
 p
ric
in
g.
 It
 is
 n
ot
 u
nc
om
m
on
 fo
r p
ric
es
 in
 re
m
ot
e 
co
m
m
un
iti
es
 to
 b
e 
co
ns
id
er
ab
ly
 h
ig
he
r t
ha
n 
th
os
e 
re
po
rt
ed
 in
 u
rb
an
 lo
ca
tio
ns
. 
b.
 T
hi
s p
ric
e 
is 
ba
se
d 
on
 th
e 
re
po
rt
ed
 p
ric
e 
fo
r 5
00
 M
DM
A 
ta
bl
et
s,
 v
al
ue
d 
at
 $
3,
62
5.
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STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
20
 
TA
BL
E 
43
: M
et
hy
la
m
ph
et
am
in
e 
pr
ic
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
) 
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
 
W
A 
Ta
s 
N
Ta
 
AC
T 
Cr
ys
ta
l f
or
m
 (‘
ic
e’
) 
  
 
  
  
  
  
  
 
1 
st
re
et
 d
ea
l (
0.
1 
gr
am
) 
50
 
50
 
20
–1
50
 
50
 
50
–2
00
 
50
–1
00
 
10
0 
50
 
0.
7 
gr
am
 
na
 
na
 
na
 
na
 
20
0–
50
0 
na
 
na
 
na
 
1 
w
ei
gh
t g
ra
m
 
20
0–
40
0 
20
0 
14
0–
80
0 
25
0–
35
0 
30
0–
65
0 
50
0 
80
0 
25
0–
35
0 
Ha
lf 
8 
ba
ll 
(1
.7
5 
gr
am
s)
 
na
 
30
0 
na
 
35
0–
45
0 
35
0–
1,
00
0 
75
0 
1,
00
0 
20
0 
2 
gr
am
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
3 
gr
am
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
8 
ba
ll 
(3
.5
 g
ra
m
; i
.e
. 1
/8
 o
un
ce
) 
60
0–
90
0 
50
0–
70
0 
57
0–
1,
35
0 
60
0–
80
0 
70
0–
2,
40
0 
1,
00
0–
1,
80
0 
1,
80
0 
60
0–
1,
40
0 
1/
4 
ou
nc
e 
na
 
na
 
na
 
1,
40
0 
na
 
na
 
na
 
na
 
1 
vi
al
 (1
/2
 o
un
ce
) 
na
 
na
 
na
 
2,
20
0 
2,
50
0–
6,
00
0 
na
 
na
 
na
 
1 
ou
nc
e 
(s
tr
ee
t d
ea
l) 
na
 
3,
20
0–
3,
70
0 
3,
00
0–
8,
00
0 
3,
00
0–
5,
00
0 
1,
20
0–
12
,0
00
 
5,
00
0–
8,
00
0 
6,
00
0–
8,
00
0 
3,
50
0–
7,
00
0 
1 
ou
nc
e 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
po
un
d 
40
,0
00
–5
5,
00
0 
na
 
70
,0
00
–1
20
,0
00
 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
80
,0
00
–1
00
,0
00
 
96
,0
00
–1
05
,0
00
 
11
5,
00
0–
13
2,
00
0 
10
5,
00
0 
50
,0
00
–1
40
,0
00
 
na
 
na
 
na
 
N
on
-c
ry
st
al
 fo
rm
 
 
 
 
 
 
 
 
 
Po
w
de
r/
pa
st
e/
ba
se
 
 
 
 
 
 
 
 
 
1 
st
re
et
 d
ea
l (
0.
1 
gr
am
) 
na
 
na
 
na
 
na
 
na
 
30
 
na
 
na
 
0.
7 
gr
am
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
w
ei
gh
t g
ra
m
 
na
 
na
 
na
 
na
 
na
 
20
0 
na
 
na
 
2 
gr
am
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
3 
gr
am
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
8 
ba
ll 
(3
.5
 g
ra
m
; i
.e
. 1
/8
 o
un
ce
) 
na
 
na
 
na
 
na
 
na
 
60
0 
na
 
na
 
1/
4 
ou
nc
e 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
vi
al
 (1
/2
 o
un
ce
) 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
ou
nc
e 
(s
tr
ee
t d
ea
l) 
na
 
na
 
na
 
na
 
na
 
3,
00
0 
na
 
na
 
1 
ou
nc
e 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
po
un
d 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
M
et
h 
oi
l 
 
 
 
 
 
 
 
 
1 
lit
re
 
na
 
na
 
10
0,
00
0–
20
0,
00
0 
na
 
na
 
na
 
na
 
na
 
a.
 P
ric
es
 re
po
rt
ed
 fo
r t
he
 N
or
th
er
n 
Te
rr
ito
ry
 re
fle
ct
 u
rb
an
 p
ric
in
g.
 It
 is
 n
ot
 u
nc
om
m
on
 fo
r p
ric
es
 in
 re
m
ot
e 
co
m
m
un
iti
es
 to
 b
e 
co
ns
id
er
ab
ly
 h
ig
he
r t
ha
n 
th
os
e 
re
po
rt
ed
 in
 u
rb
an
 lo
ca
tio
ns
. 
 
171 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
STATISTICS
 
 
O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
21
 
TA
BL
E 
44
: C
an
na
bi
s p
ric
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
)
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
a 
W
A 
Ta
s 
N
Tb
 
AC
T 
Bu
sh
 
 
 
 
 
 
 
 
 
Le
af
 
 
 
 
 
 
 
 
 
De
al
 (1
 g
ra
m
 a
pp
ro
x.
) 
na
 
na
 
15
–3
0 
na
 
25
 
na
 
20
 
na
 
1/
2 
ba
g 
(1
4 
gr
am
s)
 
na
 
na
 
na
 
na
 
17
5 
na
 
na
 
na
 
O
un
ce
 b
ag
 (2
8 
gr
am
s)
 
na
 
na
 
25
0–
40
0 
na
 
20
0–
44
0 
na
 
na
 
na
 
1 
po
un
d 
na
 
na
 
1,
50
0–
4,
48
0 
na
 
2,
50
0–
4,
50
0 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
He
ad
 
 
 
 
 
 
 
 
 
De
al
 (1
 g
ra
m
 a
pp
ro
x.
) 
20
–2
5 
na
 
na
 
na
 
na
 
20
–2
5  
25
–1
00
 
20
 
1/
2 
ba
g 
(1
4 
gr
am
s)
 
na
 
na
 
na
 
na
 
na
 
13
0–
15
0 
20
0 
14
0 
O
un
ce
 b
ag
 (2
8 
gr
am
s)
 
20
0–
35
0 
na
 
na
 
na
 
na
 
25
0 
40
0–
50
0 
25
0 
1 
po
un
d 
3,
00
0–
4,
00
0 
na
 
na
 
na
 
na
 
2,
50
0–
3,
50
0 
4,
50
0–
5,
00
0 
2,
80
0–
3,
50
0 
1 
ki
lo
gr
am
 
na
 
na
 
na
 
na
 
na
 
4,
00
0–
6,
50
0 
12
,0
00
 
na
 
1 
m
at
ur
e 
pl
an
t 
2,
00
0 
na
 
2,
20
0–
4,
00
0 
na
 
na
 
na
 
10
0–
15
0 
na
 
Hy
dr
op
on
ic
 
 
 
 
 
 
 
 
 
Le
af
 
 
 
 
 
 
 
 
 
De
al
 (1
 g
ra
m
 a
pp
ro
x.
) 
na
 
na
 
10
–3
0 
na
 
na
 
na
 
na
 
na
 
1/
2 
ba
g 
(1
4 
gr
am
s)
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
O
un
ce
 b
ag
 (2
8 
gr
am
s)
 
na
 
na
 
25
0–
40
0 
na
 
40
0 
na
 
na
 
na
 
1 
po
un
d 
na
 
na
 
1,
50
0–
4,
48
0 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
He
ad
 
 
 
 
 
 
 
 
 
De
al
 (1
 g
ra
m
 a
pp
ro
x.
) 
20
–2
5 
20
 
10
–3
0 
25
 
na
 
25
–3
5 
25
–1
00
 
na
 
1/
2 
ba
g 
(1
4 
gr
am
s)
 
na
 
15
0 
na
 
11
0–
13
0 
na
 
15
0–
17
0 
20
0 
na
 
O
un
ce
 b
ag
 (2
8 
gr
am
s)
 
20
0–
35
0 
28
0 
25
0–
40
0 
20
0–
25
0 
na
 
30
0–
35
0 
40
0–
50
0 
na
 
1 
po
un
d 
3,
00
0–
4,
00
0 
2,
30
0–
2,
70
0 
1,
50
0–
4,
48
0 
2,
50
0–
3,
00
0 
na
 
3,
00
0–
4,
00
0 
5,
00
0 
na
 
1 
ki
lo
gr
am
 
na
 
na
 
na
 
na
 
na
 
5,
00
0 
12
,0
00
 
na
 
1 
m
at
ur
e 
pl
an
t 
5,
00
0 
3,
00
0 
3,
20
0–
5,
00
0 
na
 
na
 
na
 
na
 
na
 
Re
si
n 
 
 
 
 
 
 
 
 
De
al
 (1
 g
ra
m
 a
pp
ro
x.
) 
na
 
na
 
25
–5
0 
na
 
na
 
50
 
na
 
na
 
O
il 
 
 
 
 
 
 
 
 
Ca
p/
vi
al
 
na
 
na
 
50
 
na
 
na
 
50
 
na
 
na
 
a.
 S
ou
th
 A
us
tr
al
ia
 P
ol
ic
e 
ha
s n
ot
 p
ro
vi
de
d 
pr
ic
es
 fo
r c
an
na
bi
s ‘
le
af
’ a
s t
hi
s i
s b
el
ie
ve
d 
to
 n
o 
lo
ng
er
 h
av
e 
a 
m
ar
ke
t i
n 
So
ut
h 
Au
st
ra
lia
—
on
ly
 ‘h
ea
d’
 is
 so
ld
. A
 ‘d
ea
l o
f h
yd
ro
po
ni
c 
he
ad
’ q
ua
nt
ity
 is
 2
–3
 g
ra
m
s i
n 
So
ut
h 
Au
st
ra
lia
. 
b.
 P
ric
es
 re
po
rt
ed
 fo
r t
he
 N
or
th
er
n 
Te
rr
ito
ry
 re
fle
ct
 u
rb
an
 p
ric
in
g.
 It
 is
 n
ot
 u
nc
om
m
on
 fo
r p
ric
es
 in
 re
m
ot
e 
co
m
m
un
iti
es
 to
 b
e 
co
ns
id
er
ab
ly
 h
ig
he
r t
ha
n 
th
os
e 
re
po
rt
ed
 in
 u
rb
an
 lo
ca
tio
ns
. 
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O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
22
 
TA
BL
E 
45
: H
er
oi
n 
pr
ic
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
)
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
 
W
A 
Ta
s 
N
T 
AC
T 
Ha
lf 
po
in
t (
0.
05
 g
ra
m
) 
50
 
na
 
na
 
na
 
na
 
30
 
na
 
15
0 
1 
ta
st
e/
ca
p 
(0
.1
–0
.3
 g
ra
m
) 
50
–1
00
 
30
–5
0 
40
–1
00
 
50
–1
00
 
50
–1
00
 
60
–1
50
 
na
 
na
 
1/
4 
gr
am
 
na
 
na
 
10
0–
25
0 
na
 
na
 
na
 
na
 
80
 
1/
2 
w
ei
gh
t (
0.
4–
0.
6 
gr
am
)  
10
0–
20
0 
24
0 
na
 
na
 
30
0–
40
0 
20
0–
25
0 
na
 
15
0 
1 
st
re
et
 w
ei
gh
t (
0.
6–
0.
8 
gr
am
) 
na
 
na
 
na
 
na
 
50
0 
25
0–
35
0 
na
 
na
 
1 
gr
am
 
40
0–
70
0 
40
0 
25
0–
50
0 
20
0–
50
0 
na
 
40
0 
na
 
na
 
8 
ba
ll 
(3
.5
 g
ra
m
s;
 i.
e.
 1
/8
 o
un
ce
) 
85
0–
1,
10
0 
80
0–
1,
30
0 
75
0–
1,
10
0 
na
 
na
 
1,
00
0 
na
 
1,
00
0 
10
 g
ra
m
 b
ag
 
na
 
2,
40
0 
na
 
na
 
na
 
na
 
na
 
na
 
1/
2 
ou
nc
e 
na
 
1,
80
0–
4,
00
0 
na
 
na
 
na
 
4,
50
0 
na
 
na
 
1 
ou
nc
e 
6,
50
0–
8,
00
0 
5,
00
0–
6,
00
0 
5,
00
0–
6,
00
0 
5,
00
0 
4,
50
0–
16
,0
00
 
na
 
na
 
5,
00
0 
1/
2 
As
ia
n 
ca
tt
i (
35
0 
gr
am
s)
 
na
 
na
 
70
,0
00
–1
20
,0
00
 
na
 
na
 
na
 
na
 
na
 
12
.5
 o
un
ce
 b
lo
ck
 
45
,0
00
–7
0,
00
0 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
po
un
d 
 
na
 
65
,0
00
 
na
 
na
 
na
 
na
 
na
 
na
 
As
ia
n 
ca
tt
i (
70
0 
gr
am
s)
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
16
0,
00
0–
17
0,
00
0 
90
,0
00
 
na
 
na
 
na
 
na
 
na
 
na
 
    TA
BL
E 
46
: C
oc
ai
ne
 p
ric
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
) 
 
a.
 P
ric
es
 re
po
rt
ed
 fo
r t
he
 N
or
th
er
n 
Te
rr
ito
ry
 re
fle
ct
 u
rb
an
 p
ric
in
g.
 It
 is
 n
ot
 u
nc
om
m
on
 fo
r p
ric
es
 in
 re
m
ot
e 
co
m
m
un
iti
es
 to
 b
e 
co
ns
id
er
ab
ly
 h
ig
he
r t
ha
n 
th
os
e 
re
po
rt
ed
 in
 u
rb
an
 lo
ca
tio
ns
. 
 
 
W
ei
gh
t 
N
SW
 
Vi
c 
Q
ld
 
SA
 
W
A 
Ta
s 
N
Ta
 
AC
T 
1 
ca
p 
10
0–
20
0 
na
 
40
–6
0 
na
 
na
 
50
 
na
 
na
 
1 
gr
am
  
30
0–
55
0 
30
0–
40
0 
20
0–
50
0 
30
0–
35
0 
25
0–
43
0 
30
0–
50
0 
60
0–
80
0 
30
0–
35
0 
8 
ba
ll 
(3
.5
 g
ra
m
s;
 i.
e.
 1
/8
 o
un
ce
) 
1,
00
0–
1,
30
0 
1,
05
0 
90
0–
1,
30
0 
1,
10
0–
1,
30
0 
1,
40
0–
1,
50
0 
1,
00
0–
1,
20
0 
na
 
na
 
1/
4 
ou
nc
e 
 
na
 
2,
45
0 
na
 
na
 
na
 
na
 
na
 
na
 
1 
ou
nc
e 
 
6,
00
0–
8,
00
0 
6,
50
0 
8,
00
0–
9,
50
0 
6,
50
0 
6,
00
0–
9,
00
0 
8,
00
0 
na
 
6,
00
0 
1 
po
un
d 
 
na
 
80
,0
00
–1
00
,0
00
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
ki
lo
gr
am
 
16
5,
00
0–
21
0,
00
0 
16
0,
00
0–
20
0,
00
0 
90
,0
00
–3
00
,0
00
 
na
 
15
0,
00
0–
22
0,
00
0 
na
 
na
 
na
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O
FF
IC
IA
L 
Au
st
ra
lia
n 
Cr
im
in
al
 In
te
lli
ge
nc
e 
Co
m
m
iss
io
n 
| 
Ill
ic
it 
Dr
ug
 D
at
a 
Re
po
rt
 2
01
8–
19
 
CO
N
SU
LT
AT
IV
E 
DR
AF
T 
– 
St
at
ist
ic
s T
ab
le
s 
O
FF
IC
IA
L 
 
 
 
23
 
TA
BL
E 
47
: O
th
er
 d
ru
gs
 p
ric
es
 b
y 
st
at
e 
an
d 
te
rr
ito
ry
, 2
01
8–
19
 ($
) 
O
th
er
 d
ru
gs
 
N
SW
 
 V
ic
 
Q
ld
 
SA
 
W
A 
Ta
s 
N
Tb
 
AC
T 
LS
D 
 
 
 
 
 
 
 
 
 
1–
9 
ta
bs
 (d
du
a ) 
15
–3
0 
na
 
20
–5
0 
15
–2
5 
50
 
20
–3
0 
30
–4
0 
na
 
10
–1
00
 ta
bs
 (d
du
) 
8–
20
 
na
 
na
 
na
 
na
 
20
 
30
–4
0 
na
 
10
1–
99
9 
ta
bs
 (d
du
) 
na
 
na
 
80
0 
na
 
na
 
na
 
na
 
na
 
10
00
+ 
ta
bs
 (d
du
) 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
x 
20
 m
ill
ili
tr
e 
vi
al
 
na
 
na
 
80
0 
na
 
na
 
na
 
na
 
na
 
Ps
ilo
cy
bi
n 
 
 
 
 
 
 
 
 
1 
gr
am
 
na
 
na
 
na
 
15
 
na
 
na
 
na
 
na
 
Ke
ta
m
in
e 
 
 
 
 
 
 
 
 
Ta
bl
et
 
na
 
10
0 
25
–5
0 
na
 
na
 
na
 
na
 
na
 
Po
w
de
r (
1 
gr
am
) 
12
0–
22
0 
18
0 
20
0 
na
 
32
0 
na
 
na
 
na
 
Vi
al
 (5
–1
0 
m
ill
ili
tr
es
) 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
G
HB
/G
BL
/1
,4
-b
ut
an
ed
io
l 
 
 
 
 
 
 
 
 
1–
1.
5 
m
ill
ili
tr
es
 
6–
8 
7–
15
 
2–
7 
3–
8 
7–
10
 
na
 
na
 
na
 
4–
5 
m
ill
ili
tr
es
 (f
ish
) 
na
 
na
 
20
 
na
 
na
 
na
 
na
 
na
 
10
–1
5 
m
ill
ili
tr
es
 
na
 
na
 
na
 
50
 
na
 
na
 
na
 
na
 
50
 m
ill
ili
tr
es
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
10
0 
m
ill
ili
tr
es
 
65
0–
70
0 
na
 
10
0–
20
0 
na
 
na
 
na
 
na
 
na
 
Bu
lk
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
1 
lit
re
 
2,
00
0–
3,
00
0 
2,
50
0–
3,
00
0 
3,
00
0 
1,
50
0–
2,
50
0 
na
 
na
 
na
 
na
 
25
 li
tr
es
 
na
 
20
0,
00
0 
na
 
na
 
na
 
na
 
na
 
na
 
G
HB
  
 
 
 
 
 
 
 
 
Se
rv
e/
4 
m
ill
ig
ra
m
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
Vi
al
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
8 
se
rv
es
/3
2 
m
ill
ig
ra
m
s 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
O
PI
O
ID
 P
HA
RM
AC
EU
TI
CA
LS
 
 
 
 
 
 
 
 
 
Pe
r m
ill
ig
ra
m
 
na
 
na
 
na
 
1 
na
 
1 
na
 
na
 
Pe
r t
ab
le
t 
na
 
na
 
na
 
na
 
na
 
15
 
na
 
na
 
O
xy
Co
nt
in
 (p
er
 ta
bl
et
) 
40
–1
00
 
na
 
10
–2
0 
20
 
60
 
na
 
80
 
na
 
O
xy
Co
nt
in
 (6
0 
m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
na
 
na
 
na
 
60
 
na
 
na
 
O
xy
Co
nt
in
 (8
0 
m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
O
xy
Co
nt
in
 (1
00
 m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
na
 
na
 
na
 
10
0 
80
 
na
 
O
xy
Co
nt
in
 (2
00
 m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
O
xy
Co
nt
in
 (1
 b
ox
) 
na
 
na
 
2,
80
0 
20
0  
na
 
na
 
20
0 
na
 
M
S 
Co
nt
in
  
 
 
 
 
 
 
 
 
1 
m
ill
ig
ra
m
 
na
 
na
 
na
 
na
 
na
 
1 
na
 
na
 
Pe
r t
ab
le
t 
na
 
na
 
30
 
na
 
na
 
na
 
80
–1
00
 
na
 
60
 m
ill
ig
ra
m
 ta
bl
et
 
na
 
na
 
20
–6
0 
na
 
na
 
60
 
na
 
na
 
10
0 
m
ill
ig
ra
m
 ta
bl
et
 
na
 
na
 
30
–1
00
 
na
 
na
 
10
0 
na
 
na
 
Ka
pa
no
l (
pe
r t
ab
le
t)
 
na
 
na
 
15
 
na
 
na
 
na
 
na
 
na
 
Bu
pr
en
or
ph
in
e 
(2
 m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
10
–3
0 
na
 
na
 
na
 
na
 
na
 
Bu
pr
en
or
ph
in
e 
(8
 m
ill
ig
ra
m
 ta
bl
et
) 
na
 
na
 
20
–5
0 
na
 
na
 
na
 
na
 
na
 
Fe
nt
an
yl
 (1
 m
ic
ro
gr
am
 ta
bl
et
) 
na
 
na
 
4–
5 
na
 
na
 
na
 
na
 
na
 
Fe
nt
an
yl
 (1
 x
 1
00
 m
ic
ro
gr
am
 p
at
ch
) 
90
–2
50
 
na
 
20
0 
25
–3
0 
na
 
na
 
na
 
na
 
Fe
nt
an
yl
 (p
er
 g
ra
m
) 
na
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INTERNATIONAL INITIATIVES
This appendix provides an overview of some of the international initiatives that are having  
an impact on Australian illicit drug markets. Contributions to this section were provided by  
the Australian Federal Police (AFP).
The AFP increased international engagement and intelligence sharing with law enforcement 
agencies (LEAs) from regions where large scale drug manufacture and subsequent importation  
into Australia is occurring. Specifically, with the continued increase in seizures of 
methylamphetamine and cocaine in Australia, the AFP has developed strategies to assist  
targeting and disruption efforts within these regions. In 2018–19, international collaboration 
resulted in the seizure of more than 40 tonnes of illicit drugs by overseas police services  
with AFP assistance.
Examples of international collaboration include the continuation of existing successful 
international taskforces including Taskforce Blaze, Taskforce Storm and Strikeforce Dragon,  
as well as new initiatives such as the International Methamphetamine and Precursor  
Profiling Capability and the establishment of the Transnational Serious and Organised  
Crime Pacific Taskforce.
TASKFORCE BLAZE
Taskforce Blaze is a partnership between the AFP and the Chinese National Narcotics Control 
Commission. The taskforce focuses on coordinating and eradicating the sources of drugs,  
new psychoactive substances and precursor chemicals; obstructing trafficking channels; 
dismantling multinational drug smuggling organisations; and confiscating associated drug  
funds. Since commencing in November 2015, cooperation has resulted in the seizure of more  
than 26 tonnes of drugs and precursor chemicals and $2,000,000 (AUD) in proceeds of crime.
TASKFORCE STORM
Taskforce Storm is a joint Australian-Thai taskforce with a focus on drugs and transnational  
serious and organised crime. Established in May 2016, the taskforce includes the AFP, the  
Office of the Narcotics Control Board, the Royal Thai Police, the Department of Special 
Investigations and the Anti-Money Laundering Office. Initially focussed on the trafficking  
of illicit drugs between Thailand and Australia, it has evolved to include investigations  
relating to firearms trafficking and money laundering.
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STRIKEFORCE DRAGON
Strikeforce Dragon is a joint Australian-Cambodian strikeforce arrangement involving the 
AFP, the Cambodian National Police and the Cambodian General Department of Immigration. 
Established in June 2016, this strikeforce focusses on illicit drug trafficking and money 
laundering between Cambodia and Australia.
INTERNATIONAL METHAMPHETAMINE AND PRECURSOR  
PROFILING CAPABILITY
The International Methamphetamine and Precursor Profiling Capability aims to increase 
international collaboration and the sharing of forensic drug intelligence in support of 
international LEAs’ investigations. The capability collects and chemically profiles samples  
from international seizures of illicit drugs against Australian seizures. A key outcome from  
this capability is the enhancement of collaborative relationships between the AFP and 
international LEAs, and has led to the progression of a number of areas of mutual priority  
with regards to the disruption of illicit drug manufacture and supply. It has also enabled  
the AFP to provide assistance in strengthening and developing drug analysis and profiling 
capabilities in key production regions. 
TRANSNATIONAL SERIOUS AND ORGANISED CRIME PACIFIC 
TASKFORCE
The Transnational Serious and Organised Crime Pacific Taskforce is an international taskforce 
involving Australia, New Zealand, Fiji and Tonga. It was established in February 2019 to enhance 
cooperation, operations and intelligence sharing across the Pacific—specifically between the  
AFP, New Zealand Police, Fiji Police Force and Tonga Police. One of the primary objectives of  
this taskforce is to target organised crime entities or syndicates that use small craft for illicit  
drug movements. 
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2018–19 SIGNIFICANT BORDER DETECTIONS87  
(SOURCE: DEPARTMENT OF HOME AFFAIRS) 
ATS
Significant border detections of ATS (excluding MDMA) in 2018–19 include:
  1,500.0 kilograms of methylamphetamine detected on 5 April 2019 via sea cargo  
from Thailand
  650.0 kilograms of crystal methylamphetamine detected on 4 October 2018 via  
sea cargo from Mexico
  560.0 kilograms of crystal methylamphetamine detected on 30 March 2019 via  
sea cargo from Singapore
  490.0 kilograms of crystal methylamphetamine detected on 29 November 2018 via  
sea cargo
  480.0 kilograms of crystal methylamphetamine detected on 14 June 2019 via sea cargo  
from Mexico. 
These 5 detections have a combined weight of 3,680.0 kilograms and account for 71 per cent  
of the total weight of ATS (excluding MDMA) detected at the Australian border in 2018–19.
Significant border detections of MDMA in 2018–19 include:
  800.0 kilograms of MDMA detected on 28 March 2019 via air cargo from Germany
  500.0 kilograms of MDMA detected on 25 September 2018 via sea cargo from Turkey
  80.0 kilograms of MDMA detected on 11 February 2019 via air cargo from Austria
  33.0 kilograms of MDMA detected on 23 December 2018 via air cargo from the Netherlands
  10.0 kilograms of MDMA detected on 25 October 2018 via international mail from Poland.
These 5 detections have a combined weight of 1,423.0 kilograms and account for 67 per cent  
of the total weight of MDMA detected at the Australian border in 2018–19.
87 Country of embarkation information was not available for every significant detection at the Australian border in 2018–19.
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CANNABIS
Significant border detections of cannabis in 2018–19 include:
  1,500.0 kilograms of cannabis detected on 9 November 2018 via sea cargo
  11.3 kilograms of cannabis detected on 6 May 2019 via air cargo from Spain
  10.0 kilograms of cannabis detected on 31 March 2019 via air cargo from the  
United States (US)
  10.0 kilograms of cannabis detected on 15 May 2019 via air cargo from the US
  8.0 kilograms of cannabis detected on 31 March 2019 via air cargo from the US.
These 5 detections have a combined weight of 1,539.3 kilograms and account for  
85 per cent of the total weight of cannabis detected at the Australian border in 2018–19.
HEROIN
Significant border detections of heroin in 2018–19 include:
  140.0 kilograms of heroin detected on 6 January 2019 via air cargo from Malaysia
  30.0 kilograms of heroin detected on 5 April 2019 via sea cargo from Thailand
  14.0 kilograms of heroin detected on 1 November 2018 via air cargo from Malaysia
  13.5 kilograms of heroin detected on 2 November 2018 via air cargo from Malaysia
  5.0 kilograms of heroin detected on 7 October 2018 via international mail from Thailand.
These 5 detections have a combined weight of 202.5 kilograms and account for 71 per cent  
of the total weight of heroin detected at the Australian border in 2018–19.
COCAINE
Significant border detections of cocaine in 2018–19 include:
  384.0 kilograms of cocaine detected on 20 June 2019 via sea cargo from South Africa
  188.0 kilograms of cocaine detected on 5 February 2019 via sea cargo from Mexico
  68.0 kilograms of cocaine detected on 5 April 2019 via sea cargo
  55.0 kilograms of cocaine detected on 12 June 2019 via sea cargo
  50.0 kilograms of cocaine detected on 10 August 2018 via sea cargo from Fiji.
These 5 detections have a combined weight of 745.0 kilograms and account for  
71 per cent of the total weight of cocaine detected at the Australian border in 2018–19.
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PRECURSORS
Significant border detections of ATS (excluding MDMA) precursors in 2018–19 include:
  1,495.0 kilograms of ephedrine detected on 17 February 2019 via sea cargo from China
  504.0 kilograms of methylamine detected on 3 June 2019 via sea cargo from China
  200.0 kilograms of 3,4-MDP2P methyl glycidate detected on 15 January 2019 via air cargo 
from China
  100.0 kilograms of methylamine detected on 30 May 2019 via air cargo from China
  65.0 kilograms of ephedrine detected on 28 September 2019 via sea cargo from Malaysia.
These 5 detections have a combined weight of 2,364.0 kilograms and account for 90 per cent 
of the total weight of ATS (excluding MDMA) precursors detected at the Australian border in 
2018–19.
No significant border detections of MDMA precursors were identified in 2018–19.
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ENIPID FORENSIC PROFILING DATA 
(SOURCE: AUSTRALIAN FEDERAL POLICE, FORENSIC DRUG INTELLIGENCE)
TABLE 1: Synthetic route of manufacture of methylamphetamine ENIPID samples as a 
proportion of analysed jurisdictional samples, classified by precursor, 2011–June 201988
88 Consideration should be given when drawing conclusions on national trends from Table 1 and Table 2 as a significant quantity 
(approximately 50 per cent) of the samples analysed were collected from Western Australia, and the samples collected from 
South Australia and Victoria in 2019 are yet to be profiled.
Year Jurisdiction
Synthetic Route
      Total % Eph/PSE % P2P %  Mixed/ Unclassified %
Jan–Jun
2019
ACT 0.5 3.7 2.6 6.8
NSW 11.0 16.3 7.4 34.7
NT 1.6 4.2 3.7 9.5
WA 23.7 14.2 11.1 49.0
Total 36.8 38.4 24.8 100
2018
ACT 0.8 1.2 0.2 2.2
NSW 6.8 11.5 3.4 21.7
NT 4.3 4.2 1.6 10.1
SA 1.9 6.0 2.7 10.6
VIC 7.2 4.1 2.0 13.3
WA 20.4 15.4 6.3 42.1
Total 41.4 42.4 16.2 100
2017
ACT 2.2 0.3 0.3 2.8
NSW 29.7 6.3 9.1 45.1
NT 6.6 0.7 1.4 8.7
SA 14.3 2.5 10.9 27.7
VIC 11.9 1.4 2.1 15.4
WA 0.3 – – 0.3
Total 65.0 11.2 23.8 100
2016
ACT 2.8 – 0.1 2.9
NSW 25.2 1.7 3.5 30.4
NT 7.4 0.2 0.4 8.0
SA 10.4 0.8 3.2 14.4
TAS 0.2 – – 0.2
VIC 11.8 0.9 1.1 13.8
WA 28.2 1.1 1.0 30.3
Total 86.0 4.7 9.3 100
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TABLE 1: Synthetic route of manufacture of methylamphetamine ENIPID samples as a 
proportion of analysed jurisdictional samples, classified by precursor, 2011–June 2019 
(continued)
Year Jurisdiction
Synthetic Route
      Total %        Eph/PSE %      P2P %  Mixed/Unclassified % 
2015
ACT 1.1 – – 1.1
NSW 30.5 2.3 2.0 34.8
NT 5.1 0.5 – 5.6
SA 6.8 0.6 1.0 8.4
TAS 0.1 – – 0.1
VIC 10.2 0.1 0.4 10.7
WA 34.9 1.9 2.5 39.3
Total 88.7 5.4 5.9 100
2014
NSW 31.4 3.9 3.1 38.4
NT 3.7 0.9 0.4 5.0
QLD – – 0.1 0.1
SA 2.4 1.6 1.2 5.2
TAS 0.8 – 0.5 1.3
VIC 1.2 – 0.3 1.5
WA 38.9 4.8 4.8 48.5
Total 78.4 11.2 10.4 100
2013
NSW 28.4 4.5 0.9 33.8
NT 3.3 0.2 0.9 4.5
TAS 2.4 0.2 – 2.6
VIC – 0.2 – 0.2
WA 40.7 10.9 7.3 58.9
Total 74.7 16.1 9.2 100
2012
ACT 4.7 – – 4.7
NSW 38.2 0.6 6.2 45.0
NT 7.9 – 0.3 8.2
TAS 0.6 – – 0.6
WA 34.4 4.4 2.7 41.5
Total 85.8 5.0 9.2 100
2011
NSW 13.7 0.9 2.4 17.0
NT 5.7 0.5 – 6.2
TAS 2.4 – – 2.4
WA 46.0 1.9 26.5 74.4
Total 67.8 3.3 28.9 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This dataset represents a total of 1,076 methylamphetamine samples (811 cases). Due to a lack of available data, some samples 
were classified based on the sample collection date in place of the sample seizure date.
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TABLE 2: Synthetic route of manufacture of methylamphetamine ENIPID samples as a 
proportion of analysed jurisdictional cases, classified by precursor, 2011–June 201989 
Year Jurisdiction
Synthetic Route
      Total %           Eph/PSE % P2P % Mixed/Unclassified %
Jan–Jun 
2019
ACT – 1.4 2.8 4.2
NSW 6.3 11.2 9.1 26.6
NT 1.4 4.9 4.2 10.5
WA 28.0 18.2 12.5 58.7
Total 35.7 35.7 28.6 100
2018
ACT 1.1 1.5 0.3 2.9
NSW 4.8 7.3 4.2 16.3
NT 1.4 2.8 1.4 5.6
SA 2.5 7.9 3.4 13.8
VIC 3.9 1.8 1.7 7.4
WA 26.2 19.3 8.5 54.0
Total 39.9 40.6 19.5 100
2017
ACT 1.7 0.5 0.6 2.8
NSW 21.2 5.0 12.8 39.0
NT 5.6 0.6 0.6 6.8
SA 14.5 3.4 12.8 30.7
VIC 15.1 1.1 3.9 20.1
WA 0.6 – – 0.6
Total 58.7 10.6 30.7 100
2016
ACT 2.7 – 0.1 2.8
NSW 25.6 2.1 3.8 31.5
NT 4.9 – – 4.9
SA 13.5 0.8 3.3 17.6
TAS 0.3 – – 0.3
VIC 12.8 0.8 1.1 14.7
WA 26.4 0.8 1.0 28.2
Total 86.2 4.5 9.3 100
2015
ACT 1.8 – – 1.8
NSW 31.2 2.2 3.4 36.8
NT 4.8 0.4 – 5.2
SA 8.9 0.7 1.1 10.7
VIC 11.3 – 0.6 11.9
WA 29.1 0.7 3.8 33.6
Total 87.1 4.0 8.9 100
89 Consideration should be given when drawing conclusions on national trends from Table 1 and Table 2 as a significant quantity 
(approximately 50 per cent) of the samples analysed were collected from Western Australia, and the samples collected from 
South Australia and Victoria in 2019 are yet to be profiled.
185 Australian Criminal Intellegence Commission 
Illicit Drug Data Report 2018–19
A
PPEN
D
IX
TABLE 2: Synthetic route of manufacture of methylamphetamine ENIPID samples as 
a proportion of analysed jurisdictional cases, classified by precursor, 2011–June 2019 
(continued)
Year Jurisdiction
Synthetic Route
      Total %           Eph PSE %         P2P % Mixed/Unclassified %
2014
NSW 31.0 3.6 4.6 39.2
NT 4.6 0.6 0.8 6.0
QLD – – 0.2 0.2
SA 2.3 1.9 1.7 5.9
TAS 1.3 – 0.6 1.9
VIC 1.9 – 0.4 2.3
WA 35.9 4.4 4.2 44.5
Total 77.0 10.5 12.5 100
2013
NSW 33.9 4.6 1.7 40.2
NT 4.6 0.4 1.7 6.7
TAS 2.9 – 0.4 3.3
VIC – 0.4 – 0.4
WA 33.5 6.7 9.2 49.4
Total 74.9 12.1 13.0 100
2012
ACT 3.5 – – 3.5
NSW 41.3 0.5 5.5 47.3
NT 11.4 – 0.5 11.9
TAS 1.0 – – 1.0
WA 26.8 5.0 4.5 36.3
Total 84.0 5.5 10.5 100
2011
NSW 13.5 1.8 4.5 19.8
NT 8.1 1.0 – 9.1
TAS 4.5 – – 4.5
WA 32.4 2.7 31.5 66.6
Total 58.5 5.5 36.0 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This dataset represents a total of 1,076 methamphetamine samples (811 cases). Due to a lack of available data, some samples were 
classified based on the sample collection date in place of the sample seizure date.
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TABLE 3: Geographical origin of heroin ENIPID samples as a proportion of analysed 
jurisdictional samples, 2011–June 2019
Geographical origin
Total %Year Jurisdiction South-East Asia % South-West Asia % Mixed/Unclassified %
Jan–Jun
2019
ACT 6.7 – – 6.7
NSW 60.0 – – 60.0
NT 13.3 – – 13.3
WA 20.0 – – 20.0
Total 100 – – 100
2018
ACT 3.5 – – 3.5
NSW 14.0 5.3 1.8 21.1
SA 24.6 3.5 7.0 35.1
VIC 14.0 – 10.5 24.5
WA 14.0 1.8 – 15.8
Total 70.1 10.6 19.3 100
2017
ACT 2.8 – – 2.8
NSW 13.9 33.3 – 47.2
SA 2.8 – – 2.8
VIC 22.2 – 8.3 30.5
WA 8.3 5.6 2.8 16.7
Total 50.0 38.9 11.1 100
2016
ACT 4.9 2.5 – 7.4
NSW 24.7 1.2 – 25.9
NT 1.2 – – 1.2
SA 6.2 – – 6.2
VIC 37.1 1.2 1.2 39.5
WA 19.8 – – 19.8
Total 93.9 4.9 1.2 100
2015
ACT 7.2 – – 7.2
NSW 36.1 4.1 5.2 45.4
TAS 1.0 – – 1.0
VIC 38.1 2.1 – 40.2
WA 6.2 – – 6.2
Total 88.6 6.2 5.2 100
2014
NSW 47.6 7.2 – 54.8
SA – 2.4 – 2.4
VIC – 7.1 – 7.1
WA 35.7 – – 35.7
Total 80.3 16.7 – 100
2013
NSW 45.7 – 2.9 48.6
WA 34.3 17.1 – 51.4
Total 80.0 17.1 2.9 100
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TABLE 3: Geographical origin of heroin ENIPID samples as a proportion of analysed 
jurisdictional samples, 2011–June 2019 (continued)
Geographical origin
Total %Year Jurisdiction South-East Asia % South-West Asia % Mixed/Unclassified %
2012
ACT 8.5 – – 8.5
NSW 55.3 12.8 12.8 80.9
WA 2.1 8.5 – 10.6
Total 65.9 21.3 2.9 100
2011
NSW 9.8 2.0 3.9 15.7
WA 82.3 – 2.0 84.3
Total 92.1 2.0 5.9 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This dataset represents a total of 72 heroin samples. Due to a lack of available data, some samples were classified based on the 
sample collection date in place of the sample seizure date.
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TABLE 4: Geographical origin of heroin ENIPID samples as a proportion of analysed 
jurisdictional cases, 2011–June 2019
Geographical origin
Total %Year Jurisdiction South-East Asia % South-West Asia % Mixed/Unclassified %
Jan–Jun
2019
ACT 7.2 – – 7.2
NSW 57.1 – – 57.1
NT 14.3 – – 14.3
WA 21.4 – – 21.4
Total 100 – – 100
2018
ACT 5.3 – – 5.3
NSW 13.2 2.6 5.3 21.1
SA 18.3 – 13.2 31.5
VIC 13.2 – 5.3 18.5
WA 21.0 – 2.6 23.6
Total 71.0 2.6 26.4 100
2017
ACT 3.8 – – 3.8
NSW 15.4 15.4 3.8 34.6
SA 3.8 – – 3.8
VIC 26.9 – 11.6 38.5
WA 11.7 3.8 3.8 19.3
Total 61.6 19.2 19.2 100
2016
ACT 4.9 1.6 – 6.6
NSW 31.1 1.6 – 32.8
NT 1.6 – – 1.6
SA 6.6 – – 6.6
VIC 36.1 – 3.3 39.3
WA 13.1 – – 13.1
Total 93.4 3.3 3.3 100
2015
ACT 3.1 – – 3.1
NSW 35.4 6.1 6.2 47.7
TAS 1.5 – – 1.5
VIC 35.4 3.1 – 38.5
WA 9.2 – – 9.2
Total 84.6 9.2 6.2 100
2014
NSW 51.7 10.3 – 62.0
SA – 3.5 – 3.5
VIC – 3.5 – 3.5
WA 31.0 – – 31.0
Total 82.7 17.3 – 100
2013
NSW 50.0 – 5.6 55.6
WA 33.3 11.1 – 44.4
Total 83.3 11.1 5.6 100
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TABLE 4: Geographical origin of heroin ENIPID samples as a proportion of analysed 
jurisdictional cases, 2011–June 2019 (continued)
Geographical origin
Total %Year Jurisdiction South-East Asia % South-West Asia % Mixed/Unclassified %
2012
ACT 9.4 – – 9.4
NSW 46.9 12.5 18.7 78.1
WA 3.1 9.4 – 12.5
Total 59.4 21.9 18.7 100
2011
NSW 18.8 6.2 12.5 37.5
WA 56.3 – 6.2 62.5
Total 75.1 6.2 18.7 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This dataset represents a total of 72 heroin samples. Due to a lack of available data, some samples were classified based on the 
sample collection date in place of the sample seizure date.
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TABLE 5: Geographical origin of cocaine ENIPID samples as a proportion of analysed 
jurisdictional samples, 2014–June 2019
Geographical origin
TotalYear Jurisdiction   Colombia % Peru %  Bolivia %  Mixed/Unclassified %
Jan–Jun 
2019
ACT 1.7 – – 1.7 3.4
NSW 45.6 1.8 – 24.6 72.0
WA 15.8 – – 8.8 24.6
Total 63.1 1.8 – 35.1 100
2018
ACT 5.1 – – 4.0 9.1
NSW 19.9 8.0 – 23.3 51.2
NT 2.8 – – 2.3 5.1
SA 7.4 – – 1.7 9.1
VIC 8.5 2.8 – – 11.3
WA 4.5 0.6 – 9.1 14.2
Total 48.2 11.4 – 40.4 100
2017 ACT 4.6 – – – 4.6
NSW 40.7 13.9 – 20.4 75.0
NT 0.9 – – – 0.9
SA 8.3 – – 1.9 10.2
VIC 6.5 0.9 – 1.9 9.3
Total 61.0 14.8 – 24.2 100
2016
ACT 3.5 – – 0.6 4.1
NSW 47.4 0.6 – 21.4 69.4
NT 2.3 – – – 2.3
SA 4.0 – – – 4.0
VIC 2.9 – – 0.6 3.5
WA 6.9 0.6 – 9.2 16.7
Total 67.0 1.2 – 31.8 100
2015
ACT 1.1 – – – 1.1
NSW 38.1 16.5 – 15.9 70.5
NT 0.6 – – – 0.6
SA 2.8 – – – 2.8
VIC 2.8 – – 3.4 6.2
WA 5.1 8.0 – 5.7 18.8
Total 50.5 24.5 – 25.0 100
2014
NSW 10.0 26.7 – 3.3 40.0
NT 1.7 1.7 – – 3.3
QLD 1.7 3.3 – – 5.0
VIC 10.0 – – – 10.0
WA 30.0 6.7 – 5.0 41.7
Total 53.3 38.4 – 8.3 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This data represents a total of 233 cocaine samples. Due to a lack of available data, some samples were classified based on the 
sample collection date in place of the sample seizure date.
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TABLE 6: Geographical origin of cocaine ENIPID samples as a proportion of analysed 
jurisdictional cases, 2014–June 2019
Geographical origin
TotalYear Jurisdiction Colombia % Peru %  Bolivia %  Mixed/Unclassified %
Jan–Jun
2019
ACT 2.4 – – 2.4 4.8
NSW 42.8 2.4 – 16.7 61.9
WA 21.4 – – 11.9 33.3
Total 66.6 2.4 – 31.0 100
2018
ACT 3.2 – – 3.2 6.4
NSW 16.9 7.3 – 25.0 49.2
NT 2.4 – – 0.8 3.2
SA 10.5 – – 2.4 12.9
VIC 6.5 0.8 – 1.6 8.9
WA 5.7 0.8 – 12.9 19.4
Total 45.2 8.9 – 45.9 100
2017
ACT 5.9 – – – 5.9
NSW 44.1 13.2 – 19.1 76.4
NT 1.5 – – – 1.5
SA 5.9 – – 1.5 7.4
VIC 5.9 – – 2.9 8.8
Total 63.3 13.2 – 23.5 100
2016
ACT 3.5 – – 0.9 4.4
NSW 46.5 – – 26.3 72.8
NT 0.9 – – – 0.9
SA 5.2 – – – 5.2
VIC 3.5 – – 0.9 4.4
WA 7.0 0.9 – 4.4 12.3
Total 66.6 0.9 – 32.5 100
2015
ACT 1.9 – – – 1.9
NSW 38.0 14.8 – 20.4 73.2
NT 0.9 – – – 0.9
SA 2.8 – – – 2.8
VIC 4.6 – – 4.6 9.2
WA 2.8 0.9 – 8.3 12.0
Total 51.0 15.7 – 33.3 100
2014
NSW 13.5 13.5 – 5.4 32.4
NT 2.7 2.7 – – 5.4
QLD 2.7 5.4 – – 8.1
VIC 16.2 – – – 16.2
WA 24.3 2.7 – 10.8 37.8
Total 59.4 24.3 – 16.2 100
Note: Due to a lack of available data, some samples were classified based on sample collection date in place of sample seizure date.
This cocaine dataset represents a total of 166 cases. Due to lack of available data, some samples were classified based on the 
sample collection date in place of the sample seizure date.
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